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Abstract 
Background: Prediabetes is a condition where the blood glucose levels are high but not high 
enough to be classified as having type 2 diabetes mellitus (T2DM). It is also considered a 
high risk for developing T2DM. There is increasing evidence that demonstrates antioxidant-
rich plant extracts exhibiting hypoglycaemic effects in humans. Therefore the extracts may 
improve glycaemic control in individuals with prediabetes and help prevent or delay the 
progression of prediabetes towards T2DM.  
Overall Aim: To examine the acute hypoglycaemic potential of four antioxidant-rich plant 
extracts, namely the New Zealand pine bark, grape seed, rooibos tea and olive leaf extracts in 
humans.  
Methods/Design: The hypoglycaemic effects of the New Zealand pine bark was examined in 
healthy participants (n=25) in an acute, placebo-controlled, single-blind, crossover, dose-
response (50 and 400 mg), exploratory study (Pine Bark study). Blood samples were 
collected via finger pricking using disposable lancet to measure glucose levels at -20, 0, 15, 
30, 45, 60, 90 and 120 min during an oral glucose tolerance test (OGTT) with 75 g of 
glucose. The hypoglycaemic effects of grape seed, rooibos tea and olive leaf extracts matched 
for antioxidant capacity were examined in an acute, placebo-controlled, crossover study 
(GLARE study) in participants with prediabetes (n=19). Blood samples were collected via 
cannulating the antecubital fossa region of the arm at -10, 0, 15, 30, 45, 60, 90 and 120 min 
during the OGTT with 75 g of glucose. Outcome glycaemic measures were analysed in both 
clinical studies (Pine Bark study and GLARE study). An in vitro mechanistic study 
investigating the potential inhibitory action of all four plant extracts (grape seed, rooibos tea, 
olive leaf and New Zealand pine bark) on digestive enzyme α-amylase and the dipeptidyl 
peptidase-4 (DPP4) enzyme were carried out using appropriate enzymatic assays of 
inhibition. 
Results: Prior to secondary analysis in the Pine Bark study, a significant reduction in the 
primary outcome mean glucose incremental area under the curve (iAUC) was only observed 
for the 400 mg dose of pine bark (21.3% reduction, p=0.016) compared to control. After 
stratification in the monophasic glucose curve shape group (n=12), 50 and 400 mg of pine 
bark significantly reduced the mean glucose iAUC compared to control (28.1% reduction, 
p=0.034 and 29.5% reduction, p=0.012), respectively. In contrast, mean glucose iAUC was 
not significantly different in the complex glucose curve shape group (n=13). In the 
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monophasic group, 400 mg dose further improved glycaemic indices by reducing mean 
percentage increment of postprandial glucose (%PG) (33.9% reduction, p=0.010), mean 
glucose peak (11.2% reduction, p=0.025), and mean 2h postprandial glucose (2hPG) (8.9% 
reduction, p=0.027) compared to control. Within the complex group, there were no other 
significant changes except for reductions in mean %PG after 50 mg and 400 mg dose (33.8% 
reduction, p=0.012 and 41.4% reduction, p=0.025) compared to control, respectively. There 
were no significant differences between treatments in both subgroups (p>0.05). 
In the GLARE study, there were no overall significant changes in glucose and insulin 
responses between the extracts and control, or amongst the plant extracts (p>0.05). After 
secondary analysis, the less healthy subgroup (n=9), grape seed consumption showed 
significant reduction in mean glucose iAUC (21.9% reduction, p=0.016), mean 2hPG (14.7% 
reduction, p=0.034) and mean 2h postprandial insulin (2hPI) (22.4% reduction, p=0.029), 
whilst there was significant improvement in mean overall insulin sensitivity (ISIoverall) (15.0% 
increase, p=0.028) and mean glucose metabolic clearance rate (MCR) (16.7% increase, 
p=0.016) compared to control. Rooibos tea extract was shown to improve β-cell function 
measured by the mean oral disposition index (DI) (32.4% increase, p=0.031) in the less 
healthy subgroup compared to control. This was coupled with a non-significant improvement 
in insulin sensitivity measured by mean insulin-secretion-sensitivity-index-2 (ISSI-2) (18.3% 
increase, p=0.074). Olive leaf exhibited improved mean insulin sensitivity indices of 
insulinogenic index (IGI30) (27.8% increase, p=0.078), Stumvoll first phase insulin sensitivity 
(ISIfirst) (17.8% increase, p=0.075) and Stumvoll second phase insulin sensitivity (ISIsecond) 
(15.6% increase, p=0.062) in the less healthy subgroup compared to control, although 
significance was not reached. Olive leaf extract was also consistently shown to elevate 
insulin levels in the study, with a higher mean 2hPI in the healthier subgroup (49.5% 
increase, p=0.030) and an elevated mean insulin iAUC in the less healthy (16.7% increase, 
p=0.040) subgroups. There were no significant changes in glucose and insulin responses in 
the healthier subgroup (n=10) compared to control nor between treatments in both subgroups 
(p>0.05).  
The mechanistic study demonstrated that the New Zealand pine bark extract exhibited 
the greatest inhibitory effects against digestive enzyme α-amylase (IC50 3.98 ± 0.11 mg/mL) 
and DPP4 enzyme (IC50 2.51 ± 0.04 mg/mL) compared to the other extracts (p<0.001). Both 
grape seed and rooibos tea extracts showed good inhibition of both enzymes tested. Rooibos 
tea was able to inhibit DPP4 enzyme to a greater extent than grape seed (p=0.018). In 
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contrast, olive leaf extract showed minimal inhibition on α-amylase and no inhibition action 
against DPP4 enzyme. 
Conclusions: All four plant extracts (New Zealand pine bark, grape seed, rooibos tea and 
olive leaf) have shown acute hypoglycaemic potential in the Pine Bark study and the GLARE 
study by improving various indices of glucose and insulin responses in humans. The 
inhibitory action of the New Zealand pine bark, grape seed and rooibos tea extracts on DPP4 
enzyme might have contributed to the hypoglycaemic effects observed in the clinical studies 
conducted. Whereas for olive leaf extract other underlying mechanisms on glycaemia remain 
to be elucidated. Our acute studies have indicated the need to investigate the chronic impact 
of these plant extracts in longer-term studies. Future studies in the prediabetes cohort should 
also look to target different metabolic profiles of varying degrees of dysglycaemia, as this 
















	   iv	  
Acknowledgements 
First and foremost, I would like to thank all my supervisors Rachel Page, Pamela von 
Hurst, Cheryl Gammon and Lynne Chepulis for their priceless support and guidance at every 
stage of my PhD journey. I have been very blessed to have such wonderful supervisors and in 
my opinion, the best supervisors, who were always there for me to give me timely advice and 
direction for my work. I am also very grateful that I was given the opportunity to gain full 
ownership of my project and to develop the skills required to work independently on a 
research project. This has led me to attaining a great level of work satisfaction and 
accomplishment.  
I would like to specially thank Owen Mugridge very much for his unfailing assistance 
in the clinical trials, especially in the GLARE study. He was an integral part of the team and 
was involved actively in the recruitment, management of participants, and data collection for 
the GLARE study. He was our exceptional phlebotomist for the GLARE study and he also 
ensured all our participants were well looked after. Because of his dedication, all our 
participants thoroughly enjoyed the process of being part of the research contributing to the 
advancement of science. Without his expertise and help the study would not have been 
completed in a timely manner.  
I would like to thank PC Tong for helping untiringly with ordering and getting the 
materials and vouchers required for the clinical studies. His friendliness and generosity in 
giving his time for the studies have been greatly appreciated. 
I would also like to thank all my friends in New Zealand and abroad, and my friends 
and family back home, who have supported me unceasingly in this research journey, adding 
so much vibrancy and fun into my life. Thank you Liangjue and Elizabeth for being an 
irreplaceable part of my journey here. I will never forget all the meaningful discussions and 
great times we have had together and will continue to cherish the time we spend together. 
Last but not least, I would like to thank all participants for their commitment to the 
trial study. A good research would not have been possible without their participation and 
dedication. I would also like to thank all those who have in part contributed to the clinical 
studies and PhD study, with special thanks to North Shore hospital team who helped us to 
analyse the biological samples in the most prompt and professional manner. 
 
	   v	  
Table of Contents 
Abstract ...................................................................................................................................... i 
Acknowledgements ................................................................................................................. iv 
List of Tables ............................................................................................................................ x 
List of Figures .......................................................................................................................... xi 
List of Appendices ................................................................................................................. xii 
Abbreviations ....................................................................................................................... xiii 
Chapter 1  Introduction .......................................................................................................... 1 
1.1 Background ........................................................................................................................ 2 
1.1.1 Diabetes and its prevalence ............................................................................................... 2 
1.1.2 Early prevention of type 2 diabetes mellitus ..................................................................... 2 
1.1.3 Antioxidant-rich plant extracts as potential hypoglycaemic agents ................................. 4 
1.2 Justification for the PhD study ......................................................................................... 4 
1.3 Research Questions ............................................................................................................ 5 
1.3.1 Research Question 1 ......................................................................................................... 5 
1.3.2 Research Question 2 ......................................................................................................... 5 
1.3.3 Research Question 3 ......................................................................................................... 6 
1.3.4 Research Question 4 ......................................................................................................... 6 
1.4 Thesis structure .................................................................................................................. 8 
1.5 Researchers’ Contribution ................................................................................................ 9 
References ............................................................................................................................... 11 
Chapter 2  Review of the literature ...................................................................................... 17 
2.1 What is prediabetes? ....................................................................................................... 18 
2.2 Prediabetes as a global health issue ................................................................................ 18 
2.3 Prediabetes in New Zealand ............................................................................................ 19 
2.3.1 Ethnicities in New Zealand and prediabetes ................................................................... 19 
2.3.2 Work in progress in New Zealand to improve glycaemic outcomes .............................. 19 
2.4 Who may have prediabetes? ........................................................................................... 20 
	   vi	  
2.4.1 Who else may have an increased risk of developing T2DM? ........................................ 23 
2.5 Plant extract polyphenols and their health benefits ..................................................... 25 
2.5.1 What are plant polyphenols? ........................................................................................... 25 
2.5.2 Hypoglycaemic potential of plant extracts on human health .......................................... 25 
2.5.3 Hypoglycaemic potential of plant extracts on prediabetes ............................................. 26 
2.6 The plant extracts examined in the PhD study ............................................................. 29 
2.6.1 New Zealand pine bark extract ....................................................................................... 35 
2.6.2 Grape seed extract ........................................................................................................... 36 
2.6.3 Rooibos tea extract .......................................................................................................... 36 
2.6.4 Olive leaf extract ............................................................................................................. 37 
2.7 Hypoglycaemic mechanisms of action of plant extracts ............................................... 38 
2.8 Conclusion ........................................................................................................................ 43 
References ............................................................................................................................... 44 
Chapter 3  Impact of phenolic-rich plant extracts on prediabetes and its subgroups. A 
narrative review of human clinical trials on prediabetes ................................................... 77 
Abstract ................................................................................................................................... 78 
3.1 Introduction ...................................................................................................................... 79 
3.2 Human clinical trials examining effect of plant extracts on glycaemic responses in 
the prediabetes cohort ........................................................................................................... 81 
3.3 Effectiveness of plant extracts on glycaemic responses in the prediabetes subgroups
.................................................................................................................................................. 88 
3.3.1 Hypoglycaemic effects of plant extracts on impaired fasting glucose (IFG) ................. 88 
3.3.2 Hypoglycaemic effects of plant extracts on impaired glucose tolerance (IGT) ............. 91 
3.3.3 Hypoglycaemic effects of plant extracts on combined impaired fasting glucose and 
impaired glucose tolerance (IFG/IGT) ..................................................................................... 91 
3.4 Does each prediabetes subgroup benefit from different plant extracts? .................... 95 
3.5 Strengths and limitations ................................................................................................ 96 
3.6 Conclusion ........................................................................................................................ 97 
References ............................................................................................................................... 98 
	   vii	  
Chapter 4 An acute, placebo-controlled, single-blind, crossover, dose-response, 
exploratory study to assess the effects of New Zealand pine bark extract (Enzogenol®) 
on glycaemic responses in healthy participants ................................................................ 114 
4.1 Introduction .................................................................................................................... 116 
4.2 Methods ........................................................................................................................... 118 
4.2.1 Study Population ........................................................................................................... 118 
4.2.2 Study Design ................................................................................................................. 118 
4.2.3 Treatments ..................................................................................................................... 119 
4.2.4 Parameters of Glycaemic Response during the OGTT ................................................. 119 
4.2.5 Statistical Analysis ........................................................................................................ 120 
4.3 Results ............................................................................................................................. 120 
4.4 Discussion ....................................................................................................................... 126 
4.5 Conclusions ..................................................................................................................... 130 
References ............................................................................................................................. 131 
Chapter 5 Hypoglycaemic effects of antioxidant-rich plant extracts on postprandial 
glycaemic responses in participants with prediabetes (GLARE study): A single-blind, 
placebo-controlled, crossover study ................................................................................... 136 
Abstract ................................................................................................................................. 137 
5.1 Introduction .................................................................................................................... 138 
5.2 Materials and Methods .................................................................................................. 139 
5.2.1 Study participants .......................................................................................................... 139 
5.2.2 Study design .................................................................................................................. 140 
5.2.3 Treatments ..................................................................................................................... 141 
5.2.4 Measures of glucose and insulin responses during the OGTT ..................................... 142 
5.2.5 Analysis of blood samples ............................................................................................ 143 
5.2.6 Stratification into prediabetes subgroups ...................................................................... 143 
5.2.7 Statistical analysis ......................................................................................................... 143 
5.3 Results ............................................................................................................................. 144 
5.3.1 Participant characteristics at baseline ........................................................................... 144 
5.3.2 Plant extracts and their impact on overall glucose and insulin indices in participants . 145 
	   viii	  
5.3.3 Plant extracts and their impact on glucose and insulin indices after stratification of 
participants based on glucose and insulin peak time patterns ................................................ 147 
5.4 Discussion ....................................................................................................................... 151 
Appendix ............................................................................................................................... 157 
References ............................................................................................................................. 158 
Chapter 6 Short communication: Inhibitory actions of antioxidant-rich plant extracts 
on alpha-amylase and dipeptidyl peptidase-4 enzymatic activities. A mechanistic insight 
into their hypoglycaemic effects ......................................................................................... 170 
Abstract ................................................................................................................................. 171 
6.1 Introduction .................................................................................................................... 172 
6.2 Methods ........................................................................................................................... 173 
6.2.1 Materials ....................................................................................................................... 173 
6.2.2 Sample preparation ....................................................................................................... 173 
6.2.3 Enzyme inhibition assays .............................................................................................. 174 
6.2.3.1 α-amylase inhibition assay ..................................................................................... 174 
6.2.3.2 Dipeptidyl peptidase-4 (DPP4) inhibition assay ................................................... 174 
6.2.4 IC50 determination of pine bark extract on enzymes .................................................... 174 
6.2.5 Statistical analysis ......................................................................................................... 175 
6.3 Results ............................................................................................................................. 175 
6.3.1 α-amylase activity inhibition ........................................................................................ 175 
6.3.2 Dipeptidyl peptidase-4 (DPP4) activity inhibition ....................................................... 175 
6.3.3 IC50 of pine bark extract on enzymes ............................................................................ 175 
6.4 Discussion ....................................................................................................................... 176 
6.5 Conclusions ..................................................................................................................... 181 
References ............................................................................................................................. 182 
Chapter 7 Discussion and conclusions ............................................................................... 189 
7.1 Summary of key findings .............................................................................................. 190 
7.2 Discussion of main findings ........................................................................................... 191 
7.3 Strengths ......................................................................................................................... 197 
	   ix	  
7.4 Limitations ...................................................................................................................... 198 
7.5 Future directions ............................................................................................................ 201 
7.6 Conclusions ..................................................................................................................... 204 
References ............................................................................................................................. 205 






































	   x	  
List of Tables 
Table 1.1 Contributions by each researcher involved in this PhD study ___________ 9 
Table 2.1 Diagnostic criteria for impaired glycaemic control and T2DM _________ 21 
Table 2.2 Pathophysiological differences between IFG and IGT ________________ 22 
Table 2.3 New Zealand Guidelines for screening of individuals at risk of diabetes _ 23 
Table 2.4 Human clinical studies to date that investigated the hypoglycaemic  
effects of the plant extracts under study ___________________________________ 30 
Table 2.5 In vitro and in vivo studies on the hypoglycaemic mechanisms of action  
of the plant extracts and their bioactive phenolic components __________________ 42 
Table 3.1 Human clinical trials involving plant extracts and their hypoglycaemic  
impact in participants with prediabetes ___________________________________ 83 
Table 3.2 Changes in glycaemic clinical outcomes in participants with  
prediabetes classified by their subgroups __________________________________ 93 
Table 3.3 Hypoglycaemic effects of plant extracts on fasting and postprandial  
glycaemic measurements ______________________________________________ 95 
Table 4.1 Baseline characteristics of participants in the Pine Bark study ________ 121 
Table 4.2 Parameters of glycaemic response in participants classified as having  
either a monophasic or complex glucose curve shape at control visit and  
treatments with 50 and 400 mg of Enzogenol® _____________________________ 125 
Table 5.1 Baseline characteristics of participants in the GLARE study __________ 145 
Table 5.2 Overall results of glycaemic indices of participants in all the trials ____ 146 
Table 5.3 Results of glycaemic indices of participants with prediabetes in the  













	   xi	  
List of Figures 
Figure 1.1 Flow diagram of the PhD research work __________________________ 7 
Figure 2.1 Sites of action of anti-diabetic drugs and their associaed potential  
adverse effects _______________________________________________________ 28 
Figure 2.2 Hypoglycaemic potential of dietary polyphenols ___________________ 41 
Figure 4.1 Mean postprandial glucose (±SEM) of participants with a  
monophasic glucose curve shape during the control and treatment visits with  
(A) 50 and (B) 400 mg of Enzogenol® ___________________________________ 123 
Figure 4.2 Mean postprandial glucose (±SEM) of participants with a complex  
glucose curve shape during the control and treatment visits with (A) 50 and  
(B) 400 mg of Enzogenol® ____________________________________________ 124 
Figure 5.1 CONSORT flow diagram for the GLARE study ___________________ 157 
Figure 5.2 Unadjusted mean postprandial plasma glucose and insulin of  
participants during an oral glucose tolerance test (OGTT) ___________________ 149 
Figure 6.1 Bar charts showing percentage inhibition of grape seed, rooibos  
tea and pine bark extracts on (A) α-amylase at 5 mg/mL and (B) 






















	   xii	  
List of Appendices 
Appendix 1 – List of research outputs .................................................................................. 222 
Appendix 2 – Pine Bark study documents ........................................................................... 224 
Appendix 2.1 – Pine Bark study recruitment poster .............................................................. 225 
Appendix 2.2 – Pine Bark study participant information sheet ............................................. 226 
Appendix 2.3 – Pine Bark study reference during screening ................................................. 233 
Appendix 2.4 – Pine Bark study case record form ................................................................. 237 
Appendix 2.5 – Pine Bark study consent form ....................................................................... 243 
Appendix 2.6 – Pine Bark study record sheet for participants to take home ......................... 244 
Appendix 2.7 – Pine Bark study visit form ............................................................................. 245 
Appendix 3 – GLARE study documents ............................................................................... 247 
Appendix 3.1 – GLARE study recruitment poster .................................................................. 248 
Appendix 3.2 – GLARE study online screening questionnaire .............................................. 249 
Appendix 3.3 – GLARE study participant information sheet ................................................. 252 
Appendix 3.4 – GLARE study reference during screening .................................................... 261 
Appendix 3.5 – GLARE study case record form .................................................................... 265 
Appendix 3.6 – GLARE study consent form ........................................................................... 267 
Appendix 3.7 – GLARE study record sheet for participants to take home ............................ 268 
Appendix 3.8 – GLARE study visit form ................................................................................ 269 
Appendix 4 – GLARE study analysis resources ................................................................... 273 
Appendix 4.1 – Formulas of glucose and insulin indices considered in the GLARE study. .. 274 
Appendix 4.2 – Data analysis stratification options considered in the GLARE study. ......... 280 
Appendix 5 – DRC 16 forms ................................................................................................. 284 
Appendix 5.1 – DRC 16 form for Chapter 3 of the thesis ...................................................... 285 
Appendix 5.2 – DRC 16 form for Chapter 4 of the thesis ...................................................... 286 
Appendix 5.3 – DRC 16 form for Chapter 5 of the thesis ...................................................... 287 









	   xiii	  
Abbreviations 
1,5-AG  1,5-anhydroglucitol 
2hPI   2h postprandial insulin 
2hPG   2h postprandial glucose  
%PG   Percentage increment of postprandial glucose 
ACO-1  Acyl CoA oxidase-1 
ADA   American Diabetes Association 
ALT   Alanine aminotransferase 
AI   Atherogenic index 
AMPK   5’ adenosine monophosphate-activated protein kinase 
AST   Aspartate aminotransferase 
AUCglucose  Area under the curve of glucose 
AUCinsulin  Area under the curve of insulin 
BFP   Body fat percentage 
BMI   Body mass index 
BP   Blood pressure 
BW   Body weight 
CRF   Case record form 
CRP   C-reactive protein 
COX2   Cyclooxygenase-2 protein 
CPT-1β  Carnitine palmitoyltransferase-1β 
CVD   Cardiovascular disease 
DBP Diastolic blood pressure 
DI   Oral disposition index 
DMSO   Dimethyl sulfoxide 
DNS   3,5-dinitrosalicylic acid 
DNJ   1-deoxynojirimycin 
DPP   Diabetes Prevention Program 
DPP4 enzyme  Dipeptidyl-peptidase-4 enzyme 
DPS   The Finnish Diabetes Prevention Study 
DREAM Diabetes Reduction Assessment with ramipril and rosiglitazone 
Medication 
EDTA   Ethylenediaminetetraacetic acid 
	   xiv	  
EGCG   epigallocatechin-3-gallate 
EGP   Endogenous glucose production 
FBG Fasting blood glucose 
FCP Fasting C-peptide 
FFA Free fatty acid 
FI Fasting insulin 
FOXO1 Forkhead box protein O1 
G6Pase Glucose-6-phosphatase 
GA Glycated albumin 
GDM Gestational diabetes mellitus 
GIP   Gastric inhibitory polypeptide 
GK   Glucokinase 
GLARE study  Glucose Lowering Antioxidant-Rich plant Extracts study 
Glcmax   Glucose maximum concentration 
GLP-1   Glucagon-like peptide-1 
GLUT2  Sodium-independent glucose transporter-2 
GMP   Good manufacturing practice 
GP   General practitioner  
GSP   Glycated serum protein 
H-Gly-Pro-AMC Gly-Pro-Aminomethylcoumarin 
HbA1c   Glycated haemoglobin (A1c) 
HDL   High-density lipoprotein cholesterol 
HOMA-β  Homeostatic model assessment-beta 
HOMA-IR  Homeostatic model assessment-insulin resistance 
HTR High-density lipoprotein cholesterol (HDL) to total cholesterol (TC) 
ratio 
iAUCglucose   Incremental area under the curve of glucose 
iAUCinsulin  Incremental area under the curve of insulin 
iAUCsucrose   Incremental area under the curve of sucrose 
IDF   International Diabetes Federation 
IFG   Impaired fasting glucose 
IFG/IGT Combined impaired fasting glucose and impaired glucose tolerance 
IGI30   Insulinogenic index 
IGT   Impaired glucose tolerance 
	   xv	  
IL-6   Interleukin-6 
IRS2   Insulin receptor substrate 2 
ISIfirst   Stumvoll first phase insulin sensitivity index 
ISIoverall  Stumvoll overall insulin sensitivity index 
ISIsecond  Stumvoll second phase insulin sensitivity index 
ISI/M   Matsuda-DeFronzo insulin sensitivity index 
ISSI-2   Insulin-secretion-sensitivty-index-2 
LDL   Low-density lipoprotein cholesterol 
KATP channel  Adenosine triphosphate-sensitive potassium channel 
MCP-1  Monocyte chemoattractant protein-1 
MCR   Metabolic clearance rate of glucose 
MMTT  Mixed meal tolerance test 
MUHEC  Massey University Human Ethics Committee 
MUHNRC  Massey University Human Nutrition Research Centre 
NaCl   Sodium chloride 
Na2CO3  Sodium carbonate 
NF-κB   nuclear factor kappaB 
NGT   Normal glucose tolerance 
NZ PHO  New Zealand Primary Health Organisation 
NZSSD  New Zealand Society for the Study of Diabetes 
OGIS   Oral glucose insulin sensitivity  
OGTT   Oral glucose tolerance test 
ORAC   Oxygen radical absorbance capacity 
PAI-1   Plasminogen activator inhibitor-1 
PBS   Phosphate saline buffer 
PCP Postprandial C-peptide 
PCP AUC Area under the curve of postprandial C-peptide 
PCP iAUC Incremental area under the curve of postprandial C-peptide 
PEPCK Phosphoenolpyruvate carboxykinase 
PG   Postprandial glucose 
PG AUC Area under the curve of postprandial glucose 
PG iAUC Incremental area under the curve of postprandial glucose 
PI Postprandial insulin 
PI3K Phosphoinositide 3-kinase 
	   xvi	  
PI AUC  Area under the curve of postprandial insulin 
PI iAUC Incremental area under the curve of postprandial insulin 
PL Phospholipid 
PPAR-γ Peroxisome proliferator-activated receptor-gamma 
PTP1B Protein tyrosine phosphatase 1B 
p-NPG   p-nitro-phenyl- α-D-glucopyranoside 
QUICKI  Quantitative insulin sensitivity check index 
RCT Randomised controlled trial 
REML Restricted maximum likelihood (statistics) 
SAM San Antonio Metabolism study 
SBP Systolic blood pressure 
SEM   Standard error of the mean 
SGLT1  Sodium-dependent glucose co-transporter-1 
SGLT2  Sodium-dependent glucose co-transporter-2 
SPARCL1  SPARC-like protein 1 precursor 
STOP-NIDDM Study to Prevent Non-Insulin-Dependent Diabetes Mellitus 
SUR1   Sulfonylurea receptor-1 
T2DM   Type 2 diabetes mellitus 
TAC   Total antioxidant capacity 
TC   Total cholesterol 
TE   Trolox equivalent 
TG   Triglyceride 
TNF-α   Tumor necrosis factor-α 
Tris-HCl  Tris hydrochloride 
WC   Waist circumference 
WHO   World Health Organization 


















Chapter 1  
Introduction 
 
This chapter introduces the relevance of this PhD study followed by outlining four specific 
research questions. The chapter will conclude with a discussion of the outline of the thesis, 
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1.1 Background 
1.1.1 Diabetes and its prevalence 
It is estimated that there are currently 463 million (ages 20-79 years) (9.3%) people 
living with diabetes worldwide, and this number is expected to increase to an alarming 700 
million (10.9%) by 2045 [1]. Last year it was estimated that about 4.2 million adults (20-79 
years) died from diabetes and its complications, equivalent to one death every eight seconds 
[1]. Diabetes imposes a significant economic impact, with the current annual global health 
expenditure on diabetes estimated to be USD 760 billion and this is projected to reach USD 
845 billion by 2045 [1]. 
Type 2 diabetes mellitus (T2DM) is a state of hyperglycaemia where glucose levels 
are higher than normal levels indicating insulin deficiency and pancreatic β-cell dysfunction 
[1, 2]. According to American Diabetes Association (ADA) and World Health Organization 
(WHO), T2DM is defined by fasting blood glucose (FBG) ≥7.0 mmol/L (≥126 mg/dL), or 2h 
postprandial glucose (2hPG) ≥11.1 mmol/L (≥200 mg/dL), or glycated haemoglobin A1c 
(HbA1c) ≥48 mmol/mol (≥6.5%) [1, 3].  
Type 2 diabetes mellitus is the predominant form of diabetes, comprising 90 to 95% 
of all diagnoses [4, 5]. Although certain factors such as the environment, genetics, 
urbanisation, political and socioeconomic influences may determine individual susceptibility 
towards T2DM, poor diet choices with high levels of red meat and processed meat, refined 
grains, and sugary beverages, and a sedentary lifestyle also contribute to the obesity epidemic 
that may increase T2DM risk [6, 7]. Type 2 diabetes mellitus is independently associated 
with all-cause and cardiovascular disease (CVD) mortality [8]. This may be attributed to the 
development of macrovascular and microvascular complications from increased insulin 
resistance, inflammation, endothelial dysfunction, dyslipidaemia and glucotoxicity caused by 
elevated levels of blood glucose [9].  
1.1.2 Early prevention of type 2 diabetes mellitus  
Preventing T2DM brings substantial benefits, where the individual is able to avoid 
entering into years of drug therapy and complications [2]. Preventing T2DM has been shown 
to be more cost-effective than treating T2DM and its complications [10-12]. A mathematical 
model created by Ha and colleagues (2016) demonstrated that it is easier to prevent T2DM 
than to manage or cure it [13]. To minimise the health and economic burden of T2DM, it is 
important that strategies are found to prevent or slow down the progression from 
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normoglycaemia, prediabetes and into T2DM by putting a halt or delay of deteriorating 
glucose homeostasis [14]. 
The development of T2DM is often preceded by an interlude of intermediate 
dysglycaemia, or otherwise known as the state of prediabetes [15]. Prediabetes is an 
intermediate state of hyperglycaemia where blood glucose levels are elevated from 
normoglycaemia but they are not high enough to be classified as having T2DM [16]. Indeed, 
the development of hyperglycaemia is a continuum and the classification of prediabetes is to 
some extent an arbitrary number [17]. Research indicates that by the time individuals reach a 
state of impaired glycaemic control or prediabetes, their risk of mortality and morbidity, due 
to the development of cardiovascular and microvascular complications, has already increased 
[15, 16, 18, 19]. It is therefore vitally important to remedy the state of prediabetes as soon as 
possible, with interventions targeting the state of prediabetes as a form of early diabetes 
prevention treatment [20, 21].  
Research has shown that reversion of high blood glucose levels to normal levels or a 
reduction in T2DM risk in the state of prediabetes is usually achievable when adequate 
lifestyle modification is in place including increasing adherence to a healthy dietary pattern 
and sufficient physical activity [22-24]. Large cohort studies in diabetes prevention such as 
The Finnish Diabetes Prevention Study (DPS) [25-27], Diabetes Prevention Program (DPP) 
[28-30], and Da Qing Diabetes Prevention study [31-33] have demonstrated that intensive 
lifestyle modification through diet and exercise interventions can reduce T2DM risk. A recent 
ADA consensus report summarises the current recommendations on nutrition therapy 
combined with physical activity for people with prediabetes [34]. Early drug therapy to 
prediabetes in studies such as the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus 
(STOP-NIDDM) with acarbose [35], DPP with metformin [28], and the Diabetes Reduction 
Assessment with ramipril and rosiglitazone Medication (DREAM) [36] have also seen 
reduction in risk of T2DM development, with participants with prediabetes returning to 
having normal blood glucose levels. The DPP study demonstrated that lifestyle modification 
was more effective than drug therapy in reversing prediabetes back to normoglycaemia and 
delaying the onset of T2DM [28]. 
The DPP [37, 38] and STOP-NIDDM [39] studies showed that instigating early 
treatment in people with prediabetes was associated with a CVD risk reduction, which is an 
important clinical endpoint. However other studies including DPS [40], and the Da Qing IGT 
Diabetes study [31, 33] were less conclusive of lifestyle modification conferring CVD risk 
reduction benefits. The Whitehall II cohort study in free-living conditions recently reported 
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reversion from prediabetes to normoglycaemia in 37% of the participants with prediabetes 
based on 2hPG criterion, and was associated with a reduction of CVD risk by half (12.7 vs 
29.1 per 1000 person-years, p=0.020) during five years of follow-up [41]. Early diagnosis 
and treatment could therefore provide an opportunity to reduce the risk of prediabetes 
developing into T2DM and minimise the damage caused by hyperglycaemia [22, 42, 43].  
1.1.3 Antioxidant-rich plant extracts as potential hypoglycaemic agents  
Antioxidant-rich plant extracts have been shown to engage multi-targeted 
mechanisms of action to treat hyperglycaemia with little to no adverse effects compared to 
anti-diabetic drugs [44-55]. This may make them ideal candidates for the therapeutic 
treatment of complex metabolic diseases such as prediabetes [44-55]. This has led to 
increasing interest in the potential of antioxidant-rich plant extracts, abundant in polyphenols, 
to compliment the diet and improve glycaemia, and therefore help to prevent or delay T2DM 
development [44-55]. Plant extracts have been demonstrated to modulate various glycaemic 
pathways such as glycolysis, Krebs cycle, gluconeogenesis and carbohydrate metabolism 
such as suppressing glucagon release, enhancing the incretin effect, delaying carbohydrate 
digestion and glucose absorption to maintain glucose homeostasis [45, 50, 55, 56]. The 
complex and unique phenolic structures of the plant extracts have been shown to be 
responsible for the major multifaceted role in their hypoglycaemic effects [57-62]. More 
details are discussed in Chapter 2.4-2.6 of the thesis. There is a growing number of human 
studies done to date examining the beneficial effects of a range of extracts on glucose and 
insulin responses in both healthy and diabetes cohorts [63, 64] compared to the prediabetes 
cohort [65]. 
1.2 Justification for the PhD study  
Few studies have explored the hypoglycaemic potential of antioxidant-rich plant 
extracts in a prediabetes cohort. Therefore, the focus of this PhD work is to conduct 
nutritional intervention at the prediabetes stage, with the aim of identifying potential plant 
extracts that could improve glycaemic control and ultimately stop or delay the progression 
towards T2DM. A literature search identified four antioxidant-rich plant extracts, which are 
the New Zealand pine bark, grape seed, rooibos tea and olive leaf to be examined for their 
hypoglycaemic potential in humans. There have been no studies yet conducted on the New 
Zealand pine bark on glycaemic responses in humans. Plant extracts such as grape seed, 
rooibos tea and olive leaf have not been examined for their acute hypoglycaemic impact in 
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individuals with prediabetes.  Therefore the primary objectives of the PhD work are to 
investigate the effects of these plant extracts on acute postprandial blood glucose responses in 
two separate human studies; Pine Bark study (investigating hypoglycaemic potential of New 
Zealand pine bark in healthy subjects) and GLARE study (investigating hypoglycaemic 
potential of extracts of grape seed, rooibos tea, and olive leaf in prediabetes cohort). The 
underlying mechanisms of action of the potential hypoglycaemic effects of the plant extracts 
will also be explored in order to understand how they work to improve glycaemic responses 
in humans.  
1.3 Research Questions 
The PhD work aims to answer four research questions arising from the study of the 
hypoglycaemic potential of plant extracts (Figure 1.1). The first research question aims at 
gathering evidence and having an overall review on the current studies that have examined 
the impact of plant extracts in improving glycaemic control in the prediabetes cohort. 
Research questions 2-4 are aligned to the four plant extracts: New Zealand pine bark, grape 
seed, rooibos tea and olive leaf being examined in this PhD study.  
1.3.1 Research Question 1  
Do plant extracts improve postprandial glycaemia in individuals with prediabetes? 
 Human clinical trials on plant extracts (years 2010-2020) and their impact on 
hypoglycaemic effects in individuals with prediabetes will be reviewed and summarised in a 
narrative review. The narrative review aims to achieve increased awareness of plant extract 
consumption as a potential adjunct to prediabetes management. 
	  
1.3.2 Research Question 2 
Does New Zealand pine bark improve postprandial glycaemia in healthy individuals? 
The New Zealand pine bark (Enzogenol®) is obtained from Pinus radiata trees grown 
commercially in New Zealand. The New Zealand pine bark has gained interest in its potential 
hypoglycaemic effects, partly because of its close relation to Pcynogenol®, a French pine 
bark, which has been reported in in vitro and human studies to regulate and improve markers 
of glucose metabolism [66-68]. To date, no clinical study examining the impact of New 
Zealand pine bark on glycaemic response in humans has been conducted. Therefore, an acute, 
placebo-controlled, single-blind, crossover, dose-response, exploratory study (Pine Bark 
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study) has been designed to investigate its potential hypoglycaemic effects at low and high 
doses during an oral glucose tolerance test (OGTT) in healthy participants.  
1.3.3 Research Question 3 
Do extracts of grape seed, rooibos tea and olive leaf improve postprandial glycaemia in 
individuals with prediabetes? 
In previous work, the following plant extracts (grape seed, rooibos tea, amla berry, 
and green tea) have been shown to reduce postprandial blood glucose in healthy participants 
from between 20 to 40%, p<0.05, compared to control [69]. de Bock and colleagues (2013) 
conducted a 12-week study involving the consumption of olive leaf extract on overweight, 
middle-aged men, and they demonstrated improved insulin sensitivity and improved 
pancreatic function [70]. It has been proposed that the positive outcomes of grape seed, 
rooibos tea and olive leaf in improving glycaemic control could be translated to the 
prediabetes population in New Zealand. Hence, an acute, single-blind, placebo-controlled, 
crossover study (GLARE study) is designed to investigate whether these three plant extracts: 
grape seed, rooibos tea and olive leaf could improve postprandial blood glucose and insulin 
responses in participants with prediabetes.  
	  
1.3.4 Research Question 4 
What are the underlying hypoglycaemic mechanisms of these plant extracts on 
improving glucose homeostasis? 
The potential mechanism of action of plant extracts in controlling glucose metabolism 
is discussed in Chapter 2.6. The New Zealand pine bark, grape seed, rooibos tea and olive 
leaf extracts have been shown to influence glucose metabolism via different underlying 
mechanisms. However, studies on the enzyme inhibition of α-amylase and dipeptidyl-
peptidase-4 (DPP4) that are key enzymes for the regulation of postprandial glycaemia have 
been scarce and often subject to different assay methodologies resulting in varying study 
outcomes. Therefore the inhibition of the two aforementioned enzymes will be explored and 
their efficacy of inhibition compared amongst the extracts in order to gain insight into how 
New Zealand pine bark, grape seed, rooibos tea and olive leaf extracts can improve 
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Figure 1.1 Flow diagram of the PhD research work 
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1.4 Thesis structure 
This thesis follows the format of a PhD by publication. The thesis chapters are 
outlined below with identification of those chapters representing materials that have been 
published, submitted, or ready for submission for publication.  
Chapter 1 introduced the aims and objectives of the PhD study summarised into four 
research questions to be answered. It also provides the rationale and importance of the work 
presented in this thesis in the area of exploring nutritional alternatives for the prediabetes 
cohort in order to prevent or slow prediabetes progression to T2DM.  
Chapter 2 presents an overview of what prediabetes is and the criteria for diagnosis, 
followed by the discussion on the important role of antioxidant-rich plant extracts in 
glycaemic control. Evidence from in vitro and in vivo studies including human clinical trials 
involving plant extracts focusing on four identified plant extracts, namely the New Zealand 
pine bark, grape seed, rooibos tea and olive leaf, and their impact on glycaemic control, are 
extensively covered in this chapter. Research investigating the hypoglycaemic mechanisms of 
action of these extracts will also be discussed. 
Chapter 3 is an extension of the literature review and addresses Research Question 1. 
This chapter focuses on gathering clinical evidence on the hypoglycaemic impact of plant 
extracts in the prediabetes cohort. This chapter has been prepared as a narrative review for 
submission to the Critical Reviews in Food Science and Nutrition Journal. 
Chapter 4 presents the first results chapter and focuses on the hypoglycaemic 
potential of the New Zealand pine bark in healthy participants and addresses Research 
Question 2. This chapter is a published manuscript in Nutrients Journal on the Pine Bark 
study regarding the impact of the New Zealand pine bark (Enzogenol®) in healthy 
participants. 
Chapter 5 is the second results chapter examining the hypoglycaemic potential of 
three plant extracts: grape seed, rooibos tea and olive leaf in participants with prediabetes in 
the GLARE study and addresses Research Question 3. This study has been prepared as a 
manuscript for submission to The Journal of Nutrition. 
Chapter 6 is the third results chapter focusing on determining some of the underlying 
mechanistic actions of New Zealand pine bark, grape seed, rooibos, and olive leaf extracts on 
glycaemic control and addresses Research Question 4. This data has been prepared as a short 
communication manuscript for the Nutrients Journal. 
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Chapter 7 is the overall discussion and conclusion of the PhD study highlighting the 
main findings of the research. The strengths and limitations of the research and 
recommendations for future studies on prediabetes are discussed. 
The Appendices chapter contains the research outputs associated with this PhD study 
and other study protocol diagrams, templates of participant information sheet and consent 
forms of the Pine Bark study and the GLARE study, as well as other relevant information 
pertaining to the clinical trials. 
1.5 Researchers’ Contribution 
Table 1.1 outlines the contribution of researchers involved in this PhD study. 
 
Table 1.1 Contributions by each researcher involved in this PhD study 
Researchers  Contribution 
Wen Xin Janice Lim 
PhD researcher 
Responsible for all aspects of the two human 
clinical trials (Pine Bark study and the 
GLARE study) involving study design, 
human ethics application, participant 
recruitment, data collection, statistical 
analysis and interpretation of data 
 
Responsible for all aspects of the 
mechanistic study on the enzyme inhibition 
of plant extracts including sample 
preparation to be analysed by external lab 
(Callaghan Innovation), statistical analysis 
and interpretation of data 
 
Responsible for all aspects of the 
manuscripts involving conceptualisation and 
design of manuscripts, literature search, data 
extraction and analysis, drafting, editing and 
submission of manuscripts 
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Assoc Prof Rachel A. Page 
Primary supervisor 
Conceptualisation and design of the Pine 
Bark study and the GLARE study, 
acquisition of funding and human ethics 
approval, supervision of trials and reviewing 
of thesis and all manuscripts 
Dr Cheryl S. Gammon 
Co-supervisor 
Conceptualisation and design of the Pine 
Bark study and the GLARE study, 
supervision of trials, reviewing of thesis and 
all manuscripts 
Assoc Prof Pamela R von Hurst 
Co-supervisor 
Conceptualisation and design of the Pine 
Bark study and the GLARE study, 
acquisition of funding, supervision of trials 
and reviewing of thesis and all manuscripts 
Lynne Chepulis 
External Co-supervisor 
Conceptualisation and design of the Pine 
Bark study and the GLARE study, 
acquisition of funding, supervision of trials 
and reviewing of thesis and all manuscripts 
Owen Mugridge  
Research Trials Manager 
Participant recruitment and management, 
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Chapter 2  
Review of the literature 
	  
This chapter begins with an overview of prediabetes and its diagnosis criteria, followed by 
discussing the important role of antioxidant-rich plant extracts in glycaemic control, with 
special attention given to the New Zealand pine bark, grape seed, rooibos tea and olive leaf 
extracts, which are plant extracts that will be included in the two human clinical trials in this 













	   18	  
2.1 What is prediabetes? 
In normal healthy individuals blood glucose is strictly regulated to maintain glucose 
concentration between 3.9 and 5.6 mmol/L [5]. After a meal glucose is absorbed and blood 
glucose levels begin to increase. A rise in blood glucose stimulates insulin secretion that 
facilitates glucose uptake into the cells and blood glucose level returns to normal blood 
glucose concentration range after 1-3 h [7].  
However in prediabetes, the glucose homeostasis becomes increasingly disturbed, 
which leads to uncontrolled higher levels of blood glucose or an intermediate state of 
hyperglycaemia but not high enough to be diagnosed with T2DM [9]. As hyperglycaemia 
persists, prolonged excessive glucose in the bloodstream may start to induce oxidative stress 
that promotes the development of insulin resistance [5, 10-12]. However, with increasing 
insulin resistance individuals may still remain glucose tolerant if their pancreas is able to 
compensate with hypersecretion of insulin [13]. Nonetheless, as damage to β-cell function 
continues, the compensatory hyper-secretion of insulin is lost and T2DM gradually develops, 
giving rise to complications such as nerve damage (neuropathy), kidney damage 
(nephropathy) and eye disease (retinopathy, visual loss or blindness) [14, 15] and increasing 
the risk of developing cardiovascular disease (CVD) and hypertension [13, 16]. 
2.2 Prediabetes as a global health issue 
Individuals with prediabetes have a high risk for developing T2DM [6, 17, 18], with 
an annual conversion rate of 5-10% into T2DM [9, 19]. Eventually up to 70% of the people 
with prediabetes will develop T2DM [20]. Nonetheless, a recent statement by the American 
Diabetes Association (ADA) showed that an estimated two-thirds of people with prediabetes 
do not progress into T2DM, even after many years. Furthermore, approximately one-third of 
people with prediabetes return to normoglycaemia [21]. More research is required to 
understand the prevalence and pathogenesis of prediabetes developing into T2DM. 
Essentially, there exists a proportion of individuals with prediabetes progressing into T2DM 
if their suboptimal glycaemic condition is not managed, and hence is be an important area of 
research.  
Globally, 373.9 million adults (20-79 years) (7.5%) have been estimated to have 
impaired glucose tolerance (IGT) in 2019 [15]. This has been projected to increase to 548.4 
million (8.6%) by 2045. The regional prevalence is highest in North America and Caribbean 
(55.5 million, 12.3%), followed by Western Pacific (136.5 million, 10.4%), and Africa (45.3 
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million, 10.1%) [15]. With respect to countries, the highest prevalence of IGT is in China 
(54.5 million), followed by the United States of America (37.4 million), Indonesia (29.1 
million), and India (25.2 million) [15]. It is noteworthy that the estimates were based only on 
IGT measures, the most studied prediabetes subgroup.  
2.3 Prediabetes in New Zealand 
In New Zealand there are few statistics on the prevalence of prediabetes. A 2015 
Ministry of Health report estimated that 257,700 people have diabetes (6%), and that diabetes 
prevalence had been rising on average 7% annually for the past eight years [22]. The 2008/09 
adult nutrition survey reported that approximately 7% of the population as having diabetes 
and 25.5% of the population as having prediabetes [23]. However, the data from this survey 
is now quite old [23].  
2.3.1 Ethnicities in New Zealand and prediabetes 
The prevalence of both prediabetes and T2DM in New Zealand are higher in certain 
population groups. It has been estimated that 40% of people of Māori, Pacific and Indian 
ethnicity living in the Auckland metro region have prediabetes at 35-39 years and over 50% 
have prediabetes at 45-49 years of age [24]. Māori and Pacific people have been shown to 
have two to fourfold rates of T2DM as European New Zealanders [25]. Those with T2DM 
also tend to have poorer health outcomes such as poorer blood glucose, blood pressure and 
blood lipid control, leading to higher rates of diabetic complications such as nephropathy 
[25]. Robinson and colleagues (2006) highlighted that risk factors such as smoking, an 
HbA1c > 8% (64 mmol/mol), and having microalbuminuria in the Māori and Pacific 
community might have contributed to the development of diabetic complications [26]. 
Therefore more research and investment of resources should target the Māori and Pacific 
group, particularly with the involvement of family support being a vital part, as well as 
providing trustworthy sources of dietary information to more effectively manage prediabetes 
and T2DM in this group [27].  
2.3.2 Work in progress in New Zealand to improve glycaemic outcomes 
In recent decades prediabetes has been recognised as a stage vital for early 
intervention to prevent or delay T2DM development [28, 29]. In New Zealand, various 
initiatives by the government have been laid out. These include the Green Prescriptions and 
Healthy Families NZ programmes with a unique community approach to promote physical 
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activity and improve nutrition, as well as funding the Healthier Lives National Science 
Challenge to conduct research on slowing or halting the progression of T2DM [22]. These 
initiatives are aimed at increasing current levels of health literacy, support healthy living, and 
provide preventive measures against T2DM development. The Green Prescriptions has since 
received positive behavioural changes and improved health outcomes in participants who 
have taken part in the programme [30-34].  
2.4 Who may have prediabetes? 
Table 2.1 shows the diagnostic criteria for impaired glycaemic control based on 
established criteria by the World Health Organization (WHO) [15, 35, 36], the American 
Diabetes Association (ADA) [37, 38], and The New Zealand Society for the Study of 
Diabetes (NZSSD) [39]. The glycated haemoglobin A1c (HbA1c) is the recommended 
diagnostic screening test in New Zealand to identify individuals with prediabetes (HbA1c 41-
49 mmol/mol) in both clinical and research settings. Different countries may follow slightly 
different criteria for the identification of prediabetes, with for example the ADA using lower 
fasting blood glucose (FBG) of 5.6-6.9 mmol/L (100-125 mg/dL) and HbA1c level of 39-47 
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Table 2.1 Diagnostic criteria for impaired glycaemic control and T2DM 
Blood test Unit Normal IFG IGT IFG/IGT T2DM
†
 
World Health Organization (1999) 
Fasting blood 
glucose  
mmol/L <6.1 6.1-6.9 <7.0 6.1-6.9 ≥7.0 
mg/dL <110 110-125 <126 110-125 ≥126 








7.8-11.0 7.8-11.0 ≥11.1 
mg/dL <140 <140 140-199 140-199 ≥200 
 NA OR 
HbA1c 
mmol/mol Currently HbA1c is not considered a suitable 




American Diabetes Association (2010) 
Fasting blood 
glucose  
mmol/L <5.6 5.6-6.9 <5.6 5.6-6.9 ≥7.0 
mg/dL <100 100-125 <100 100-125 ≥126 




mmol/L <7.8 <11.1 7.8-11.0 7.8-11.0 ≥11.1 
mg/dL <140 <200 140-199 140-199 ≥200 
 OR 
HbA1c mmol/mol <39 39-47 ≥48 % <5.7 5.7-6.4 ≥6.5 
New Zealand Society for the Study of Diabetes (2012) 
Fasting blood 
glucose  
Recommended only if HbA1c measurement is not possible 
mmol/L ≤6.0 6.1-6.9 ≥7.0 
mg/dL ≤110 110-125 ≥126 




Recommended only if results from HbA1c is inconclusive for specific patients 
(e.g. presence of haemoglobinopathy or abnormal red cell turnover). Take 
fasting blood glucose prior to requesting an oral glucose tolerance test to 
confirm. 
mmol/L <7.8 7.8-11.0 ≥11.1 
mg/dL <140 140-199 ≥200 
 OR 
HbA1c mmol/mol ≤40 41-49 ≥50 % ≤5.8 5.9-6.6 ≥6.7 
* 2h postprandial glucose is determined by a standard 2h oral glucose tolerance test (OGTT) with 75 
g of carbohydrates. 
†
 A random plasma glucose ≥11.1 mmol/L (≥200 mg/dL) alone may be used to 
diagnose type 2 diabetes mellitus (T2DM) according to American Diabetes Association (ADA) and 
The New Zealand Society for the Study of Diabetes NZSSD guidelines. ‡ A glycated haemoglobin 
A1c (HbA1c) value of less than 6.5% does not exclude diabetes diagnosed using glucose tests. NA: 
not applicable. 
 
Glycated haemoglobin A1c was introduced in NZ as diagnostic criteria for diabetes 
and prediabetes in 2012. Prior to that, IFG and IGT were the measurements used for 
diagnosis of T2DM and impaired glycaemic control. The impaired glycaemia measured by 
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IFG, IGT and combined IFG/IGT represent different glycaemic pathophysiological 
abnormalities [40, 41]. Individuals with IGT have more muscle insulin resistance and mild 
hepatic insulin resistance, in contrast to those with IFG having increased hepatic insulin 
resistance but near normal muscle insulin sensitivity [42, 43] (Table 2.2). The combination 
of IFG and IGT marks a more advanced disturbance of glycaemic homeostasis with the 
inclusion of glycaemic abnormalities observed in both IFG and IGT [44-48].  
 
Table 2.2 Pathophysiological differences between IFG and IGT 
Differences between IFG and IGT 
IFG IGT 
Increased hepatic insulin resistance Increased muscle insulin resistance 
Normal or near to normal muscle insulin 
sensitivity 
Normal or near to normal hepatic insulin 
sensitivity 
Elevated fasting blood glucose Normal or near to normal fasting blood glucose 
Reduced early-phase insulin secretion 
during oral glucose tolerance test (0-30 min) 
Reduced early-phase insulin secretion 
during oral glucose tolerance test (0-30 min) 
Normal or near to normal late-phase insulin 
secretion during oral glucose tolerance test 
(60-120 min) 
Impaired late-phase insulin secretion during 
oral glucose tolerance test (60-120 min) 
Normal or near to normal fall in 
postprandial blood glucose Sustained rise in postprandial blood glucose 
Adapted from [42, 43]. 
 
Screening individuals for prediabetes is important as it provides the opportunity to 
begin early treatment. Table 2.3 shows the New Zealand Guidelines for screening of 
individuals at risk of diabetes. Having certain risk factors can put individuals at a higher risk 
of developing T2DM and so it is important that they should be screened to detect for the 
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Table 2.3 New Zealand Guidelines for screening of individuals at risk of diabetes  
1. Adults over 25 years of age who has one or more of the following risk 
factors: 
• Have known ischaemic heart (angina or myocardial infarction, 
cerebrovascular or peripheral vascular disease) 
• Are on long-term steroid or antipsychotic treatment 
• Are obese (body mass index (BMI) ≥30 kg/m2, or ≥27 kg/m2 in Indo-Asian*) 
• Have a family history of early age onset T2DM in more than one first-degree 
relative 
• Are women with past history of gestational diabetes mellitus (GDM) 
• Women with polycystic ovary syndrome 
2. Obese children and young adults (BMI ≥30 kg/m2, or ≥27 kg/m2 in Indo-
Asian) who has one or more of the following risk factors: 
• Have a family history of early age onset T2DM, e.g. < 40 years 
• Are of Maori, Pacific or Indo-Asian* ethnicity 
*Indo-Asian includes Indian, Fijian Indian, Sri Lankan, Afghani, Bangladeshi, Nepalese, 
Pakistani, and Tibetan. Adapted from [39, 49]. 
 
 
2.4.1 Who else may have an increased risk of developing T2DM? 
Both healthy, normoglycaemic individuals as well as individuals with prediabetes 
may eventually develop T2DM [19, 50-53] depending on their existing patterns of 
postprandial glucose shapes [54-60], postprandial glucose measures [55, 61-65], and patterns 
of insulin levels [66-68] indicating the varying degrees of risk towards T2DM. This is 
because the progress from normoglycaemia towards hyperglycaemia is often a heterogeneous 
continuum [19, 41, 50, 52, 69, 70], and responses to intervention may thus differ depending 
on individual metabolic profiles.  
Research is still uncovering the possible reasons why different metabolic profiles, for 
example, different postprandial glucose curve shapes (monophasic, biphasic and triphasic), 
could elucidate alterations in glucose metabolism. In healthy, normoglycaemic individuals, 
who are also more likely to exhibit biphasic and triphasic glucose curve shapes (also known 
as complex shapes), postprandial glucose tends to follow an oscillating pattern that is 
synchronised with the oscillations of insulin responses, suppression of endogenous glucose 
production, as well as insulin-stimulated glucose disposal and absorption that is influenced by 
rate of gastric emptying [54, 71]. Studies have elucidated that early insulin responses 
associated with insulin hypersensitivity may play a part in biphasic glucose curve shapes [58, 
60]. Furthermore, Kaga and colleagues (2020) demonstrated that better insulin clearance in 
biphasic glucose curve shapes might have led to a second rise in glucose levels after reaching 
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nadir in order to prevent hypoglycaemia, signifying higher muscle insulin sensitivity [56].  
This observation was in agreement with other researchers who explained that internal body 
impulse responses of the hepatic and renal endogenous glucose releases, also named 
endogenous excitations, were present to regulate the dynamic behaviour of blood glucose 
concentrations during an OGTT until blood level returned to basal value [59].  
It has been suggested that it might be due to the over-compensation of insulin 
secretion during meal times, however due to insulin resistance in individuals with 
monophasic glucose curve shapes, the blood glucose remains higher than normal (hence only 
having one glucose peak) [57]. Other factors such as impairment in the ultradian and 
circadian oscillation cycles, as well as depressed pulsatility of insulin secretion in the insulin-
glucose regulation system serving as an indication of reduced β-cell function that may also 
give rise to the monophasic shape [57]. Kim and colleagues (2016) postulated that the 
inadequate suppression of glucagon secretion resulting in higher endogenous glucose 
production would have contributed to the monophasic shape, whilst incretin and pancreatic 
hormones had no significant impact [55]. Due to the sub-optimal insulin and glucagon 
responses leading to higher postprandial glucose in monophasic shapes, it is undoubtedly 
indicative of increased risk for development of T2DM [54-59], and therefore an area of 
research for interventions.  
Therefore, due to this difference in pathophysiology of glycaemic metabolic profiles 
in each individual, it is likely that individuals with different metabolic profiles will respond 
differently to a given intervention. More recent human studies looking at interventions with 
food products/ plant extracts have begun stratifying participants based on their degree of 
glucose metabolic profiles to achieve better intervention outcome in glucose responses [72-
74]. Therefore, stratification of participants into their respective subgroups based on their 
glycaemic patterns and responses were therefore carried out as a form of secondary 
exploratory analysis in both human clinical trials performed in this PhD study: Pine Bark 
study (Chapter 4) and the GLARE: Glucose Lowering Antioxidant-Rich plant Extracts study 
(Chapter 5) to determine effectiveness of intervention. The narrative review (Chapter 3) will 
also elucidate the relevance of subgrouping based on different metabolic profiles of 
individuals for a more targeted treatment to improve glycaemic control. 
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2.5 Plant extract polyphenols and their health benefits 
2.5.1 What are plant polyphenols? 
Plant polyphenols are divided into flavonoids that include anthocyanidins, and several 
classes of non-flavonoids: phenolic acids, stilbenes, and lignans [3]. Over 8000 polyphenols 
have been identified and are present in fruit and beverages such as fruit juice, wine, tea, 
coffee, chocolate and beer, and to a lesser extent vegetables, dry legumes, and cereals [75, 
76]. A typical total intake could amount up to 1 g/day [77]. Polyphenols are ubiquitously 
present in plant foods, thus partly explaining the good health effects of consuming vegetables 
and fruits or polyphenol-rich foods that are characteristic of a Mediterranean diet [78-81].  
2.5.2 Hypoglycaemic potential of plant extracts on human health 
Phenolic compounds from antioxidant-rich dietary sources such as edible plant 
extracts have attracted a great deal of attention for the past two decades due to the increasing 
evidence regarding their beneficial effect on human health in the prevention of metabolic 
diseases such as diabetes, cardiovascular diseases, neurodegenerative diseases and cancer 
[82-85]. Extracts from plant sources may be taken from different parts of the plant such as the 
root, stem, leaf, flower or fruit [86].  
Consumers are also increasingly becoming more receptive towards the use of natural 
health products derived from plants containing high levels of polyphenols for the treatment of 
chronic health conditions including T2DM [87]. A 2018 comprehensive dose-response meta-
analyses and systematic review of 18 prospective cohort studies has corroborated that higher 
amounts of polyphenol intake is associated with the lowest risk of T2DM [84]. The study 
concluded that an inverse association existed between polyphenols such as flavonoids, 
flavonols, flavan-3-ols, catechins, anthocyanidins, isoflavones, daizdzein, genistein, and 
stilbenes and T2DM [84].  
Meta-analyses and systematic reviews of commonly consumed phenolic-rich plant 
sources such as teas, coffees and chocolates have revealed the importance of a diet rich in 
polyphenols in managing T2DM risk [88-91]. Study outcomes showed that drinking more 
than 3 cups of tea a day has been associated with a reduction in T2DM risk [88, 89]. 
Similarly, every cup-per-day increase in coffee consumption was associated with a 6% 
reduction in T2DM risk [90]. However, there is much less certainty regarding chocolate 
consumption and reduction in T2DM risk [91]. 
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To further elaborate on a few examples of extensively studied plant extracts and their 
impact on glycaemic control and T2DM, green tea has been one of the more extensively 
studied plant-derived dietary sources of polyphenols. The high concentrations of flavonols 
such as epigallocatechin-3-gallate (EGCG) might have contributed to the health-promoting 
effects of green tea on diabetes, including obesity and CVD [92]. Meta-analysis conducted by 
Liu and co-workers (2013) examining 17 chronic randomised controlled trials (RCTs) in 
healthy, obese participants, those with T2DM, and only with two studies on prediabetes, 
concluded that green tea was able to improve glycaemic control and insulin sensitivity with 
significant reductions in FBG, fasting insulin (FI) and HbA1c [93]. A meta-analysis 
conducted by Zheng and colleagues (2013) examining the impact of green tea consumption in 
22 chronic RCTs in participants who were healthy, obese, having metabolic syndrome or 
T2DM, and only one study on prediabetes showed FBG improvement as well [94]. However, 
Wang and colleagues (2014) in a meta-analysis of seven chronic RCTs showed no significant 
improvement in glycaemic parameters such as FBG, FI, 2hPG, HbA1c and homeostatic 
model assessment: insulin resistance (HOMA-IR) in populations at risk of T2DM with 
prolonged green tea consumption [95].  
 In other studies coffee and coffee polyphenol extract have also been shown to 
increase insulin secretion, raise GLP-1 response, and improve glycaemic control in humans, 
of which chlorogenic acid is a major component of coffee [96-99].  
Cinnamon, which is a widely available and utilised spice, has also been increasingly 
known for its hypoglycaemic effects, which have been largely attributed to its active 
component cinnamaldehyde [100, 101]. A recent meta-analysis consisting of 16 RCTs on 
cinnamon elucidated favourable changes on FBG and HOMA-IR in participants with 
prediabetes but mostly were with T2DM [102]. Another spice derivative, curcumin, a 
phenolic compound found in turmeric, has been shown to have glucose-lowering and insulin 
sensitising effects for T2DM treatment [103, 104].  
However to date, most of the human studies investigating the impact of phenolic-rich 
plant sources on improving glycaemic control have largely focused on healthy or obese 
participants, and mostly on the T2DM and metabolic syndrome cohorts. 
2.5.3 Hypoglycaemic potential of plant extracts on prediabetes 
There have been fewer human studies done to examine the impact of antioxidant-rich 
plant sources on prediabetes compared to T2DM. Longer-term, chronic studies on glucose 
and insulin responses have been conducted to date with spices [73, 105, 106], seeds [107], tea 
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beverages [108-110], pure bioactive components from plants [74, 111], fruits and fruit 
components [112-115], plants and their parts [116, 117], combined mixture of polyphenols, 
plant extracts and other nutrients [118-124], and traditional Chinese medicine [125, 126]. 
Chapter 3 is a narrative review that focuses on RCTs performed in the prediabetes cohort 
examining hypoglycaemic impact of plant extracts more similar in nature to the extracts 
examined in this PhD study. 
A clear benefit of using antioxidant-rich plants or plant extracts to improve glycaemic 
control is there is minimal to no adverse effects as observed with anti-diabetic drug therapy 
[1, 127]. Figure 2.1 shows how anti-diabetic drugs treat hyperglycaemia via different modes 
of actions in the body but are associated with various adverse effects. Currently there is a lack 
of clinical evidence regarding the chronic benefits of plant extracts on glycaemic control, 
including gaps in our understanding regarding potential drug-herb interactions, and 
interaction with food proteins during consumption would influence the efficacy and 
pharmacokinetics of the plant extracts on glucose metabolism [6, 75, 83, 128-130]. 
Pancreas 
Impaired insulin 
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Multifaceted channels of anti-diabetic drugs to improve glycaemic control in prediabetes and diabetes [1] 
    Specific side effects of the drug: 
Gastrointestinal adverse effects  Increased hypoglycaemia risk  Weight gain  Weight gain and hypoglycaemia       Increased pancreatitis risk 
Dizziness, nausea and fatigue              Possible genital and urinary tract infections, osmotic diuresis, hypotension and falls, diabetic ketoacidosis 
	   	   	  
	  	  
	  
ê Hyperglycaemia and possibly reduce metabolic disease risk?	  
Figure 2.1 Sites of action of anti-diabetic drugs and their associated potential adverse effects 
28 
AMPK: 5’ adenosine monophosphate-activated protein kinase; DPP4: dipeptidyl-peptidase-4 enzyme; GLP-1: glucagon-like peptide-1; KATP channel: adenosine triphosphate-sensitive potassium 
channel; SGLT2: sodium-dependent glucose co-transporter-2; SUR1: sulfonylurea receptor-1; PPAR-γ: peroxisome proliferator-activated receptor-gamma 
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2.6 The plant extracts examined in the PhD study 
Even though there have been many animal and human studies investigating the 
hypoglycaemic potential of plant extracts [131], the aim of this PhD study was to identify 
suitable plant extracts easily accessible in New Zealand that have not been investigated for 
their hypoglycaemic potential in the prediabetes cohort. Therefore, four plant extracts, 
namely the New Zealand pine bark, grape seed, rooibos tea, and olive leaf, have been 
selected to examine their impact on glycaemic control in humans. To date, no studies have 
been done to investigate the impact of the New Zealand pine bark on glycaemic control. 
There have also been no prior studies conducted examining acute glycaemic responses on 
individuals with prediabetes for grape seed, rooibos tea and olive leaf extracts. The GLARE 
study (Chapter 5) is a continuation of the previous work conducted by this research group 
that grape seed and rooibos tea significantly reduced postprandial blood glucose in healthy 
participants compared to control [132]. de Bock and colleagues (2013) also demonstrated 
improved insulin sensitivity and improved pancreatic function after 12 weeks of olive leaf 
consumption in cohort of obese men [133]. It is therefore hypothesised that grape seed, 
rooibos tea and olive leaf may have the potential to also improve glycaemic control in 
individuals with prediabetes. 
This section provides the background of all four extracts for the designing of the 
human clinical trials: Pine Bark study and the GLARE study. Most of the studies are chronic 
studies spanning one week to six months. Improvements observed in both the acute and 
chronic studies were in the outcome measurements of glucose metabolism, such as HbA1c, 
FBG, FI, and insulin sensitivity. Some studies also showed improvements in inflammation 
and oxidative stress [133, 134]. The studies were mainly conducted on individuals who were 
healthy, diagnosed with T2DM, or having metabolic syndrome risk factors, obese or 
overweight (Table 2.4). 
As whole plant extracts may elucidate more hypoglycaemic effects than their 
individual bioactive fractions [135-144], the extracts investigated in the PhD work, namely 
the New Zealand pine bark, grape seed, rooibos tea and olive leaf were whole extracts 
comprising a range of naturally occurring phenolic compounds. 
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Table 2.4 Human clinical studies to date that have investigated the hypoglycaemic effects of the plant extracts examined in the PhD study 
Plant extract Study (Type, duration) Dosage Participants Significant hypoglycaemic outcome 
Pine bark extract 
Pine bark extract 
(Pycnogenol, French 




study, 8 weeks. A further 
60 days for open design 
study (n=20) 
300 mg/day 
Venous insufficiency, n=40 
(n=10 placebo, n=30 
pycnogenol) 
No significant change in FBG 
Pine bark extract 
(Pycnogenol, French 
maritime pine bark) [146] 
RCT, double-blind, 
placebo-controlled, parallel 
study, 8 weeks. A further 
60 days for open design 
study (n=20) 
150 mg/day 
Vascular retinopathy, n=40 
(n=10 placebo, n=30 
pycnogenol) 
êFBG 
Pine bark extract (New 
Zealand pine bark, Pinus 
radiata) with added 
vitamin C [147] 
Open-labelled, 
uncontrolled, pilot study, 
12 weeks 
480 mg of flavonoid extract 
and 240 mg vitamin C/day Healthy, n=24 No significant change in FBG 
Pine bark extract 
(Pycnogenol, French 
maritime pine bark) [148] 
RCT, double-blind, 
placebo-controlled, parallel, 
multi-centre study, 12 
weeks 
100 mg/day T2DM, n=77 (n=34 treatment, n=43 placebo) 
êFBG  
êHbA1c (first month only)	  
Pine bark extract 
(Pycnogenol, French 
maritime pine bark) [149]  
Open, controlled, dose-
response, crossover study, 
12 weeks (each dose for 3 
weeks) 
50, 100, 200, 300 mg/day T2DM, n=30 
êFBG, but 300 mg no greater effect 
ê2hPG, but 300 mg no greater effect 
êHbA1c at 9 and 12 week 
No significant changes in insulin levels	  
Pine bark extract 
(Pycnogenol, French 
maritime pine bark) [150] 
Controlled, parallel study, 4 
weeks 150 mg/day 
Severe diabetic 
microangiopathy, n=30 
(n=16 placebo, n=14 
Pycnogenol) 
No significant change in FBG and HbA1c 
Pine bark extract 
(Pycnogenol, French 
maritime pine bark) [151] 
RCT, double-blind, 
placebo-controlled and 
active drug, parallel study, 
2 weeks 
180 mg/day Healthy, n=16 (n=8 in each group) No significant change in FBG 
Pine bark extract 
(Pycnogenol, French 




study, 12 weeks 
125 mg/day 
T2DM and mild to 
moderate hypertensive, 
n=48 (n=24 in each group) 
êFBG and HbA1c	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Pine bark extract 
(Pycnogenol, French 
maritime pine bark) [153] 
Double-blind, placebo-
controlled, matched-pair 
design study, 12 weeks 
150 mg/day Healthy elderly, n=101 No significant change in FBG 




study, 12 weeks 
200 mg/day 
Overweight and obese, 
n=130 (n=64 treatment, 
n=66 placebo) 
No significant changes in insulin and FBG 
Pine bark extract 
(Pycnogenol, French 
maritime pine bark) [155] 
RCT, double-blind, 
placebo-controlled, 
crossover study, 8 weeks 
200 mg/day Coronary heart disease, n=23 No significant change in FBG 
Pine bark extract 
(Pycnogenol, French 
maritime pine bark) [156] 
Open, controlled, parallel 
study, 6 months 150 mg/day 
Metabolic syndrome, 
n=130 (n=64 treatment, 
n=66 placebo) 
êFBG	  
Pine bark extract 
(Pycnogenol, French 
maritime pine bark) [157] 
Controlled, parallel study, 8 
weeks 100 mg/day 
Peri-menopausal women 
with CVD risk factors, 
n=70 (n=35 in each group) 
êFBG	  
Grape seed extract 
Grape seed extract [158] 
 
RCT, single-blind, placebo-
controlled, parallel study, 
12 weeks 
200 mg/day or 400 mg/day 
(total procyanidins in grape 
seed extract) 
Healthy, n=53 (n=18 in 
placebo and 200 mg/day, 
n=17 for 400 mg/day) 
No significant change in FBG and HbA1c 
Grape seed extract [159] RCT, placebo-controlled, crossover study, 4 weeks 600 mg/day 
High-risk CVD with 
T2DM, n=32 
êFructosamine 
No significant changes in FBG 
No significant change in HOMA-IR 
Grape seed extract [160] 
RCT, double-blind, 
placebo-controlled, parallel 
study, 4 weeks 
150 mg or 300 mg/day 
(Meganatural BP) 
Metabolic syndrome, n=27 
(n=9 in each group) No significant change in FBG and FI 
Grape seed extract [161] 
RCT, double-blind, 
placebo-controlled, 
crossover study, 4 weeks 
1300 mg/day (Nature’s 
Pearl muscadine grape 
seed, Vitis rotundifolia) 
Metabolic syndrome, n=50 No significant change in FBG 
Grape seed extract [162] 
RCT, double-blind, 
placebo-controlled, parallel 
study, 8 weeks 
200 mg/day T2DM, n=48 (n=26 treatment, n=22 placebo) No significant change in FBG and HbA1c 
Grape seed extract [163] 
RCT, double-blind, 
placebo-controlled, parallel 
study, 8 weeks 
300 mg/day (Meganatural 
BP) 
Pre-hypertensive, n=32 
(n=16 in each group) No significant change in FBG 
Grape seed extract [164] 
RCT, placebo-controlled, 
crossover, acute study, 6h 
OGTT (high fat-
carbohydrate meal, 670 
kcal) 
300 mg Metabolic syndrome, n=12 êiAUC glucose  No significant change in AUC insulin	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Grape seed extract [165] 
RCT, controlled, crossover, 
acute study, 2h OGTT 
(high carbohydrate meal, 
92 g carbohydrates) 
100, 300 mg Healthy, n=8  
ê2hPG	  
êiAUC glucose and AUC glucose	  
Grape seed extract 
beverage [166] 
RCT, placebo-controlled 
study, parallel, 6 weeks, 4 
week follow-up 
300 mg/day (juice) 
 
Pre-hypertensive, n=29 
(n=17 in placebo, n=12 in 
grape seed extract) 
No significant change in FI and HOMA-IR  
No significant change in FBG	  
Grape seed extract [132] 
RCT, crossover, acute 
study, 2h OGTT (Study 1: 
oral glucose, 50 g 
carbohydrates; study 2: 
simple meal with white 
bread and ham, 50 g 
carbohydrates) 
500 mg Healthy, n=10 êiAUC glucose	  
Rooibos tea extract 
Rooibos tea extract [167] 
Non-randomised, 
controlled, crossover study, 
6 weeks 
6 cups of rooibos tea/day (1 
cup constitutes 1 tea bag 
(Rooibos Ltd.) with 200 
mL boiled water) 
Healthy but with at least 
two or more CVD risk 
factors, n=40 
No significant change in FBG 
 
 
Rooibos tea extract [132] 
 
RCT, controlled, crossover, 
acute study, 2h OGTT 
(Study 1: oral glucose with 
50 g carbohydrates; study 
2: simple meal with white 
bread and ham, 50 g 
carbohydrates) 
760 mg Healthy, n=10 êiAUC glucose	  
Olive leaf extract 
Olive leaf extract [168]  
Exploratory, crossover, 
acute study, 3h OGTT 
(300g of cooked rice) 
1000 mg olive leaves 
Healthy, n=7, 
borderline diabetic, n=7 
(FBG: 6.1-7.8 mmol/L) 
êPG at 30min and 1h (p<0.05) in borderline 
diabetic participants 
 
No significant changes in healthy, 
normoglycaemic participants 
Olive leaf extract [169] 
RCT, open, placebo-
controlled, two-arm 
parallel, co-twin study, 8 
weeks 
500 mg/day or 1000 
mg/day (EFLA 943) 
Borderline hypertensive 
monozygotic twins, n=40 
(n=10 in each group) 
No significant change in FBG 
Olive leaf extract [170] RCT, placebo-controlled, parallel study, 14 weeks 500 mg/day 
T2DM, n=79 (n=41 
treatment, n=38 placebo) 
êHbA1c	  
êFI 
No significant changes in PI and glucose levels 
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crossover study, 12 weeks 
(OGTT, 75 g carbohydrates 
for postprandial 
measurement) 
Olive leaf extract (51.1 mg 






éinsulin sensitivity (Matsuda index) 
édisposition index	  
épancreatic β-cell secretory capacity	  
Olive leaf extract [171] 
RCT, double-blind, 
placebo-controlled, 
crossover study, 6 weeks 
500 mg olive leaf extract, 
100 mg green coffee bean 
extract, 150 mg beet 
powder (per capsule)/day 
Adults with untreated high 
normal or borderline 
elevated BP, n=37 
No significant change in FBG, insulin and 
HOMA-IR 
Olive leaf extract [172] 
RCT, double-blind, 
placebo-controlled, 
crossover study, 6 weeks 





No significant change in FBG, insulin, 
HOMA-IR, QUICKI and fructosamine 
Olive leaf extract [173] 
8 acute studies conducted: 
 




Study 3: RCT, controlled, 
crossover study  
 
Studies 4-8: RCT, 
controlled, crossover study 
 
1 and 2: 500 mg olive leaf 
extract in capsule (100 mg 
of oleuropein), or 1000 mg 
olive leaf extract (200 mg 
oleuropein) with 109 g of 
bread (50 g carbohydrates) 
 
Study 3: 100 g de-pitted 
olives (35 mg oleuropein) 
with 109 g bread (50 g 
carbohydrates) 
 
4-7: 125 mg olive leaf 
extract (50 mg oleuropein) 
in water either with white 
or wholemeal bread, 
glucose or sucrose (50 g 
carbohydrates) 
 
Study 8: 0.4 g of OLE (160 




1 and 2: n=24 
 
Study 3: n=16 
 
Studies 4-8: n=10 
Consumption of olive leaf extract in capsules 
with white bread did not influence PG over  
3 h 
 
Consumption of olives, or olive leaf extract in 
solution, with white or wholemeal bread also 
produced no significant changes in PG 
 
Higher doses of olive leaf extract with 25 g 
sucrose consumption êPG peak and iAUC 
glucose 
Olive leaf extract [174] 
RCT, double-blind, 
placebo-controlled, 
crossover pilot study, 1 
week (OGTT, 25 g sucrose 
solution)  
150 mg oleuropein/day Healthy women, n=11 No significant changes in postprandial Glcmax, time to reach Glcmax, and iAUC sucrose 
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AUC glucose: area under the curve of glucose; AUC insulin: area under the curve of insulin; BP: blood pressure; CVD: cardiovascular disease; FBG: fasting blood glucose; 
FI: fasting insulin; Glcmax: glucose maximum concentration; HbA1c: glycated haemoglobin A1c; HOMA-IR: homeostatic model assessment of insulin resistance; iAUC 
glucose: incremental area under the curve of glucose; iAUC sucrose: incremental area under the curve of sucrose; PG: postprandial glucose; PI: postprandial insulin; QUICKI: 
quantitative insulin sensitivity check index; RCT: randomised controlled trial; T2DM: type 2 diabetes mellitus; 2hPG: 2h postprandial glucose; êmeans a decrease in value in 
the clinical outcome 
 
 
Olive leaf extract [175] 
 
RCT, parallel study, 12 
weeks 
 
330 mL of olive leaf tea 3 
times/day 
 
Prediabetes, n=57 (n=28 in 
olive leaf tea group, n=29 
in low olive leaf tea group) 
 
êFBG in higher olive leaf tea dose 
No significant change in HbA1c, FI, and 
HOMA-IR	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2.6.1 New Zealand pine bark extract 
Pine bark extract has stimulated much interest in its potential health benefits, and 
more recently in its hypoglycaemic properties in those with impaired glucose metabolism and 
diabetic complications such as microangiopathy and retinopathy [176, 177].  
However, most of the research has been done on French maritime pine bark, also 
known as Pycnogenol, which is produced from the outer bark of Pinus pinaster Ait. Subsp. 
Atlantica growing in the Southwest coastal region in France [178], standardised to contain 
approximately 70% of procyanidins, [179]. Clinical studies to date on pine bark extract were 
chronic trials spanning from two weeks to six months, with doses from 50 to 480 mg/day 
(Table 2.4). Studies focusing on T2DM indicated significant improvements in glycaemic 
control [148, 149, 152], whereas other studies with other chronic conditions showing mixed 
hypoglycaemic responses with pine bark extract consumption [145-147, 150, 151, 153-157].  
The New Zealand pine bark extract (Enzogenol®), is produced from Pinus radiata trees 
grown in New Zealand by a water-based extraction [180, 181]. The dry powder contains 
greater than 80% proanthocyanidins, 1–2% taxifolin, other flavonoids and phenolic acids, 
and some carbohydrates [181]. The proanthocyanidin content in the New Zealand pine bark 
was also shown to be even higher than Pcynogenol® [179]. Only three in vivo studies (mouse 
model and two human studies) to date have been conducted specifically on the New Zealand 
pine bark obtained from Pinus radiata trees and its impact on glycaemia, CVD risk factors 
and inflammation [147, 182, 183]. In the mouse model fed with the New Zealand pine bark 
significant improvements in diabetes-related biomarkers with a reduction in HbA1c, insulin, 
and glucagon levels, and an elevation of hepatic AMP-activated protein kinase (AMPK) 
activity were observed [182].  In the pilot study conducted by Shand et al. (2003) with 
healthy older participants beneficial effects on a range of CVD risk factor endpoints 
including reductions in weight and blood pressure (BP) were shown [147]. A further study 
done by Young et al. (2005) on the impact of the New Zealand pine bark on endothelial 
function and inflammation concluded no significant changes to glucose levels in chronic 
smokers after 12 weeks, although there was significant reduction in oxidative stress [183]. 
However, in both studies vitamin C was added in the mixture together with pine bark (480 
mg/day) as part of the intervention, hence study outcome benefits could not be attributed 
solely to pine bark [147, 183]. More clinical research in humans is warranted to see if pure 
extracts of the New Zealand pine bark have hypoglycaemic effects on glycaemia. 
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2.6.2 Grape seed extract 
The grape seed extract is isolated from the seeds of white grapes, Vitis vinifera, in the 
Southwest of France [184]. Research has shown the health beneficial effects of grape seed 
extract on diabetes [185] and cardiovascular conditions [186]. Studies looking at grape by-
products reported that the seeds particularly contained high amounts of phenolics, compared 
to stems or pomace (seed and skin) [187, 188]. Flavonoids such as procyanidins, also known 
as proanthocyanidins or condensed tannins, are the main bioactive components found in 
grape seed extract [184, 189]. Various reviews have elucidated proanthocyanidins as 
modulators of glucose metabolism [190-192]. 
Grape seed extract has been more extensively studied compared to the other extracts 
(Table 2.4). Studies comprised of both acute and chronic trials spanning four to 12 weeks, 
with doses from 150 to 1300 mg/day for chronic trials and 100 to 500 mg for acute trials. 
Some studies reported significant reductions in postprandial glucose (PG) in healthy 
individuals and those with metabolic syndrome [132, 164, 165], whilst other studies on 
healthy participants and those with T2DM or metabolic syndrome did not show similar 
effects [158-163, 166]. The hypoglycaemic potential of grape seed has yet to be explored in 
people with prediabetes.  
2.6.3 Rooibos tea extract 
Rooibos, also known as Aspalathus linearis, or redbush, contains a rich source of 
glycosylated polyphenols, which have been shown to have potential benefit in diabetic 
conditions from studies conducted in vitro [193, 194] (Table 2.4). Rooibos tea is a caffeine-
free beverage containing low amounts of tannins but is polyphenol-rich, generally including 
C-glucosyl dihydrochalcones (aspalathin and nothofagin), phenylpropenoids (phenylpyruvic 
acid-2-O-glucoside), C-glycosyl-containing flavones (isoorientin and orientin) and flavonols 
(quercetin-3-O-robinobioside) [142, 193]. Rooibos tea that is not fermented (green) has been 
demonstrated to contain three times the total phenolic content than the fermented extract 
[193], of which is also used in the GLARE study (Chapter 5).  
To date, only one human clinical study has been conducted to examine the acute 
effects of unfermented rooibos tea on postprandial blood glucose as the primary outcome. 
Chepulis et al. (2016) showed that the consumption of rooibos tea extract significantly 
reduced postprandial blood glucose by approximately 34% in healthy individuals [132]. This 
gives an indication that rooibos tea extract could potentially alleviate poor glycaemic control 
in prediabetes. Other clinical studies relating to comorbidities of diabetes looked at the 
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consumption of rooibos tea and reductions in angiotensin-converting enzyme activity [195], 
improvements in markers for blood lipid levels and oxidative stress [167], and also increased 
antioxidant capacity in healthy humans [196]. Clinical research is required to determine the 
glucose modulating effects of unfermented green rooibos tea extract for people with 
prediabetes. 
2.6.4 Olive leaf extract 
Olive leaf obtained from the olive tree (Olea europaea L.) has been consumed in the 
Mediterranean region as a form of traditional herbal tea [197]. Phenolic compounds from 
olive leaf have been known to be high in antioxidant activity [143, 187]. The most abundant 
bioactive components in olive leaf is the secoiridoid compound oleuropein, followed by 
hydroxytyrosol, apigenin-7-glucoside and luteolin-7-glucoside, and verbascoside [198-200] 
and the compositions change with maturation or processing [201]. Lately, olive leaf has been 
implicated in improving metabolic syndrome risk factors [136], ameliorating high blood 
pressure [172, 202], improving lipid metabolism [203], and appears to possess cardio-
protective [204], anti-inflammatory effects [143], and hypoglycaemic benefits [136]. 
Chronic studies on olive leaf extract spanned from one to 14 weeks, with doses 60 to 
1000 mg/day (Table 2.4). Acute studies used doses of between 125 and 1000 mg along with 
oral glucose tolerance test (OGTT). Various forms of olive leaf extract were tested, mainly in 
capsules [133, 169-171, 173] but also in the form of liquid [172] and tea [175], as well as 
with real olive fruit [173]. Some trials with diabetic, hypertensive and overweight individuals 
demonstrated significant improvements in either fasting or postprandial glycaemic responses 
such as insulin sensitivity, β-cell function, 2hPG, HbA1c, FI, and FBG [133, 168, 170, 175]. 
However, other studies conducted in individuals with metabolic syndrome, in particular 
hypertensive individuals, did not demonstrate significant improvement in glucose response 
and insulin sensitivity with olive leaf extract, likely because their primary endpoint was blood 
pressure [169, 171, 172].  
There have been two studies examining effect of olive leaf extract in a prediabetes 
cohort and a group that may have included participants with T2DM and prediabetes [168, 
175]. Araki and colleagues (2019) conducted a 12-week study where participants were given 
olive leaf extract, but in the form of a tea beverage [175]. They showed that the higher dose 
of olive leaf tea significantly reduced FBG but not HbA1c, FI and HOMA-IR [175]. This 
study was reported since the GLARE study was completed. An earlier study by Komaki and 
co-workers (2003) investigated the anti-α-amylase components of olive leaf extract [168]. 
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They also conducted a small, acute study in 14 healthy participants who consumed 1000 mg 
of olive leaves with 300 g of cooked rice to examine potential α-amylase inhibition in 
humans [168]. In a subgroup analysis the study outcome showed that participants in the 
borderline diabetic group (n=7; FBG of 6.1-7.8 mmol/L) demonstrated a significant reduction 
in PG [168]. However, the greater range used to define the borderline diabetic group means 
that whilst some participants could have had prediabetes others were likely to have T2DM. 
2.7 Hypoglycaemic mechanisms of action of plant extracts 
In the last decade, focus has begun to shift towards more complex biological modes of 
action of plant extract polyphenols in the body, such as their ability to improve glucose 
metabolism via modulating different metabolic pathways such as glycolysis, Krebs cycle, 
gluconeogenesis and carbohydrate metabolism [7, 86, 128, 139, 190, 205-211]. Different 
mechanisms of action exhibited by plant extracts to improve postprandial glycaemia include 
inhibiting hepatic gluconeogenesis and suppressing glucagon release, enhancing incretin 
effect and insulin response, delaying carbohydrate digestion by inhibiting α-amylase and α-
glucosidase, inhibition of sodium-dependent glucose co-transporter-1 (SGLT1) and sodium-
independent glucose transporter-2 (GLUT2) to prevent or delay glucose absorption and 
uptake [7, 208, 212, 213].  
The hypoglycaemic effect of plant polyphenols is derived from their unique structural 
properties such as the number and position of hydrogen moieties (e.g. OH) and double bonds 
that determine their bioavailability and subsequent interaction with membrane-bound brush 
border enzymes, apically located transporters and receptors involved in glucose metabolic 
pathways [214-219]. Their hypoglycaemic effects often depend on the cultivars and variety, 
environmental factors such as season, climate, topography and soil type, method of extraction 
and treatment to retain or enhance the potency of the polyphenols [140, 220-223]. 
Figure 2.2 summarises how dietary sources of polyphenols from plants can 
potentially impact multiple organ levels via various mechanisms of glucose metabolism in a 
holistic manner to improve glycaemic control. This is an advantage over anti-diabetic drug 
therapy, although often well-characterised, but nonetheless exhibits solitary actions that 
disrupt metabolic equilibrium within the body [2]. Nutritional studies have been designed to 
elucidate the underlying mechanisms of action of natural plant extracts likened to 
pharmacological functionalities of anti-diabetic drugs, but with minimal to no adverse effects 
[7, 86, 128, 139, 190, 205-211]. Taking a multimodal approach such as with plant extracts is 
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highly attractive for the treatment of hyperglycaemia and T2DM due to the heterogeneous 
nature of T2DM involving multifaceted aetiologies [224].  
Table 2.5 shows the mechanistic studies that have been conducted to date for the 
specific plant extracts (New Zealand pine bark, grape seed, rooibos tea, and olive leaf) that 
are examined in this PhD work. Although there may be multiple underlying mechanisms of 
action involved in the potential hypoglycaemic impact of plant extracts, a feasible 
mechanistic study on the enzyme inhibition of digestive enzymes: α-amylase and the 
dipeptidyl peptidase-4 (DPP4) enzyme, has been identified to be relevant to this PhD work. 
Alpha-amylase is an important brush-border digestive enzyme located in the intestine 
and is involved in the breaking down of carbohydrates or starch into maltose and maltotriose. 
These sugars are further broken down by α-glucosidase to release glucose for absorption 
[213]. The inhibition of α-amylase may play a critical role in controlling the amount of 
carbohydrate digestion and reducing the glucose available for absorption and uptake, 
potentially leading to improved glycaemia [213]. The inhibition study employs a simple in 
vitro enzymatic assay methodology and for this advantage it has been widely used in research 
to screen for potential inhibitors in plant extracts and their phenolic components [225-229]. 
Using this method, many plant extracts have been identified to exhibit inhibitory action 
against α-amylase [225-229].  
Several in vitro and in vivo studies have investigated the inhibitory effects of extracts 
of pine bark [230-232], grape seed [216, 233-236], rooibos tea [237, 238], and olive leaf 
[168, 170, 173, 174, 236, 239-242] on digestive enzymes such as α-amylase although 
comparative results are inconclusive due to different methodologies, types and concentrations 
of products tested. Therefore, this mechanistic action of inhibition on α-amylase will be 
explored in the New Zealand pine bark, grape seed, rooibos tea and olive leaf extracts. The 
understanding of the potential inhibition on α-amylase will help inform future chronic trials 
looking at the impact of these plant extracts on postprandial glycaemia in the prediabetes 
cohort. 
The glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) are 
responsible for the incretin effect that helps reestablish PG homeostasis. However, decreased 
incretin concentrations have been observed in prediabetes and T2DM [243-252]. 
Furthermore, the incretins are degraded by DPP4 enzyme rendering them functionally 
inactive to participate in glycaemic control [253-256]. In addition, research has advocated 
that it is pivotal to restore β-cell function in prediabetes and not just treating its symptoms in 
order to sustain glycaemic control and delay T2DM development [257-260]. An effective 
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way is to enhance the incretin effect to amplify insulin response without overworking the β-
cell [260]. Therefore, interventions aimed at restoring the incretin effect may be useful. 
Hence, the investigation of the potential inhibition of DPP4 enzyme by New Zealand 
pine bark, grape seed, rooibos tea and olive leaf extracts will help elucidate if the incretin 
levels can be preserved and amplify the incretin effect. More details regarding the 
mechanistic work can be found in Chapter 6 of the thesis. 
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Dietary polyphenols  
Maximal plasma concentrations (Cmax) of total metabolites (0-4 µmol/L) with an intake of 50 mg aglycone equivalents (polyphenol with no sugar group attached) [6]; Time to Cmax (Tmax) (1.5-5.5 h) [6]; 
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Multifaceted channels of dietary polyphenols to improve glycaemic control in prediabetes and diabetes [1-4] 
 
ACO-1: acyl CoA oxidase-1; AMPK: 5’ adenosine monophosphate-activated protein kinase; COX2: cyclooxygenase-2 protein; CPT-1β: carnitine palmitoyl transferase-1β; CRP: C-
reactive protein; FOXO1: forkhead box protein O1; G6Pase: glucose-6-phosphatase; GK: glucokinase; GLUT4: glucose transporter 4; IL-6: interleukin-6; IRS2: insulin receptor 
substrate 2; MCP-1: monocyte chemoattractant protein-1; NF-κB: nuclear factor kappaB; PI3K: phosphoinositide 3-kinase; PEPCK: phosphoenolpyruvate carboxykinase; SGLT1: 
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Figure 2.2 Hypoglycaemic potential of dietary polyphenols 
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 Table 2.5 In vitro and in vivo studies on the hypoglycaemic mechanistic actions of plant extracts and their phenolic components examined in the PhD study
Mechanistic actions Pine bark extract Grape seed extract Rooibos tea extract Olive leaf extract In vitro In vivo In vitro In vivo In vitro In vivo In vitro In vivo 
Insulin secretagogue or reduction? [261]  [188, 262, 263] [263-265] [266] [267, 268] [269-272] [273-275] 
Increase in amylin or inhibition of 
amyloid fibril aggregation?    [276] [277]  
[271, 278-
285]  
Glucokinase activator?  [182]  [286] [287]    
Increase in adiponectin levels?  [288]  [134, 158, 289-291] [292] [293]  [275, 294] 
Insulin sensitisation via peroxisome 
proliferator-activated receptors? [295] [182, 296]  
 
 
[287, 292, 297, 
298]   [275, 294] 
Inhibition of hepatic gluconeogenesis?  [182]  [289, 290, 299, 300]  [293]   
Inhibition of glucagon release?  [182]       
Inhibition of glycogen synthase kinase-3?  [182]  [264, 290]     










Inhibition of lipase activity? [288]  [216, 236, 306] [307]   [236]  
Inhibition or enhanced translocation of 
glucose transporters to promote glucose 
uptake? 
[308, 309]  [144, 265, 310] [290] 
[268, 287, 293, 
297, 311-314] [268] 
[173, 174, 
315-318] [275, 317] 
Increase in incretin levels?   [319, 320] [321-324]   [325] [325] 
Inhibition of dipeptidyl peptidase-4 
enzyme?   [322, 326] 
[321, 322, 
326]     
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[268, 277, 292, 
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The areas highlighted in grey are areas of potential research in order to elucidate the specific glucose-lowering mechanisms of action of these plant extracts. 
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2.8 Conclusion 
The number of individuals diagnosed with prediabetes and progressing to T2DM 
continues to rise. Alternative treatments to improve glycaemic control are needed as current 
pharmacological and lifestyle changes are not reducing the increasing prevalence. 
Antioxidant-rich New Zealand pine bark, grape seed, rooibos tea and olive leaf extracts have 
been shown to be potential hypoglycaemic modulators and may be used as an adjunct to anti-
diabetic drugs to improve glycaemic control in prediabetes. This review has identified the 
gaps in knowledge of these plant extracts and their potential hypoglycaemic effects in 
humans, with more research warranted in the prediabetes cohort. Additionally, the 
mechanisms of action underlying the desired hypoglycaemic effects such as the investigation 
of potential enzyme inhibition of digestive enzyme α-amylase and DPP4 enzyme have been 
identified and will be carried out as part of this PhD study. 
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Chapter 3  
Impact of phenolic-rich plant 
extracts on prediabetes and its 
subgroups. A narrative review of 
human clinical trials on prediabetes 
	  
This chapter discusses randomised controlled trials that have investigated the effects of 
phenolic-rich plant extracts on glycaemic control in people with prediabetes. This report has 
been presented in manuscript format and prepared for submission to the Critical Reviews in 
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Abstract 
Phenolic-rich plant extracts have been demonstrated to improve glycaemic control in 
individuals with prediabetes. However, there is increasing evidence that people with 
prediabetes are not a homogeneous group but exhibit different glycaemic profiles leading to 
the existence of prediabetes subgroups. Prediabetes subgroups have been identified as: 
isolated impaired fasting glucose (IFG), isolated impaired glucose tolerance (IGT), and 
combined impaired fasting glucose and glucose intolerance (IFG/IGT). The present review 
investigates human clinical trials examining the hypoglycaemic potential of phenolic-rich 
plant extracts in prediabetes and prediabetes subgroups. Artemisia princes Pampanini, soy 
(Glycine max (L.) Merrill) leaf and Citrus junos Tanaka peel have been demonstrated to 
improve fasting glycemia and thus may be more useful for individuals with IFG with 
increasing hepatic insulin resistance. In contrast, white mulberry (Morus alba Linn.) leaf, 
persimmon (Diospyros kaki) leaf and Acacia. Mearnsii bark were shown to improve 
postprandial glycemia and hence may be preferably beneficial for individuals with IGT with 
increasing muscle insulin resistance. Elaeis guineensis leaf was observed to improve both 
fasting and postprandial glycaemic measures depending on the dose. Current evidence 
remains scarce regarding the impact of the plant extracts on glycaemic control in prediabetes 
subgroups and therefore warrants further study. 
 
Keywords: functional food; polyphenol; impaired glycaemic control; impaired glucose 
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3.1 Introduction 
Globally, diabetes rates have been increasing at an alarming rate. In 2019 it was 
estimated that 463 million (ages 20-79 years) (9.3%) people were living with diabetes 
worldwide, an increase of 62% from 2009 with the number expected to increase to 700 
million (10.9%) by 2045 [1]. According to the International Diabetes Federation (IDF) the 
current annual global health expenditure on diabetes is estimated to be USD 760 billion and 
is projected to reach USD 845 billion by 2045 [1].  
Much of the health costs come from the complications that are associated with 
diabetes, which can affect the eyes, kidneys and nervous system [2, 3], and heightens the risk 
of cardiovascular morbidity and mortality [4]. 
Although the rates of Type 1 diabetes mellitus have also been increasing the main 
driver of the increased rates of diabetes, it is the increase in the rates of Type 2 diabetes 
mellitus (T2DM) that constitutes approximately 90% of diabetes worldwide [1]. This has 
largely occurred in parallel with the obesity epidemic. Given the burden is and will put on 
health systems it is therefore crucial to identify strategies that would prevent or slow the 
development of T2DM. 
Prediabetes is an intermediate state of hyperglycaemia with blood glucose levels 
above normal but not high enough to be classified as T2DM [5]. Prediabetes is a high-risk 
state for developing T2DM [6] and has an annual conversion rate of 5-10% [5, 7]. Therefore, 
early detection of prediabetes in conjunction with effective interventions may reduce the risk 
of developing future T2DM [8, 9]. 
There is increasing awareness that individuals with prediabetes are not a 
homogeneous group [10, 11] and show different metabolic profiles reflecting varying degrees 
of insulin resistance and β-cell dysfunction as observed in people with T2DM [10]. Three 
subgroups of glucose intolerance have been identified of which are the impaired fasting 
glucose (IFG), isolated impaired glucose tolerance (IGT), and combined impaired fasting 
glucose and impaired glucose tolerance (IFG/IGT) [10, 12]. These subgroups have distinctly 
different glycaemic metabolic profiles [7, 13-21], and exhibit different postprandial glucose 
(PG) and postprandial insulin (PI) shapes after a carbohydrate load [17, 20-23].   
According to the American Diabetes Association (ADA) guidelines, individuals with 
isolated IFG have elevated fasting blood glucose (FBG) of 100-125 mg/dL (5.6-6.9 mmol/L) 
while having a normal 2h postprandial glucose (2hPG) of <140 mg/dL (<7.8 mmol/L) [24]. 
Individuals with IFG tend to exhibit increased endogenous glucose production (EGP), 
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reduced hepatic insulin sensitivity, stationary β-cell dysfunction and/or chronic low β-cell 
mass, defective early phase insulin secretion while maintaining normal second phase insulin 
secretion with PG returning to normal after 2h, altered glucagon-like peptide-1 (GLP-1) 
secretion and inappropriately elevated glucagon secretion [12, 13, 20-23, 25-33]. They tend 
to also possess healthy or near healthy peripheral insulin sensitivity [20, 25, 27, 29]. 
Individuals with isolated IGT typically have normal FBG of <100 mg/dL (<5.6 
mmol/L), but an abnormally elevated 2hPG of 140-199 mg/dL (7.8-11.0 mmol/L) [24]. 
Characteristics specific to IGT may include increased or normal EGP, reduced peripheral 
insulin sensitivity, near-normal hepatic insulin sensitivity, impaired early and late phase 
insulin secretion with a subsequent rise in PG that is unable to return to normal baseline after 
2h, persistent and progressive loss of β-cell function, reduced secretion of gastric inhibitory 
polypeptide (GIP) and inappropriately elevated glucagon secretion [12, 13, 20-23, 25-30, 33-
35].  
Individuals with combined IFG/IGT fulfill both criteria of having elevated FBG of 
100-125 mg/dL (5.6-6.9 mmol/L) and elevated 2hPG of 140-199 mg/dL (7.8-11.0 mmol/L) 
[24]. IFG/IGT takes the worse form of impaired glucose control with a reduced glucagon 
suppression, impaired hepatic and peripheral insulin sensitivity and progressive loss of β-cell 
function, with a sustained rise in PG that does not return to normal baseline after 2h [20, 21, 
29, 36, 37]. 
Anti-diabetic pharmacological drugs have targeted various organs such as muscle, 
pancreas, liver and gut responsible for glucose metabolism with specific mechanisms of 
action to improve glycaemic control [38]. Drugs such as metformin belonging to the class of 
biguanide, sulfonylureas, and meglitinides are insulin secretagogues and insulin sensitisers 
that target liver insulin resistance and suppress endogenous glucose production that could 
potentially improve fasting glycaemic responses and hence can be utilised to treat IFG [20, 
39, 40]. In contrast, drugs targeting peripheral or muscle insulin resistance to improve 
skeletal muscle insulin sensitivity such as peroxisome proliferator-activated receptor-gamma 
(PPAR-γ) agonists, as well as α-glucosidase inhibitors, GLP-1 agonists, DPP4 inhibitors and 
thiazolidinediones that are most efficacious when taken together with a meal could 
potentially improve postprandial glycaemic responses and hence may be better utilised by 
those with IGT [20].  
Phenolic-rich plant extracts have increasingly been known for their hypoglycaemic 
effects [41-43], and have the potential to be used as an alternative to anti-diabetic 
medications but with few to no adverse effects such as abdominal discomfort or weight gain 
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[38, 44]. Similarly, plant extracts have been shown to possess different hypoglycaemic 
mechanisms of action to affect glucose regulation in the human body [43, 45-53].  
The question is whether plant extracts could emulate how these pharmacological 
agents are being categorised for a more effective, targeted clinical outcome for individuals in 
each prediabetes subgroup. A deeper understanding of the impact of plant extract 
interventions on prediabetes subgroups could enable the development of more targeted 
treatment strategies, with greater potential for slowing or stopping the development of 
T2DM.  
In order to obtain results that elucidate the impact of interventions on individuals with 
varying degrees of dysglycaemia [10, 54, 55], stratification based on the glycaemic profile of 
the cohort is important. This will enable more specific identification of interventions 
appropriate for those having worsening glycaemic profiles [56-59]. 
The present review therefore aims to 1) investigate human clinical trials that have 
been conducted to examine the impact of plant extracts on glycaemic responses in individuals 
with prediabetes, and 2) examine the effectiveness of each plant extract intervention in the 
prediabetes subgroups. 
3.2 Human clinical trials examining effect of plant extracts on glycaemic 
responses in the prediabetes cohort 
Acute and chronic human clinical trials on plant extracts and involving participants 
with prediabetes were considered based on the ADA definition for prediabetes: IFG (FBG of 
100-125 mg/dL and/or 2hPG <140 mg/dL), IGT (2hPG of 140-199 mg/dL and/or FBG <100 
mg/dL) and IFG/IGT (FBG of 100-125 mg/dL and 2hPG of 140-199 mg/dL) [24]. Studies 
that included at least two glycaemic measurement outcomes such as fasting glycaemic 
indices: FBG, fasting insulin (FI), fasting C-peptide (FCP), and homeostasis model 
assessment-insulin resistance (HOMA-IR), and postprandial glycaemic indices: PG, PI, 
postprandial C-peptide (PCP), and glycated hemoglobin A1c (HbA1c) were included. Only 
those published in English were considered. Studies that have incorporated other 
administered therapies such as lifestyle modifications (e.g. physical activity) or concomitant 
glucose-lowering medications, or that involved fruit-based extracts, spices, and traditional 
Chinese medicine were beyond the scope of this review and therefore excluded.   
Ten RCT studies including one randomized, uncontrolled, parallel study covering 
eight different plant extracts and their impact on glycaemic responses in prediabetes were 
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identified for this review (Table 3.1). Two of the identified studies were acute studies and the 
rest chronic studies of intervention duration ranging from 4 weeks to 12 weeks. Plant extracts 
examined were Artemisia princes Pampanini (Sajabalssuk) [60, 61], Elaeis guineensis leaf 
[62], Ficus deltoidea leaf [62], soy (Glycine max (L.) Merrill) leaf [63, 64], white mulberry 
(Morus alba Linn.) leaf [65-67], persimmon (Diospyros kaki) leaf [68], Citrus junos Tanaka 
peel [69], and Acacia Mearnsii bark [70]. Nine trials involved participants with IFG. One 
trial recruited participants with IGT. Three trials recruited participants with combined 
IFG/IGT. All plant extracts examined were able to elicit certain improvement in either fasting 
glycaemic measures such as FBG, FI, FCP and HOMA-IR, or postprandial glycaemic 
responses such as PG, PI, PCP, as well as HbA1c in participants with prediabetes, except 
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profile (TG, TC, 
HDL, non-HDL, 
HTR, AI and 
PL), SBP, DBP, 
BMI, WHR, 
BFP, ALT and 
AST 
Significant reduction in FBG and HbA1c compared to positive 
control, placebo and baseline. 
 
Significant reduction in HOMA-IR compared to placebo but 
not to positive control or baseline.  
 
No significant change in FI compared to positive control, 
placebo and baseline. 
 
Significant increase in HDL and decrease in non-HDL 
compared to positive control, placebo and baseline. 
 
Significant reduction in TC compared to positive control and 
baseline but not placebo. 
 
No significant changes in TG, HTR, AI, PL, SBP and DBP 
compared to positive control, placebo and baseline. 
 
No significant changes in BMI, WHR, BFP, ALT and AST 






















ALT, AST, SBP 
and DBP 
Significant reduction in FBG and HbA1c with both doses 
compared to baseline.  
 
No significant changes in FI, FCP, HOMA-IR, glucagon and 
DBP with both doses compared to baseline. 
 
Significant reduction in FFA and SBP with higher dose (4000 
mg/day) compared to baseline. 
 
Significant reduction in AST with both doses compared to 
baseline and a significant reduction in AST with lower dose 
(2000 mg/day) compared to positive control, but no significant 


















FBG, FI, insulin 
sensitivity (%), 
HOMA-IR, PG 
AUC, PI AUC, 
BW and WC 
Significant reduction in FBG, FI, insulin sensitivity (%) and 
WC compared to baseline, but no significant changes in 





Significant reduction in PG AUC, PI AUC and WC compared 
to baseline but no significant changes to FBG, FI, HOMA-IR, 












mg/day 8 weeks 
FBG, FI, insulin 
sensitivity (%), 
HOMA-IR, PG 
AUC, PI AUC, 
BW and WC 






















(TG, TC, HDL, 
LDL, HTR, and 
AI), ALT, AST, 
SBP and DBP 
Significant reduction in FBG, HOMA-IR, HbA1c, WC, BFP, 
TG, AI, ALT and AST compared to placebo but not when 
compared to baseline. 
 
Significant increase in HDL and HTR compared to placebo but 
not when compared to baseline. 
 
No significant changes in FI, BW, BMI, WHR, TC, LDL, SBP 





























FFA, TC, HDL, 
non-HDL, LDL, 





leptin, AST and 
ALT 
Significant reduction in HOMA-IR and HbA1c compared to 
placebo and baseline. 
 
Significant reduction in FBG, FI, TC and SBP compared to 
baseline but not when compared to placebo. 
 
No significant changes to BW, BMI, BFP, WHR, DBP, AST 
and ALT compared to placebo and baseline.  
 
No significant changes to lipid profile except significant 
reductions in FFA and non-HDL compared to placebo and 
baseline. 
 
No significant changes to plasma adipokine and cytokine 
levels except significant reductions in PAI-1 and TNF-α 
compared to placebo and baseline, and significant reduction in 
IL-6 compared to baseline. 
 
[64] 

























PG iAUC, PI 
iAUC, PCP 
iAUC 
Significant reduction in PG iAUC, PI iAUC and PCP iAUC 








No significant changes to PG iAUC, PI iAUC, PCP iAUC 











































6 mg DNJ 
 
12 weeks FBG, FI, GA, 1,5AG, HbA1c 
Significant reduction in HbA1c from week 4 and GA from 
week 8 compared to baseline, but not when compared to 
placebo. 
 
No significant changes in FBG and FI compared to baseline 
and placebo. 
 
Significant increase in 1,5 AG from week 4, 8 and 12 
compared to baseline, and overall significant increase 
compared to placebo. 
[66] 

















PG and PG 
iAUC, PI and PI 
iAUC, PCP and 
PCP iAUC, 
ALT and AST 
Significant reduction in PG and PI only at 30 min compared to 
placebo.  
 
Significant reduction in PCP at 30 and 60 min compared to 
placebo. 
 
No significant changes in PG iAUC, PCP iAUC, ALT and 


























8 weeks FBG, FI, FCP, PG, HOMA-IR 
Significant reduction in FBG, FI and HOMA-IR compared to 
placebo but not when compared to baseline. 
 
No significant change in PG compared to placebo or baseline. 
 
No significant change in FCP when compared to placebo but 






























































and PG AUC 












Significant reduction in PG at 90min and PI at 90 and 120 min 
compared to baseline. 
 
Significant reduction in PG at 120 min and PI at 90 min after 8 
weeks compared to placebo. 
 
No significant changes in PG AUC and PI AUC compared to 
placebo but a significant reduction compared to baseline after 8 
weeks. 
 
No significant changes in FBG, FI, HOMA-IR and HbA1c 
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ALT: alanine aminotransferase; AI: atherogenic index; AST: aspartate aminotransferase; BFP: body fat percentage; BMI: body mass index; BW: body weight; DBP: diastolic 
blood pressure; DNJ: 1-deoxynojirimycin; FBG: fasting blood glucose; FCP: fasting C-peptide; FFA: free fatty acid; FI: fasting insulin; GA: glycated albumin; GSP: glycated 
serum protein; HbA1c: glycated hemoglobin A1c; HDL: high-density lipoprotein cholesterol; HOMA-IR: homeostasis model assessment-insulin resistance; HTR: high-
density lipoprotein cholesterol (HDL) to total cholesterol (TC) ratio; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; IFG/IGT: combined impaired fasting 
glucose and impaired glucose tolerance; IL-6: interleukin-6; LDL: low-density lipoprotein cholesterol; MCP-1: monocyte chemotactic protein-1; PAI-1: plasminogen 
activator inhibitor-1; PCP: postprandial C-peptide; PCP iAUC: incremental area under the curve of postprandial C-peptide; PG: postprandial glucose; PG AUC: area under the 
curve of postprandial glucose; PG iAUC: incremental area under the curve of postprandial glucose; PI: postprandial insulin; PI AUC: area under the curve of postprandial 
insulin; PI iAUC: incremental area under the curve of postprandial insulin; PL: phospholipid; SBP: systolic blood pressure; TC: total cholesterol; TG: triglyceride; TNF-α: 

















with 3 mg 
DNJ 
No significant change in PG compared to placebo but a 
significant reduction in PI at 30min compared to placebo. 
 
Extract 
with 6 mg 
DNJ 
Significant reduction in PG at 30min and significant reduction 
in PI at 30min compared to placebo. 
Extract 
with 9 mg 
DNJ 
Significant reduction in PG at 30min and significant reduction 
in PI at 30min compared to placebo. 
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3.3 Effectiveness of plant extracts on glycaemic responses in the 
prediabetes subgroups 
With the prediabetes cohort from these trials being classified into their respective 
subgroups, Table 3.2 summarises the significant changes in glycaemic clinical outcomes of 
the interventions with the plant extracts based on each subgroup.  
3.3.1 Hypoglycaemic effects of plant extracts on impaired fasting glucose (IFG) 
Artemisia princeps Pampanini (A. princeps) belongs to one of the 500 plants under 
the genus Artemisia, and is commonly found in China, Korea and Japan [72, 73], and has 
been used to treat diabetes [74, 75]. High concentrations of antioxidants and flavonoids such 
as eupatilin and jaceosidin have likely contributed to its anti-diabetic effects [72, 73, 76, 77]. 
The Korean A. princeps or Sajabalssuk extract (3000 mg/day) has also been examined in a 
prediabetes cohort for its glucose-lowering effects [60]. There were significant reductions in 
FBG (-16.5 ± 2.8%, p<0.05) compared to placebo and positive control after nine weeks of 
intervention, thus restoring normal FBG levels. Sajabalssuk extract also significantly 
decreased HbA1c (-7.8 ± 3.4%, p<0.05) and insulin resistance (HOMA-IR) (-14.7 ± 20.4%, 
p<0.05) with improvement in high-density lipoprotein (HDL) cholesterol level (p<0.05) 
compared to control (Table 3.2) [60]. An earlier study conducted by the same group also 
showed significant reductions in FBG and HbA1c at both doses (2000 and 4000 mg/day) in 
participants with IFG and borderline T2DM (FBG 123.3 ± 5.7 – 125.8 ± 6.1 mg/dL) 
compared to participant baseline after eight weeks of intervention. High dose (4000 mg/day) 
of the extract was also able to significantly decrease plasma free fatty acid (FFA) levels 
(p<0.05) compared to participant baseline [61]. These chronic studies have demonstrated that 
sajabalssuk extract was able to improve fasting glycaemic responses in IFG participants. 
Elaeis guineensis (E. guineensis) leaf comes from oil palm and is commonly found in 
Malaysia, Thailand, Indonesia, Africa and South America [62, 78, 79]. It has been known to 
contain high levels of antioxidant activity rich in phenolic compounds such as catechin, 
apigenin and luteolin [80, 81], and in vitro and animal studies have elucidated E. guineensis 
to be beneficial for metabolic syndrome and T2DM by promoting vascular relaxation and 
reducing inflammation and lipid oxidation [78, 80, 82-84]. Kalman and group investigated 
the hypoglycaemic effects of E. guineensis leaf extract at two doses (500 and 1000 mg) in 
participants with IFG for eight weeks [62]. E. guineensis leaf extract at a lower dose (500 
mg) was able to significantly improve FBG (p=0.02), fasting insulin (FI) (p=0.04), and 
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HOMA-IR (p=0.03) compared to participant baseline levels (Table 3.2). In contrast, the 
higher dose (1000 mg) was only able to significantly improve PG and PI responses (p=0.046 
and p=0.006, respectively) compared to participant baseline levels. Having no placebo group 
was a limitation of the study. Due to the paucity of clinical data regarding E. guineensis leaf, 
more research is required to investigate the glucose-lowering potential of E. guineensis leaf 
in people with prediabetes.  
Ficus deltoidea (F.deltoidea) belongs to the Moraceae plant family and is native to 
the Malayan Archipelago [85]. It is high in phenolic content such as flavan-3-ol monomers, 
catechin and afzelechin and antioxidant activity [86, 87]. In the past decade in vitro and 
animal studies have shown F.deltoidea as a potential anti-diabetic treatment owing to its 
glucose-lowering effects and its ability to stimulate insulinotropic activity and glucose uptake 
[85, 88-93]. There was only one 8-week prospective, randomized, double-blind, parallel 
study conducted investigating the impact of a single dose of F.deltoidea leaf extract (1000 
mg) on individuals with IFG [62]. No significant changes in glucose and insulin responses 
were observed (Table 3.2).  
Soy (Glycine max (L.) Merrill) leaf is common in Korea and Japan [94-96]. Soy leaf 
is rich in polyphenols such as kaempferol glycosides, coumestrol and pterocarpan [95-98], 
which have been shown to contain anti-diabetic properties [95, 98, 99]. Choi and colleagues 
(2014) showed that consuming soy leaf extract (2000 mg/day) for 12 weeks led to significant 
reductions in baseline-adjusted FBG, HOMA-IR, HbA1c, and lipid profile in overweight 
participants with IFG compared to placebo (p<0.05) [63] (Table 3.2). This finding was with 
agreement with another RCT investigating the impact of pterocarpan-high soy leaf extract 
(2000 mg/day) for 12 weeks on glucose tolerance in overweight and obese IFG participants 
with borderline metabolic syndrome [64]. Significant reductions in HbA1c, HOMA-IR, FFA 
and non-HDL cholesterol were observed in the intervention compared to control group [64]. 
FBG and FI were also reduced after intervention compared to participant baseline [64]. The 
clinical outcomes suggest that that the intervention with soy leaf extract could potentially 
benefit those with IFG as seen in the improvements in fasting glycaemic indices (FBG and 
HOMA-IR), with the addition of improved long-term glycaemic measurement, HbA1c and 
improved lipid profile.  
White mulberry (Morus alba Linn.) leaf comes from the mulberry tree belonging to 
the family Moraceae and is native to Korea, Japan and China but also widely cultivated in 
other parts in Europe [100]. Mulberry leaf has been extensively studied and reviews have 
been written regarding its hypoglycaemic effects [100-102]. A variety of polyphenols such as 
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quercetin, chlorogenic acid, and rutin, and nitrogen-containing glucose analog 1-
deoxynojirimycin (DNJ) contained in mulberry leaf contribute to the hypoglycaemic effects 
observed [103-108]. DNJ has been shown as a strong α-glucosidase inhibitor due to its size 
and structural similarity to glucose [109, 110] and has been used to standardise mulberry leaf 
extracts, with other phenolic components in the leaf contributing to its combined inhibitory 
action [65, 103, 109, 111-114]. Considerable human studies have further elucidated the 
hypoglycaemic effects of mulberry leaf extract in healthy participants, with fewer studies on 
prediabetes and T2DM [65-67, 113, 115-123]. Liu and colleagues (2020) investigated the 
hypoglycaemic effects of an extract mixture of mulberry leaf and white kidney bean in 
participants with IFG [71]. A significant reduction in glycaemic responses of incremental 
area under the curve (iAUC) such as PG iAUC, PI iAUC and PCP iAUC was observed 
compared to control in the acute trial. In contrast, the same study did not observe similar 
improvements in a 4-week chronic trial [71]. Hwang and co-workers (2016) investigated the 
impact of 50% ethanolic extract of mulberry leaf (20% in mixture) with onion extract coated 
on 75 g cooked rice (11.77 ± 1.67 mg DNJ/ 100 g rice) and observed an improvement in PG 
(p<0.05) and postprandial glucose area under the curve (PG AUC) (p<0.001) after an oral 
glucose tolerance test (OGTT) (75g cooked rice) in participants with IFG compared to 
placebo group [65] (Table 3.2). Asai and co-workers (2011) observed a significant increase 
in serum 1,5-anhydroglucitol (1,5-AG) concentration, a sensitive marker of postprandial 
hyperglycaemic spikes, in participants with IFG after consuming mulberry leaf (6 mg DNJ) 
for 12 weeks (p<0.001) in comparison to control [66]. However no significant changes were 
found in FBG, FI, HbA1c, and glycated albumin (GA) concentrations compared to placebo, 
but HbA1c was significantly reduced from 4-week onwards within the intervention group 
compared to participant baseline (6.0 ± 0.4% vs 5.9 ± 0.3%, p<0.05) (Table 3.2). Kim and 
colleagues (2014) investigated the impact of 4-week mulberry leaf extract (5000 mg/day, 
0.36% or 18 mg DNJ) in IFG participants and demonstrated significant reductions in PG, PI 
and postprandial C-peptide (PCP) especially at 30 min post-load compared to placebo [67] 
(Table 3.2). However, no significant changes were found in FBG, FI and HbA1c compared 
to placebo [67]. Studies on mulberry leaf extract on healthy participants and individuals with 
prediabetes or T2DM have consistently shown non-significant changes in FBG and FI [66, 
67, 115, 121-123]. This may suggest that mulberry leaf extract, which is functionally similar 
to acarbose, may be more beneficial for individuals with IGT due to its inhibitory action on 
digestive enzyme (α-glucosidase) post-load. Future studies on mulberry leaf could ascertain 
the inhibition of α-glucosidase in participants with prediabetes using hydrogen tests and 
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starch 13C breath test that have been conducted in healthy and T2DM participants to indicate 
carbohydrate indigestion [117-119, 123].  
3.3.2 Hypoglycaemic effects of plant extracts on impaired glucose tolerance 
(IGT) 
Persimmon (Diospyros kaki) leaf belongs to the family of Ebenaceae and has been 
traditionally used in Japan, South Korea and China as a folk medicine [124]. The persimmon 
leaf has shown to possess anti-oxidative properties mediated by its rich phenolic 
concentration [125-127]. Phenolic compounds such as triterpenoids isolated from persimmon 
leaf have been shown to exhibit anti-diabetic properties via inhibiting protein tyrosine 
phosphatase 1B (PTP1B) activity (>80% inhibition at 30 µg/mL) [128]. Vomifoliol, which is 
found in persimmon leaf, has been identified as a potent a α-glucosidase inhibitor and an 
enhancer of peripheral glucose utilisation [129]. Khan and colleagues (2017) demonstrated 
consuming 2000 mg of persimmon leaf extract for eight weeks in IGT participants led to 
significant PG reduction in the intervention group compared to control (p=0.029) [68] (Table 
3.2). Within the same study, samples of saliva, urine, and serum collected from a subgroup of 
five participants with combined IFG/IGT were analysed for potential protein markers of 
persimmon leaf treatment. Outcomes showed Tamm-Horsfall protein, uromodulin, SPARC-
like protein 1 precursor (SPARCL1) and Complement C7 were down-regulated while Ezrin 
was up-regulated, indicating ameliorating effects of persimmon leaf on glycaemia [68]. In 
vitro and animal studies on persimmon leaf have elucidated the mechanistic action of α-
amylase and α-glucosidase inhibition [130-132], which might have led to the PG reduction 
observed in the IGT participants due to reduced carbohydrate digestion [68]. Another 
mechanism of action demonstrated by persimmon leaf might be the inhibition Na+/glucose 
co-transporter (SGLT1) as the final stage of glucose absorption, as demonstrated by 
significant reductions in PG in rats after glucose loading [132].  
3.3.3 Hypoglycaemic effects of plant extracts on combined impaired fasting 
glucose and impaired glucose tolerance (IFG/IGT) 
The Citrus junos Tanaka (C. junos) fruit, also known as yuja or yuzu, is a yellow 
citrus fruit easily obtainable in Japan, Korea and China, and contains a high concentration of 
phenolic content and vitamin C compared to the flesh [133-137]. The major phenolic 
compounds hesperidin and naringin [133], which have been known for improving glycaemia 
[138]. Hwang and co-workers (2015) determined the impact of C. junos peel extract on 
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glycaemic responses in participants with combined IFG/IGT [69]. After eight weeks of 
intervention (4250 mg/day), the intervention group showed significantly reduced FBG 
(p=0.049), FI (p=0.038), and HOMA-IR (p=0.019) compared to the placebo group [69]. C-
peptide in the intervention group was also marginally reduced (p=0.057) but no significant 
improvement in PG compared to placebo [69] (Table 3.2). The study showed that C. junos 
peel could only improve fasting glycaemic indices in combined IFG/IGT participants [69]. 
The hypoglycaemic mechanism might be due to increased glucose uptake via increased 
insulin action in the peripheral tissues [136]. 
Acacia. Mearnsii (A.mearnsis) bark from the black wattle tree of the legume family 
has been gaining attention for its anti-diabetic effects [139, 140]. Its anti-diabetic potential 
may be attributed to the abundant antioxidants and proanthocyanidins, such as catechin-like 
flavan-3-ols, and in particular robinetinidol and fisetinidol present in the bark [139]. An 8-
week consumption of A. mearnsii bark (1000 mg/day) led to significant reduction in PG at 
120 min (p=0.013) and PI at 90 min (p=0.032) compared to placebo in participants with 
combined IFG/IGT [70]. There was also a significant reduction in glucose at 90 min 
(p=0.014), and a reduction in insulin concentration at 90 and 120 min (p=0.002 and p=0.004, 
respectively), with an overall reduction in PG AUC and postprandial insulin area under the 
curve (PI AUC) (p=0.018 and p=0.009, respectively) within the intervention group [70] 
(Table 3.2). However there was no change in fasting glycaemic measures such as FBG, FI, 
HOMA-IR, and HbA1c compared to placebo [70]. Mechanistic in vitro studies indicate that 
the postprandial hypoglycaemic effects of A. mearnsii bark could be due to inhibition of the 
digestive enzymes α-amylase and α-glucosidase [139-145]. This study suggests that A. 
mearnsii bark preferentially improved postprandial glycaemic responses instead of fasting 
glycaemic responses in IFG/IGT participants. 
The mulberry leaf extract was also examined in participants with combined IFG/IGT 
by Asai and co-workers (2011) [66]. They found that the extract (3, 6 or 9 mg DNJ) 
significantly reduced acute PG responses in a dose-dependent manner compared to placebo 
(p=0.006) (Table 3.2). This indicates that mulberry leaf may preferentially improve 
postprandial glycaemic responses in individuals with IFG/IGT. As discussed earlier, 
mulberry leaf extract was shown to improve postprandial glycaemic responses in IFG 
participants as well. 
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Table 3.2 Changes in glycaemic clinical outcomes in participants with prediabetes classified by their subgroups. The significant outcomes are 
presented as comparison with control, then comparison within intervention group.  
Plant extract Dose 
Fasting state Postprandial state HbA1c Reference 




AUC   








2000 mg/day na, ê na, - na, - na, - na na na na, ê [61] 
4000 mg/day na, ê na, - na, - na, - na na na na, ê 
Elaeis guineensis 
leaf  
500 mg/day na, ê na, ê na na, - na, - na, - na na [62] 1000 mg/day na, - na, - na na, - na, ê na, ê na na 
Ficus deltoidea leaf 1000 mg/day na, - na, - na na, - na, - na, - na na [62] 
Soy (Glycine max 
(L.) Merrill) leaf  2000 mg/day ê, - -. - na ê, - na na na ê, - [63] 
Pterocarpan-high 
Soy (Glycine max 
(L.) Merrill) leaf  
2000 mg/day -, ê -, ê na ê, ê na na na ê, ê [64] 
White mulberry 
(Morus alba Linn.) 
leaf and white 
kidney bean extract 
1500 mg na na na na ê ê ê na 
[71] 
4500 mg/day na, na na, na na, na -, na -, na -, na -, na -, na 
White mulberry 
(Morus alba Linn.) 






na na na na ê na na na [65] 
White mulberry 
(Morus alba Linn.) 
leaf  
Extract with 
6 mg DNJ 
 
-, - -, - na na na na na -, ê [66] 
White mulberry 
(Morus alba Linn.) 
leaf  
5000 mg/day  
(18 mg DNJ) -, na -, na -, na na ê, na ê, na ê, na -, na [67] 
















DNJ: 1-deoxynojirimycin; FBG: fasting blood glucose; FCP: fasting C-peptide; FI: fasting insulin; HbA1c: glycated hemoglobin A1c; HOMA-IR: homeostasis model 
assessment-insulin resistance; IFG: impaired fasting glucose; IFG/IGT: combined impaired fasting glucose and impaired glucose tolerance; IGT: impaired glucose tolerance; 
PCP: postprandial C-peptide; PCP AUC: area under the curve of postprandial C-peptide; PG: postprandial glucose; PG AUC: area under the curve of postprandial glucose; PI: 
postprandial insulin; PI AUC: area under the curve of postprandial insulin; RCT: Randomised controlled trial; ê: a significant decrease in the measured value (p<0.05); -: no 
significant changes to measured value (p>0.05); na: not applicable. 
Human clinical trials on impaired glucose tolerance (IGT) 
Persimmon 
(Diospyros kaki) leaf  
2000 
mg/day na na na na ê, na na na na [68] 
Human clinical trials on combined impaired fasting glucose and impaired glucose tolerance (IFG/IGT) 
Citrus junos Tanaka 
peel  
4250 




mg/day -, - -, - na -, - ê, ê ê, ê na -, - [70] 
White mulberry 
(Morus alba Linn.) 
leaf  
Extract with 
3 mg DNJ - - na na - ê na na 
[66] Extract with 6 mg DNJ - - na na ê ê na na 
Extract with 






3.4 Does each prediabetes subgroup benefit from different plant extracts? 
Phenolic-rich plant extracts have been known to improve glucose regulation in 
individuals with prediabetes, however not all plant extracts may benefit both fasting and 
postprandial hyperglycaemia. Table 3.2 shows how the different plant extracts can be more 
appropriately used for individuals with IFG, or IGT based on whether they could improve 
fasting or postprandial glycaemic responses, respectively. Plant extracts that were able to 
demonstrate improvements in fasting glycaemic indices such as FBG, FI and HOMA-IR were 
categorised as being useful for IFG. In contrast, plant extracts that demonstrated to improve 
postprandial glycaemic indices such as PG and PI were grouped as being helpful for IGT. 
This is likely due to the different phenolic structures of each plant extract that enables 
varying kinds of hypoglycaemic mechanisms of action [42, 48, 146, 147]. Table 3.3 
summarises how the discussed plant extracts can help individuals with IFG or IGT. 
Individuals with IFG/IGT are likely to benefit from both categories of glycaemic 
improvement.  
 
Table 3.3 Hypoglycaemic effects of plant extracts on fasting and postprandial glycaemic 
measurements 
Plant extracts with potential hypoglycaemic effects on fasting glycaemic 
measurements 
Sajabalssuk (Artemisia princeps Pampanini)  
Elaeis guineensis leaf (500 mg/day)  
Soy (Glycine max (L.) Merrill) leaf  
Citrus junos Tanaka peel  
Plant extracts with potential hypoglycaemic effects on postprandial glycaemic 
measurements 
White mulberry (Morus alba Linn.) leaf 
Elaeis guineensis leaf (Higher dose, 1000 mg/day)  
Persimmon (Diospyros kaki) leaf  






3.5 Strengths and limitations 
The merits of the present review were the inclusion of a range of human clinical trials 
investigating plant extracts with promising hypoglycaemic potential in individuals with 
prediabetes, and examination of the effectiveness of each plant extract intervention on the 
various prediabetes subgroups.  
However, the review is not without limitations. The review has included single dose 
studies with some studies having only small sample sizes. More human studies are necessary 
to ascertain the hypoglycaemic impact of the plant extracts on people with prediabetes.  
Most of the studies included did not clearly differentiate between the subgroups of 
prediabetes during recruitment. For example, nine studies that were included have only 
measured FBG to recruit participants with IFG, however these participants might also have 
IGT, but participant baseline PG during screening was not measured. This limitation 
highlights the importance of measuring both fasting and postprandial indices in future studies 
and for the purpose of classifying participants into the different prediabetes subgroups. 
Additionally, owing to the lower reproducibility with current measurements using FBG and 
2hPG, caution should be exercised when classifying individuals into IFG or IGT based on a 
single test [11, 148]. However, the cost and practicality may need to be considered. 
Furthermore, studies have not included both fasting and postprandial measurements. 
For example, the study on persimmon leaf extract only measured postprandial glycaemic 
response such as PG in IGT participants. On the other hand, studies on sajabalssuk and 
soybean leaf extract only measured fasting glycaemic responses without investigating 
postprandial glycaemic measures in IFG participants. Therefore the extensive impact of the 
plant extracts on both fasting and postprandial glycaemia could not be known. 
Most of the studies included in this review did not take into account possible changes 
in β-cell function, insulin sensitivity and changes to lipid metabolism. This is important 
because the preservation or restoration of β-cell function is pivotal in slowing or halting the 






prediabetes and may gradually impair insulin signaling and function and is therefore an 
important endpoint measurement in interventions [153]. 
3.6 Conclusion  
 This review has explored a new perspective in viewing how nutritional interventions 
could cater to the different classifications of prediabetes such as IFG, IGT and a combination 
of IFG/IGT. Among these studies, interventions with plant extracts have elucidated 
preferential improvements of certain glycaemic measurements. It follows that to obtain 
optimal glycaemic outcomes treatments should be made available that are specific for each of 
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An acute, placebo-controlled, single-
blind, crossover, dose-response, 
exploratory study to assess the effects 
of New Zealand pine bark extract 
(Enzogenol®) on glycaemic responses 
in healthy participants 
 
This chapter presents the study outcomes investigating the effect of New Zealand pine bark 
extract on glycaemic control in healthy participants. This pine bark study has been presented 
in manuscript format and has been published in the Nutrients Journal. 
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Zealand pine bark extract (Enzogenol®) on glycaemic responses in healthy 









An acute, placebo-controlled, single-blind, crossover, dose-response, exploratory study was 
designed to investigate the hypoglycaemic effects of New Zealand pine bark extract 
(Enzogenol®). Twenty-five healthy participants categorised into having a monophasic or 
complex (biphasic or triphasic) glucose curve shape at the control visit consumed a placebo 
and Enzogenol® (50 and 400 mg) on three separate occasions before an oral glucose tolerance 
test (OGTT). In the monophasic group, 50 and 400 mg of Enzogenol® significantly reduced 
the mean glucose incremental area under the curve (iAUC) compared to control 241.3 ± 20.2 
vs. 335.4 ± 34.0 mmol/L·min, p=0.034 and 249.3 ± 25.4 vs. 353.6 ± 31.5 mmol/L·min, 
p=0.012, respectively. The 400 mg dose further reduced the percentage increment of 
postprandial glucose (%PG) 31.4% ± 7.9% vs. 47.5% ± 8.6%, p=0.010, glucose peak 7.9 ± 
0.3 vs. 8.9 ± 0.3 mmol/L, p=0.025 and 2h OGTT postprandial glucose (2hPG) 6.1 ± 0.3 vs. 
6.7 ± 0.3 mmol/L, p=0.027. Glucose iAUC was not significantly different in the complex 
group, except for reductions in %PG 28.7% ± 8.2% vs. 43.4% ± 5.9%, p=0.012 after 50 mg 
dose and 27.7% ± 5.4% vs. 47.3% ± 7.2%, p=0.025 after 400 mg dose. The results suggest 
that Enzogenol® may have hypoglycaemic effects in healthy participants, especially those 
exhibiting monophasic shapes. 
Keywords: New Zealand pine bark extract; Enzogenol®; proanthocyanidins; impaired 













Type 2 diabetes mellitus (T2DM) is characterised by abnormally high blood glucose 
levels otherwise termed as hyperglycaemia [1]. It accounts for over 90% of diabetes 
diagnoses [2], and can result in significant morbidity and mortality from macrovascular and 
microvascular complications, such as retinopathy, nephropathy, and neuropathy [3-5]. 
Natural plant extracts have been increasingly explored as options to treat and manage 
impaired glycaemic control [6-9]. They are seen as a potential alternative to anti-diabetic 
medications that are associated with a range of adverse effects, including weight gain, risk of 
hypoglycaemia, and gastrointestinal discomfort [10]. One such natural extract is food-grade 
pine bark, obtained from the bark of pine trees in timber industries that otherwise would be 
discarded [11, 12]. Recent studies examining various sources of pine bark extracts have 
shown that pine bark possessed antioxidant properties, anti-inflammatory, neuro-protective, 
and anti-diabetic effects [11, 13, 14]. 
Naturally occurring polyphenols have been suggested to play a major role in the anti-
diabetic properties exhibited by pine bark extracts, and proanthocyanidins are the main and 
most abundant bioactive components [11, 12, 15, 16]. The New Zealand pine bark extract, 
trade name Enzogenol®, is produced from Pinus radiata trees grown in New Zealand by a 
water-based extraction [11, 12]. The dry powder contains greater than 80% 
proanthocyanidins, 1–2% taxifolin, other flavonoids and phenolic acids, and some 
carbohydrates [12]. The proanthocyanidin content in Enzogenol® was also shown to be even 
higher than Pcynogenol®, a French Maritime pine bark produced from the outer bark of Pinus 
pinaster Ait. Subsp. Atlantica growing in the Southwest coastal region in France [16, 17]. 
There is increasing evidence showing that healthy individuals with normal glucose 
tolerance (NGT) may still eventually develop T2DM [18-22] depending on their patterns of 
postprandial glucose [23-28]. It is suggested that 20% of NGT individuals already have a 
certain degree of insulin resistance [25, 29-31], although their postprandial blood glucose 
may fall within the normal range. 
Patterns of postprandial glucose obtained from the 2h oral glucose tolerance test (OGTT) 
have been extensively used in research to predict future T2DM in NGT individuals before its 
onset [32, 33]. Studies have shown that individuals with monophasic glucose curve shapes 
during a 2h OGTT, defined by having only one peak in the glucose curve, tended to have a 
heightened risk of T2DM [23-28]. On the other hand, those exhibiting biphasic or triphasic 






are more likely to have a lower risk of T2DM [23-28]. Cross-sectional and longitudinal 
studies have observed that NGT individuals possessing monophasic glucose curve shapes, in 
contrast to those having complex shapes, tended to have a significantly higher glucose, 
insulin, C-peptide, free fatty acid, and visceral fat [24-26], with significantly reduced insulin 
sensitivity, a lack of compensatory first and second phase insulin secretion, and higher levels 
of insulin resistance [23-25, 27, 33]. 
Clinical studies have also revealed that depending on the degree of glucose tolerance in 
individuals defined by various glucose response indices including glucose curve shapes, they 
may either be responders or non-responders to a given intervention such as with natural plant 
extracts [34-37]. Krishnan and colleagues (2012) have also emphasised the importance of 
examining dietary interventions using an integrated physiological approach that stratified 
participants with varying glycaemic responses into subgroups in contrast to overall group 
responses [37]. 
To date, no human study has been conducted on the hypoglycaemic effects of 
Enzogenol® that was based on subgroup glycaemic responses to the intervention given. 
Hence, this present study was an exploratory study to first investigate the acute, dose-
dependent, hypoglycaemic potential of Enzogenol® on healthy, NGT participants stratified 
into subgroups of glycaemic responses. The subgroups were based on their postprandial 
glucose curve shapes (monophasic vs. complex) after an OGTT at the control visit. Further to 
this, by stratifying participants according to their postprandial glucose curve shapes, we 
aimed to investigate if there was a difference in treatment outcome and dose response to 
Enzogenol® between the two groups. The study examined both the primary outcome 
measurement of glucose incremental area under the curve (iAUC) and secondary changes in 
glycaemic response indices, such as the percentage increment of postprandial glucose (%PG), 
the time to glucose peak, the glucose peak value, and 2h postprandial glucose at 120 min of 
OGTT (2hPG), to enhance the understanding of the potential hypoglycaemic effects of 
Enzogenol®. Any observed acute effects from this preliminary intervention with Enzogenol® 
in healthy population would help inform future studies that include investigating the impact 
of Enzogenol® over at least 8–12 weeks in both normo- and hyperglycaemic participants with 
worsening glucose intolerance, such as those with prediabetes or T2DM. Additionally, future 
studies can determine the effects of Enzogenol® on insulin secretion and sensitivity, as well 
as β-cell function (e.g., HOMA-IR, Matsuda index, and other measures), and explore the 







4.2.1 Study Population 
The study was approved in March 2018 by the Massey University Human Ethics 
Committee (MUHEC) (ref: SOA 17/73). The clinical trial was registered retrospectively at 
anzctr.org.au (Australia New Zealand Clinical Trials Registry Number: 
ACTRN12619001571167). The study was conducted in accordance with the Declaration of 
Helsinki and all participants gave their informed consent prior to participating in the study. 
Participants were recruited from Auckland, New Zealand using poster advertisements 
(Appendix 2.1) within the local university and community (March–December 2018). They 
were selected according to the following inclusion criteria: (i) healthy Body Mass Index 
(BMI) of 18.5–25.0 kg/m2, (ii) aged 18–40 years, (iii) not suffering from any impaired 
glycaemic control (fasting blood glucose (FPG) < 5.5 mmol/L) and glycated haemoglobin 
A1c (HbA1c) < 40 mmol/mol (Cobas b 101 HbA1c test, CV 0.8–1.7%, Roche Diagnostics), 
(iv) not taking any forms of glucose-lowering medications or medications that may affect 
glucose metabolism, (v) free from any form of illnesses or chronic diseases. Participants were 
excluded from the study if they had any form of cardiovascular, metabolic diseases, digestive 
ailments, if they smoked, were pregnant or lactating, and if they had any known allergies to 
pine bark extract. Documents of recruitment can be found in Appendix 2.2-2.6.  
4.2.2 Study Design 
The study was an acute, placebo-controlled, single-blind, crossover, dose-response, 
exploratory study. The study required participants to come to the research facility at Massey 
University, Auckland, New Zealand for three separate visits with at least a 48 h washout 
period. 
Briefly, at every visit, participants arrived at the facility after at least a 10 h overnight 
fast (water was allowed). The first study visit was a control visit whereby participants 
consumed a single placebo capsule containing microcrystalline cellulose. The second and 
third visits were treatment visits where patients consumed a single capsule of 50 and 400 mg 
of Enzogenol®, respectively. An OGTT was commenced at all three visits 20 min after 
consuming the capsule. Participants were given a bottle of 300 mL of glucose drink Carbotest 
(Fronine, Thermo Fisher Scientific, Victoria, Australia) containing 75 g of carbohydrates to 






Capillary blood samples were obtained via finger pricking with a single use disposable 
lancet (Accu-Chek Safe T-Pro Plus) 20 min before the commencement of OGTT, and again 
at 0, 15, 30, 45, 60, 90, and 120 min during the OGTT. Blood glucose levels were 
immediately measured using a glucose meter (MediSense, Optium, Abbott, Auckland, New 
Zealand, 2.7–4.0% CV). 
Participants were instructed to maintain a consistent diet without any dietary alterations 
throughout the duration of the study. They were also asked to abstain from alcohol and 
beverages such as teas, coffees, and energy drinks (both caffeinated and decaffeinated), all 
health supplements that might influence glucose metabolism, including any form of pine bark 
products, and strenuous activity during the 24h period before each visit. Compliance was 
checked at every visit by the researcher, including what they had eaten the previous day in 
order to ensure that they had been adhering to the dietary requirements regarding what they 
could eat or drink. Data collection form can be found in Appendix 2.7.  
4.2.3 Treatments 
Active capsules contained either 50 mg Enzogenol® plus 350 mg microcrystalline 
cellulose or 400 mg Enzogenol® prepared from the same batch of product. Placebo capsules 
contained 400 mg microcrystalline cellulose, which is commonly used as a filler in placebo 
capsules in clinical studies [38]. Both were supplied by ENZO Nutraceutical Limited (Paeroa, 
New Zealand). The doses chosen for this study were based on previous studies investigating 
the impact of pine bark (French Maritime) on glycaemic control in people with diabetes [39-
41]. The doses chosen reflected the low and high doses used in previous studies with the 
focus on examining the acute hypoglycaemic impact of Enzogenol® in healthy participants. 
The doses selected represented concentrations with no known toxicity [12]. The identical 
looking capsules were of opaque white appearance, concealing the visibility of the contents, 
and were produced to the standards of dietary supplement preparations and quality control in 
New Zealand. 
4.2.4 Parameters of Glycaemic Response during the OGTT 
The shape of the control glucose curve of each participant was determined using 
calculations employed by Tschritter et al. (2003) [23], Briefly, monophasic, biphasic, and 
triphasic curves were defined as Gluc120-Gluc90 <0.25 mmol/L, Gluc120-Gluc90 >0.25 mmol/L 






triphasic glucose curve shape were grouped together as having a complex glucose curve 
shape. 
The primary outcome, iAUC of postprandial glucose, was calculated during the OGTT 
from 0 to 120 min using the trapezoidal rule [42]. 
The %PG was defined by the percentage increment of 2hPG with respect to fasting blood 
glucose (FBG), using the formula [(2hPG-FBG)/FBG] × 100 [30]. 
The time to glucose peak was defined as the time point on the OGTT when the glucose 
level was highest. For complex glucose curve shapes (biphasic or triphasic), the time of the 
first glucose peak was considered [43]. 
The glucose peak value and the 2hPG were also recorded. 
4.2.5 Statistical Analysis 
A sample size calculation was performed on the change in postprandial capillary blood 
glucose based on a previous study conducted by our group on the acute responses of several 
plant extracts [44]. A minimum sample size of ten was required to detect a difference in 
postprandial glucose levels. However, to allow for potential withdrawals and the stratification 
of participants into two groups with either monophasic or complex glucose curve shapes, 25 
participants were recruited. 
A one-way factorial repeated measures ANOVA (95% confidence interval) was 
conducted to examine the effects of Enzogenol® on postprandial blood glucose and glucose 
response indices in participants within each glucose curve shape classification. Statistical 
analysis was done comparing each dose (50 mg and 400 mg) with control. 
Monophasic and complex groups were statistically compared with an Independent 
Student two-tailed t-test assuming equal variance. Analyses were performed with the SPSS 
software version 25 (IBM Corporation, New York, NY, USA). The results were reported as 
mean ± S.E.M. 
4.3 Results 
Twenty-five healthy participants (ten men and fifteen women, mean age 24.8 ± 0.8 
years) were recruited into the study. All participants completed both the control and the 50 
mg Enzogenol® visit, and 20 also completed the 400 mg Enzogenol® study visit. The 
demographics of this group and the comparison between the monophasic and complex groups 






data of mean BMI (21.2 ± 0.4 kg/m2), FBG (4.4 ± 0.1 mmol/L), HbA1c (33 ± 0 mmol/mol), 
blood pressure (systolic 109 ± 2, diastolic 67 ± 1 mmHg), and lipid profiles [45]. There was 
no significant difference in baseline characteristics between the monophasic and complex 
groups (p>0.05). 
 




















N 25 NA 12 13 - 
Gender (M/F) 10/15 NA 3/9 7/6 - 
Age (years) 24.8 ± 0.8 20–33 25.4 ± 1.1 24.2 ± 1.2 0.44 
BMI (kg/m2) 21.2 ± 0.4 18.1–25.3 21.2 ± 0.6 21.2 ± 0.5 1.00 
FBG (mmol/L) 4.4 ± 0.1 3.6–5.2 4.5 ± 0.1 4.3 ± 0.1 0.55 
HbA1c 
(mmol/mol) 33 ± 0 29–38 33 ± 1 34 ± 1 0.24 
SBP (mm Hg) 109 ± 2 89–133 112 ± 4 107 ± 2 0.30 
DBP (mm Hg) 67 ± 1 47–77 66 ± 2 68 ± 2 0.45 
TC (mmol/L) 4.09 ± 0.12 3.06–5.27 4.07 ± 0.13 4.10 ± 0.20 0.89 
TG (mmol/L) 1.15 ± 0.13 0.56–3.71 1.30 ± 0.25 1.02 ± 0.11 0.30 
HDL-C 
(mmol/L) 1.50 ± 0.08 0.98–2.49 1.47 ± 0.11 1.54 ± 0.11 0.67 
LDL-C 
(mmol/L) 2.06 ± 0.09 1.23–2.93 2.01 ± 0.13 2.10 ± 0.12 0.60 
Non-HDL-C 
(mmol/L) 2.58 ± 0.09 1.88–3.32 2.60 ± 0.13 2.57 ± 0.13 0.87 
TC/HDL-C 
ratio 2.82 ± 0.10 1.8–4.1 2.89 ± 0.17 2.75 ± 0.12 0.49 
Values are means (± SEM). Abbreviations: BMI: body mass index; FBG: fasting blood 
glucose; HbA1c: glycated haemoglobin A1c; SBP: systolic blood pressure; DBP: 
diastolic blood pressure; TC: total cholesterol; TG: triglycerides; HDL-C: high-density 
lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol. 
 
The overall data obtained from all participants was first analysed before the stratification 
of participants into two groups. There was no significant reduction in the primary outcome 
mean glucose iAUC observed between control and intervention with 50 mg of Enzogenol® 
(239.8 ± 19.2 vs. 276.8 ± 23.9 mmol/L·min, 13.4% reduction, p=0.123), but a significant 
reduction between the control and 400 mg of Enzogenol® (235.7 ± 16.5 vs. 299.5 ± 26.9 
mmol/L·min, 21.3% reduction, p=0.016). There was no significant dose response between 






The participants were then classified into two distinct groups based on their glucose 
curve shapes at the control visit, either monophasic or complex group. Participants with 
monophasic shapes were shown to have a significantly higher mean glucose iAUC (p=0.015) 
and glucose peak values (p=0.021) than participants with complex shapes at the control visit, 
indicating the presence of two distinct groups with dissimilar glycaemic control. The effects 
of Enzogenol® on postprandial glucose excursion differed depending on the type of 
postprandial glucose curve shapes participants exhibited at the control visit (Figures 4.1 and 
4.2). In Figure 4.1, involving participants with monophasic shapes, a consistent trend of 
reduced glucose levels was observed with both doses of Enzogenol® compared to the control, 
although significantly lower glucose levels at 30, 60, and 120 min were only seen in the 
intervention with a 400 mg dose. Figure 4.2 illustrated more heterogeneous glucose 
excursions involving participants having complex shapes with no obvious trend after 
consuming both doses of Enzogenol®. 
In the monophasic group, 33.4% of participants shifted from monophasic to having 
complex shapes (16.7% with biphasic and 16.7% with triphasic) after consuming 50 mg of 
Enzogenol®, and 54.6% of participants shifted to having complex shapes (18.2% with 
biphasic and 36.4% with triphasic) after consuming 400 mg of Enzogenol®. 
With reference to Table 4.2, Enzogenol® significantly reduced mean glucose iAUC in 
participants with a monophasic shape compared to control at both 50 mg (241.3 ± 20.2 
mmol/L·min vs. 335.4 ± 34.0 mmol/L·min, 28.1% reduction, p=0.034) and 400 mg of 
Enzogenol® (249.3 ± 25.4 mmol/L·min vs. 353.6 ± 31.5 mmol/L·min, 29.5% reduction, 
p=0.012). However, there was no significant dose response observed between 50 and 400 mg 
of Enzogenol® within the monophasic group (p=0.881), suggesting that a smaller dose of 50 
mg was equally effective in reducing mean glucose iAUC of participants. In contrast, neither 
dose of Enzogenol® significantly reduced the glucose iAUC in the complex group.  
Mean %PG was reduced in both monophasic and complex groups compared to control. 
Treatment with 400 mg of Enzogenol® in the monophasic group significantly reduced mean 
%PG compared to control (31.4% ± 7.9% vs. 47.5% ± 8.6%, 33.9% reduction, p=0.010). No 
significant reduction in mean %PG was observed in this group after consuming 50 mg 
Enzogenol®. In the complex group, compared to control, the mean %PG was significantly 
reduced by both 50 mg (28.7% ± 8.2% vs. 43.4% ± 5.9%, 33.8% reduction, p=0.012) and 400 








Figure 4.1 Mean postprandial glucose (±SEM) of participants with a monophasic 
glucose curve shape during the control and treatment visits with (A) 50 and (B) 400 mg 








































































Figure 4.2 Mean postprandial glucose (±SEM) of participants with a complex glucose 
curve shape during the control and treatment visits with (A) 50 and (B) 400 mg of 
Enzogenol®. † p<0.05 for 50 mg Enzogenol® compared to control, * p<0.05 for 400 mg 




































































Table 4.2 Parameters of glycaemic response in participants classified as having either a monophasic or complex glucose curve shape at control visit 




Monophasic Group Complex Group 
Control 
Paired to 
50 mg of 
Enzogenol® 




400 mg of 
Enzogenol® 




50 mg of 
Enzogenol® 




400 mg of 
Enzogenol® 
400 mg of 
Enzogenol® p 
n 12 - 11 - 13 - 9 - 




335.4 ± 34.0 




31.5 ‡ 249.3 ± 25.4 
0.012 
* 
222.7 ± 26.6 
† 238.4 ± 32.7 0.392 




Mean %PG 44.9 ± 8.3 28.9 ± 3.8 0.083 47.5 ± 8.6 31.4 ± 7.9 0.010 * 43.4 ± 5.9 28.7 ± 8.2 0.012* 47.3 ± 7.2 27.7 ± 5.4 
0.025 
* 
Mean time to 
glucose peak 
(min) 




8.8 ± 0.3† 8.3 ± 0.4 0.177 8.9 ± 0.3‡ 7.9 ± 0.3 0.025 * 7.7 ± 0.3 
† 8.2 ± 0.4 0.315 7.8 ± 0.3 ‡ 8.0 ± 0.3 0.531 
Mean 2hPG 
(mmol/L) 6.6 ± 0.2 6.3 ± 0.2 0.171 6.7 ± 0.3 6.1 ± 0.3 
0.027 
* 6.3 ± 0.2 5.9 ± 0.3 0.149 6.5 ± 0.3 6.1 ± 0.2 0.224 
* Significant difference between control and 50 or 400 mg of Enzogenol® within each glucose curve shape group (p<0.05); † Significant difference in control visit values 
between monophasic and complex glucose curve shape groups at 50 mg of Enzogenol® (p<0.05); ‡ Significant difference in control visit values between monophasic and 
complex glucose curve shape groups at 400 mg of Enzogenol® (p<0.05); Abbreviations: iAUC: incremental area under the curve of postprandial glucose; %PG: 






There was no significant difference in mean time to glucose peak observed between 
control and all treatments in monophasic and complex groups. Most participants had their 
glucose peaking at 30 min during the OGTT, with a higher percentage of participants in the 
complex group having an earlier glucose peak at 15 min compared to monophasic group. 
Within the monophasic group, a reduction in the mean glucose peak value was observed 
following both 50 and 400 mg of Enzogenol®, with the 400 mg dose being statistically 
significant (7.9 ± 0.3 vs. 8.9 ± 0.3 mmol/L, 11.2% reduction, p=0.025) (Figure 4.1). There 
was no significant difference observed between control and treatments within the complex 
group. 
Mean 2hPG was significantly reduced in the monophasic group treated with 400 mg of 
Enzogenol® (6.1 ± 0.3 vs. 6.7 ± 0.3 mmol/L, 8.9% reduction, p=0.027) (Figure 4.1). No 
significant changes were observed with 50 mg or in the complex group. 
There was a lack of significant dose response observed between the two doses 50 and 
400 mg in both the monophasic and complex groups in the primary and secondary outcome 
measurements (p>0.05). 
4.4 Discussion 
Type 2 Diabetes Mellitus is a worldwide epidemic with an increasing number of people 
not adhering to a healthy diet and an active lifestyle as key drivers in the increased risk of 
developing T2DM, although other determining factors such as genetics, environment and 
socioeconomic factors may play a part [5, 46]. Because the progression of normoglycaemia 
towards impaired glycaemic control is a continuum, and even healthy, NGT individuals have 
been shown to have a certain degree of insulin resistance [25, 29-31], it is becoming 
increasingly important to be able to classify individuals based on the varying degrees of 
dysglycaemia. 
In the present study, a significant reduction in the primary outcome mean glucose iAUC 
was only seen for the 400 mg dose of Enzogenol® (p=0.016). However, when the participants 
were stratified by their baseline postprandial glucose curve shapes, it was shown that it was 
effective in reducing the postprandial glucose iAUC at both dose levels in participants with 
monophasic shapes. This group could be termed as responders as they responded well to the 
intervention by demonstrating improved glycaemic responses, such as a significantly reduced 
postprandial glucose iAUC, with additional improvements in other glucose response indices 






who may then be termed as non-responders, as no significant improvements in the primary 
outcome glucose iAUC and other glucose response indices measured, except for %PG were 
evident. 
To the best of our knowledge this is the first study to report on the glycaemic-lowering 
properties of New Zealand pine bark extract in humans. Prior to this study, a diabetic mouse 
model fed with Enzogenol® was reported to improve diabetes-related biomarkers with a 
reduction in HbA1c, insulin, and glucagon levels, and an elevation of hepatic AMP-activated 
protein kinase (AMPK) activity [47]. Pcynogenol®, a French maritime pine bark containing 
similar types of phenolic content but in different quantities compared to Enzogenol®, has 
been more extensively studied. Several chronic human trials have examined the impact of 
Pcynogenol® in doses of 50–300 mg on glycaemic responses, such as FBG and HbA1c in 
T2DM participants [39-41]. All three studies showed a significant reduction in FBG and two 
studies showed a significant reduction in HbA1c. These studies elucidated the potential 
hypoglycaemic effects of pine bark, although they were conducted in T2DM participants, 
which differed from the present study with healthy participants. 
The present study has employed the use of various glycaemic response indices during the 
2h OGTT in relation to postprandial glucose curve shapes to investigate if Enzogenol® would 
have an impact on various indicators of glycaemic control. 
A study conducted by Schianca et al. (2010) elucidated that normoglycaemic individuals 
with lower %PG closer to FBG possessed higher insulin sensitivity and decreased insulin 
secretion compared to individuals with higher %PG [30]. Treatment with 400 mg of 
Enzogenol® in the monophasic group and both doses, 50 and 400 mg, in the complex group 
significantly reduced %PG compared to control. The reduction in %PG could indicate the 
increased rate in returning postprandial blood glucose back to baseline FBG after two hours 
in both monophasic and complex groups with the consumption of Enzogenol®, which would 
suggest that there was a potential acute improvement in glycaemic control [48]. 
Research has shown that individuals exhibiting a monophasic glucose curve shape 
compared to those with a complex glucose curve shape (biphasic or triphasic) had a delayed 
rise in glucose with a later glucose peak, a higher glucose peak value, and a higher 2h 
postprandial glucose value, and are more likely to be at an increased risk of diabetes due to 
suboptimal glycaemic control [24, 43]. Our observations agree with other studies where 
individuals with monophasic shapes exhibited higher postprandial glucose concentrations 
[23-28]. A delay in glucose peak time often indicates reduced insulin sensitivity and secretion 






was indicated to be a reproducible independent indicator of impaired glycaemic control [43, 
50]. Participants in the present study had mean glucose peaks occurring within 30 min on 
average for the complex group at control and with both treatments with Enzogenol® (p>0.05). 
In contrast, the mean time to glucose peak in the monophasic group was slightly above 30 
min for both control and treatments with Enzogenol®, although the time to glucose peak was 
shorter compared to control (p>0.05). 
The level of glucose peak has been associated with increased oxidative stress 
corresponding to the level of postprandial glucose toxicity [51]. Hulman et.al. concluded that 
a higher than normal glucose peak is more predictive of abnormality with insulin sensitivity 
than an absolute 2hPG value [52]. A recent cohort study further elucidated that individuals 
with a higher intermediate glucose value and a lower 2hPG value were associated with a 
higher risk of future diabetes than those with a higher 2hPG but a lower intermediate glucose 
value [53]. The present study found that 400 mg of Enzogenol® was able to significantly 
reduce the glucose peak value compared to control in the monophasic group (p=0.025). 
In the San Antonio Metabolism (SAM) study, so-called “normal” glucose-tolerant 
individuals having 2hPG values within the range of 6.7 to 7.8 mmol/L were found to exhibit 
a 40–50% decrease in β-cell function compared to individuals with 2hPG lesser than 5.6 
mmol/L [31]. Participants in the present study had mean 2hPG values that were lower than 
the at-risk range in all treatments except for participants in the monophasic group. 
Monophasic participants in the present study had a mean 2hPG value of 6.6 ± 0.2 mmol/L 
(this being obtained from capillary blood sample instead of plasma, as in the SAM study), 
which was close to the stated range indicative of a certain degree of β-cell dysfunction. 
However, this higher 2hPG value was diminished with a subsequent treatment with 
Enzogenol®. 
One of the merits of the study was the use of a robust crossover design where 
participants were their own control and underwent each of the treatments, and therefore a 
smaller sample size was required for the same level of significance. To our knowledge, this 
present study was one of the first intervention studies to classify normoglycaemic participants 
based on their degrees of impaired glycaemic control dependent on their glucose curve 
shapes, with the inclusion of useful glycaemic indices to determine if Enzogenol® was 
effective in improving glycaemic responses. Furthermore, the potential modification of 
monophasic shapes into complex shapes with the consumption of Enzogenol® was also 
examined. It was observed that about 33% of the monophasic participants changed to having 






participants had complex shapes after consuming 400 mg of Enzogenol®. This might 
potentially alter T2DM risk based on the glucose shapes. This observation was in line with 
Manco et al. (2017), who concluded that individuals who persisted in having monophasic 
shapes and those who switched from having biphasic to monophasic shapes over a prolonged 
period had an increased risk of impaired glycaemic control [54]. A longer-term study is 
warranted to examine the persistence in shape alteration in relation to changes in glucose 
metabolism with the consumption of Enzogenol®. 
Nevertheless, the study was not without limitations, which may include determining the 
glucose curve shapes based on the results of a single OGTT. Although, OGTT has been 
known as a sensitive test to detect mild disturbance in glucose metabolism and disposal [55], 
its reproducibility has been questioned. This was due mainly to differences in the rate of 
glucose absorption and insulin responses with varying degrees of glucose and insulin 
oscillations in individuals [56] and intra-individual variations [57-59], although one study 
found it to be repeatable in healthy individuals [60]. Hence, having repeated OGTT at 
baseline may improve reproducibility. 
The classification of individuals into different glucose curve patterns might be simple 
and useful in an acute study with a smaller sample size, such as in the present study, but 
limitations may include the possible misclassification of individuals, especially if they exhibit 
heterogeneous glucose curves. However, we have classified our participants based on the 
calculations by Tschritter et al. (2003) [23] and verified with each postprandial glucose curve 
of each participant at the control visit to ensure there was no misclassification. 
This study also only looked at postprandial glycaemic responses. Future studies should 
include insulin or C-peptide measurements to further our understanding of the effect of 
Enzogenol® consumption on insulin secretion, insulin sensitivity, and β-cell function (e.g., 
HOMA-IR, Matsuda index, and other measures). Future work may also explore the 
underlying mechanistic actions of Enzogenol® in its glucose modulating effects in order to 
optimise on the dosage effective for lowering postprandial blood glucose. More investigation 
is warranted regarding the physiological metabolism of Enzogenol® in humans through 
characterising phenolic metabolites from biological samples to investigate how the extract is 
being metabolised, absorbed, transformed, and excreted from the body. Future studies should 
also measure chronic glycaemic responses to Enzogenol® over at least 8–12 weeks in both 
normo and hyperglycaemic participants. Future studies could also look into how Enzogenol® 






consumption that helps to maintain a healthy glycaemic control and extend its functionality to 
individuals with varying degrees of impaired glycaemic control. 
4.5 Conclusions 
The present study in healthy participants shows that Enzogenol® has hypoglycaemic 
effects, however, there was significant variation in inter-individual response, which appears 
to be driven by dissimilar individual glycaemic profile, with participants having monophasic 
glucose curve shapes showing greater improvements in postprandial glucose responses. 
Compared to healthy participants with complex glucose curve shapes, monophasic 
participants showed a significant improvement in mean glucose iAUC for both 50 and 400 
mg doses of Enzogenol®, with a further reduction in glucose peak value, 2hPG, and %PG 
with 400 mg of Enzogenol® compared to control. In contrast, glycaemic responses in 
participants with complex glucose curve shapes were not altered with the ingestion of 
Enzogenol® except for significant reduction in %PG values. Although Enzogenol® appears to 
show hypoglycaemic potential, future studies are warranted to examine the effect on other 
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Hypoglycaemic effects of antioxidant-
rich plant extracts on postprandial 
glycaemic responses in participants 




This chapter presents the study outcomes examining the effect of three plant extracts: grape 
seed, rooibos tea and olive leaf on glycaemic control in participants with prediabetes. This 















Background: Prediabetes is a state of intermediate hyperglycaemia and is considered a 
critical stage for intervention to potentially reduce the risk of type 2 diabetes mellitus 
(T2DM) development. Dietary polyphenols such as plant extracts may help in glycaemic 
control.  
Objective: Investigate the acute effect of grape seed, rooibos tea, and olive leaf extracts on 
postprandial blood glucose and insulin responses in participants with prediabetes.  
Methods: An acute, single-blind, placebo-controlled, crossover study 
(ACTRN12617000837325) where extracts of grape seed, rooibos tea and olive leaf, and 
placebo were given on separate occasions with an oral glucose tolerance test to 19 
participants. Measures of glycaemic indices were performed and data analysed using linear 
mixed model for repeated-measures. 
Results: Participants were classified into either a healthier or less healthy subgroup based on 
the time to peak of glucose and insulin. In the less healthy subgroup, all extracts showed 
improvements in glycaemic responses. Compared to placebo, grape seed reduced glucose 
levels such as incremental area under the curve of glucose, iAUCglucose (p=0.016, 21.9% 
reduction), 2h postprandial glucose, 2hPG (p=0.034, 14.7% reduction) and metabolic 
clearance rate of glucose, MCR (p=0.016, 16.7% increase), and improved indices of insulin 
such as 2h postprandial insulin, 2hPI (p=0.029, 22.4% reduction) and Stumvoll overall 
insulin sensitivity index, ISIoverall (p=0.028, 15.0% increase). Rooibos tea extract significantly 
improved β-cell function as demonstrated by the increased oral disposition index, DI 
(p=0.031, 32.4% increase) and showed trend towards improvement for insulin-secretion-
sensitivity index-2, ISSI-2 (p=0.06, 19.9% increase) compared to placebo. Olive leaf extract 
significantly increased insulin secretion by an increased incremental area under the curve, 
iAUCinsulin (p=0.040, 16.7% increase) and showed trend towards improvement for indices of 
insulin sensitivity such as Stumvoll first phase insulin sensitivity index, ISIfirst (p=0.08, 
17.8% increase), Stumvoll second phase insulin sensitivity index, ISIsecond, (p=0.06, 15.6% 
increase), and insulinogenic index, IGI30 (p=0.08, 27.8% increase) compared to placebo. 
Conclusions: Grape seed, rooibos tea and olive leaf extracts demonstrated acute 
hypoglycaemic benefits in individuals with prediabetes with a less healthy metabolic profile. 
A chronic study on the plant extracts is warranted to determine their longer-term impact on 
prediabetes. 
	  





Prediabetes is characterised by isolated impaired fasting glucose (IFG) or isolated 
impaired glucose tolerance (IGT), or a combination of both (IFG/IGT) [1]. It is the 
intermediate state of hyperglycaemia with blood glucose levels above normal but below the 
threshold to be classified as type 2 diabetes mellitus (T2DM) [2]. It is estimated that globally, 
374 million (ages 20-79 years) (7.5%) people have prediabetes and the global prevalence is 
projected to be 548 million (8.6%) by 2045 [3]. Prediabetes has an annual conversion rate of 
5-10% to T2DM [2, 4]. According to an American Diabetes Association expert panel, up to 
70% of individuals with prediabetes will eventually develop T2DM [5].  
Whilst there is unequivocal evidence that many individuals with prediabetes are able 
to prevent the conversion to T2DM through lifestyle and diet modification [6-9], research is 
scarce regarding the use of complementary medicines and natural plant extracts to treat 
prediabetes. Studies of dietary polyphenols from natural plant sources have shown that some 
could have hypoglycaemic potential [10-17]. Proposed mechanisms by which they can 
improve glucose metabolism include the inhibition of digestive enzymes (α-amylase and α-
glucosidase) and glucose transporters, activation of glucokinase, increase in adiponectin 
levels, and elevation of incretin levels to stimulate glucose-dependent insulin secretion [10, 
11, 18, 19]. Hence, polyphenol-rich plant extracts might be a useful adjunct in the preventing 
progression of prediabetes to T2DM. 
Clinical trials conducted on healthy individuals and those with metabolic syndrome 
and T2DM have shown equivocal results regarding the consumption of grape seed [20-29], 
rooibos tea [29, 30], and olive leaf extracts [31-38] likely due to concomitant medications, 
small sample sizes, as well as the plant extract sources, degree of purification and varying 
concentrations of extract administered in the trials. More importantly the inherent differences 
in metabolic profiles of participants might have likely contributed to the differences observed 
in the studies.  
It is increasingly recognised that individuals with prediabetes are not a homogenous 
group and that differences in metabolic profiles identified as having different postprandial 
glucose shapes [39-44], postprandial glucose indices [40, 45-49], and patterns of insulin 
concentrations [50-52] have been associated with varying degrees of risk towards T2DM. 
Therefore stratification based on the different metabolic profiles is important in order to 
elucidate the impact of intervention on both responders and non-responders [53-55]. This 
	  




would allow the opportunity for optimisation of nutritional interventions for each specific 
metabolic profile.  
More recently, Takahashi and colleagues (2018) examined the stratification based on 
the time to peak in glucose and insulin responses to differentiate between heterogeneous 
metabolic profiles of participants [56]. They classified 62 healthy women into four groups: 
(1) normal type, (2) insulin-late type, (3) insulin- and glucose-late type, and (4) insulin-very 
late type [56]. They observed that whilst the first two groups had no significant differences in 
homeostatic model assessment-insulin resistance (HOMA-IR), homeostatic model 
assessment-beta-cell function (HOMA-β), area under the curve of glucose (AUCglucose) and 
area under the curve of insulin (AUCinsulin), (3) and (4) groups showed distinctly delayed 
insulin secretory responses and elevated AUCglucose. Other studies have corroborated that a 
delay in glucose peak time has been used as a reproducible index for T2DM risk and a value 
of above 30 min indicates presence of insulin resistance and poorer glycaemic control [46, 
47, 57]. Insulin patterns such as delayed insulin response have been linked to defects in β-cell 
function and diminished insulin sensitivity in individuals and are associated with an increased 
risk of developing T2DM [50, 52, 58-63]. Therefore it was useful to employ this stratification 
in the secondary analysis of this present study to explore the response to intervention of 
participants with prediabetes but exhibiting varying metabolic profiles.  
In our previous work we have shown that antioxidant-rich plant extracts such as the 
grape seed and rooibos tea extracts had helped to improve acute postprandial blood glucose 
response by 25-40% in healthy participants [29]. A chronic study conducted by De Bock et 
al. (2013), also demonstrated that with olive leaf insulin sensitivity and pancreatic β-cell 
responsiveness were significantly improved in normoglycaemic, overweight men [33]. To 
date no study has investigated the hypoglycaemic potential of these plant extracts in a group 
with prediabetes.  
The present GLARE (Glucose Lowering Antioxidant-Rich plant Extracts) study 
aimed to examine the acute impact of grape seed, rooibos tea and olive leaf extracts on 
postprandial blood glucose response in individuals with prediabetes living in New Zealand.  
5.2 Materials and Methods 
5.2.1 Study participants 
Participants were recruited from Auckland, New Zealand using poster advertisements 
(Appendix 3.1) within the local university and community (August 2017-May 2019). They 
	  




were selected if they met all inclusion criteria at screening: (1) having prediabetes with a 
glycated haemoglobin A1c (HbA1c) value between 41-49 mmol/mol (5.9-6.6%) or a lower 
HbA1c of 38-40 mmol/mol (5.6-5.8%) and having at least one of the T2DM risk factors 
(overweight or obese, high blood pressure, had prediabetes before, and family history of 
T2DM or cardiovascular disease (CVD)), (2) not taking any form of glucose-lowering 
medications or medications having an iatrogenic nature that may influence glucose 
metabolism, particularly β-blockers for cardiovascular diseases and thiazide diuretics for 
hypertension, (3) no known pancreatic, hepatic, renal or digestive impairments that may alter 
glucose metabolism or metabolism of plant extracts, (4) no known allergies to the plant 
extracts under study, and (5) not smoking. Interested individuals initially completed an online 
screening questionnaire (Appendix 3.2) on T2DM risk (Ministry of Health, New Zealand) 
[64] before potential participants were invited into Massey University Human Nutrition 
Research Centre (MUHNRC) in Auckland for more in-depth screening. Measurements of 
their body composition including height, weight, body fat and muscle mass (Bioelectrical 
Impedance Analysis, InBody 230, Biospace co., Ltd.), waist and hip circumference, blood 
pressure (Omron, HEM-907, Omron Healthcare Co., Ltd.), HbA1c (Cobas b 101 HbA1c test, 
CV 0.8-1.7%, Roche Diagnostics) were taken. Documents of recruitment can be found in 
Appendix 3.3-3.7. 
All participants gave their informed consent for inclusion before they participated in 
the study (Appendix 3.6). The study was conducted in accordance with the Declaration of 
Helsinki, and the protocol was approved by the Massey University Human Ethics Committee 
(MUHEC) (ref: 17/STH/82). The clinical trial was registered prospectively at the Australian 
New Zealand Clinical Trials Registry and accessible at http://www.anzctr.org.au/ 
(ACTRN12617000837325). 
5.2.2 Study design 
The study was an acute, single-blind, placebo-controlled, crossover study involving 
19 participants. The study involved four visits to where participants were required to fast for 
at least ten hours except water before each visit.  
During the control visit, participants were given two placebo capsules to swallow with 
a few sips of water. This was followed by a 2h oral glucose tolerance test (OGTT) involving 
consuming a 300 mL glucose drink containing 75 g of glucose (Carbotest, Fronine, Thermo 
Fisher Scientific, Australia) within five minutes, and repeated measures of blood glucose 
	  




during the following two hours. The subsequent three visits involved consuming one of the 
three plant extracts in the following order: grape seed, rooibos tea, and olive leaf on separate 
visits with at least a washout period of one week between visits. The OGTT procedure was 
repeated for each visit. All three plant extracts were matched for their antioxidant capacity 
and administered in standardised capsule form. Antioxidant capacity has been shown in 
previous research to correlate with total phenolics [65, 66], and hence a good indicator of 
overall phenolic composition within each plant extract. 
At each visit baseline venous blood samples were taken at 10 min prior to the 
consumption of the capsules, followed by another baseline sampling at t=0 min before the 
commencement of the OGTT. Further blood samples were obtained at t=15, 30, 45, 60, 90, 
and 120 min. Blood draws were done by having the participant lie in a supine position and 
cannulating the antecubital fossa region of the arm. Blood samples were collected into 
heparin and serum tubes and centrifuged at 3,500 rpm for 15 min at 4°C. Blood collected in 
heparin tubes were immediately centrifuged after collection, whilst blood collected in serum 
tubes were left to coagulate for at least half an hour before centrifuging. They were then 
aliquot into Eppendorf tubes and stored at -80°C until analysis.  
At each trial visit, all participants were checked for dietary and lifestyle compliance, 
such as having fasted at least 10 hours prior to the visit, keeping their diet constant, no 
strenuous physical activity, no alcohol, no caffeinated tea or coffee formulations, no health 
supplements 24 hours prior to the visit, and no consumption of active plant extracts (grape 
seed, rooibos tea, olive leaf) throughout the duration of the study. Data collection form can be 
found in Appendix 3.8.  
5.2.3 Treatments 
All the plant extract samples were obtained commercially. Grape seed extract (Vitis 
vinifera) (Nutra-Life, Vitaco Health (NZ) Ltd.) was produced with 40 g of dry grape seed and 
10 g of fresh grape seed per capsule and contained 640 mg of procyanidins in the 
concentration given to participants. Rooibos tea extract (Aspalathus linearis, E2CCJ) 
(Rooibos Limited, South Africa) contained at least 485 mg of total polyphenols in the 
concentration given to participants. Olive leaf extract (Olea europaea) (Comvita NZ Ltd) was 
made from 3.5 g of fresh leaf suspended in olive oil per capsule and contained 264 mg of 
oleuropeins in the concentration given to participants. The plant extracts were 
commercialised products and had no known adverse toxic effects associated with them or 
similar products as the levels consumed [67-69]. All extracts were prepared according to 
	  




good manufacturing practice (GMP). The placebo capsule was made of 500 mg 
microcrystalline cellulose. 
Sample extracts of grape seed, rooibos tea, and olive leaf were sent to Callaghan 
Innovation (Wellington, New Zealand) to determine their total antioxidant capacity (TAC) 
using the Oxygen Radical Absorbance Capacity (ORAC) assay. Following a previous study, 
but with some modifications [70], the ORAC assay was carried out with each sample of plant 
extract dissolved in a ratio of ethanol:water mixture (70:30, v/v) and their TAC determined.  
Extracts of grape seed, rooibos tea, and olive leaf were matched at similar TAC 
content at 8,499 trolox equivalent (TE) µmol, 8,496 TE µmol, and 9,152 TE µmol, 
respectively, with concentrations based on a previous study [29]. Due to the nature of the 
olive leaf extract that was suspended in oil in a soft-gel and packed in a hard casing, contents 
could not be modified to obtain closer TAC values with grape seed and rooibos tea extracts.  
5.2.4 Measures of glucose and insulin responses during the OGTT 
The primary outcome of this study was incremental area under the curve of glucose 
(iAUCglucose). The mean iAUC of the blood glucose (iAUCglucose) and insulin (iAUCinsulin) 
were analysed using the trapezoidal rule [71, 72]. Other indices of glucose such as 2h 
postprandial glucose value (2hPG), and glucose peak time were measured. Time to glucose 
peak was defined as the time point on the OGTT when the glucose level was highest. If two 
equal peaks occurred during the OGTT, the earlier peak was considered as the peak. 
Similarly, iAUCinsulin, 2h postprandial insulin (2hPI), and insulin peak time were calculated. 
Insulin sensitivity indices such as the Matsuda Insulin Sensitivity Index (ISI/M) [73], 
Stumvoll overall insulin sensitivity (ISIoverall) [74], and Oral Glucose Insulin Sensitivity 
(OGIS) [75] were calculated. The OGIS was calculated using a web-based computerised 
formula assessable at: http://webmet.pd.cnr.it/ogis/ogis.php). The insulin early phase 
responses were captured by insulinogenic index (IGI30) [76] and Stumvoll first (ISIfirst), 
whilst the late phase by Stumvoll second phase (ISIsecond) insulin sensitivity indices [74]. The 
pancreatic β-cell function was calculated using the Insulin Secretion-Sensitivity Index-2 
(ISSI-2) [77] and oral disposition index (DI) calculated as ratio of IGI30 to fasting insulin 
[78]. The metabolic glucose clearance rate (MCR) was also calculated [74]. The 
aforementioned glucose and insulin indices have been selected based on their reproducibility 
as surrogate measures deriving from the OGTT procedure [46, 79-82]. Refer to Appendix 
4.1 for the formulas and calculations of indices used. 
	  




5.2.5 Analysis of blood samples 
Plasma glucose and insulin samples were measured in a commercial laboratory 
(Waitemata District Health Board North Shore Hospital, Auckland, New Zealand). Plasma 
glucose concentrations were measured by the hexokinase method [83] (Vista GLU Flex® 
reagent cartridge, total CV 2-3%, Dimension Vista® 1500 System, Siemens Healthcare 
Limited). Plasma insulin was measured by a two-site sandwich immunoassay using direct 
chemiluminescent technology [84] (ADVIA Centaur Insulin assay, total CV 6.3-7.5%, 
Siemens ADVIA Centaur XP, Siemens Healthcare Limited).  
5.2.6 Stratification into prediabetes subgroups 
As impaired glycaemic control involves a set of heterogeneous disorders [55], it is 
useful in the present study to subdivide them into two distinct metabolic subgroups (healthier 
versus less healthy group) to determine their respective response to intervention using the 
Takahashi et al. (2018) stratification method [56]. Secondary analysis was therefore 
performed on subgroups of the prediabetes cohort. The healthier subgroup (n=10) consisted 
of individuals having both normal glucose and insulin peak times (30 min) or normal glucose 
peak time (30 min) with a delayed insulin peak (60 min). The less healthy subgroup (n=9) 
had delayed glucose (60 min) with delayed insulin peaks (≥60 min), or normal glucose peak 
time (30 min) with very delayed insulin peaks (120 min). Refer to Appendix 4.2 for details 
of stratification methods considered. 
5.2.7 Statistical analysis 
Statistical analyses were performed using IBM SPSS statistics version 27 (IBM 
corporation, New York, US). A power calculation was performed based on Moore et. al. 
study, with an effect reduction of 100 mmol.min/L targeted and at least 16 participants were 
required [85, 86]. A linear mixed model for repeated-measures using the repeated covariance 
compound symmetry with estimation employing restricted maximum likelihood (REML) was 
employed. Bonferroni pairwise comparison was used to observe for potential differences 
between treatments when required. A p value of ≤0.05 was considered to be significant (95% 
confidence level). A p value of <0.10 was also considered as a trend tending towards 
statistical significance. The data are expressed as model-adjusted mean ± standard error of 
the mean (SEM).  
A secondary analysis was performed on subgroups of the prediabetes cohort. 
Takahashi et al. (2018) stratification method [56] was used to subdivide the GLARE study 
	  




participants into two distinct metabolic subgroups (healthier versus less healthy group) to 
determine their respective responses to the intervention. Similarly, secondary analysis was 
conducted using linear mixed model for repeated-measures with repeated covariance 
compound symmetry after stratifying participants into two distinct metabolic profile 
subgroups (healthier versus less healthy group). A p value of ≤0.05 was considered to be 
significant (95% confidence level). A p value of <0.10 was also considered as a trend tending 
towards statistical significance. Differences between the two subgroups were analysed using 
unpaired independent Student t-test assuming equal variances. The data are expressed as 
model-adjusted mean ± standard error of the mean (SEM).  
5.3 Results  
5.3.1 Participant characteristics at baseline 
Nineteen participants with prediabetes (five men and fourteen women) completed the 
study (Refer to Figure 5.1 for CONSORT flow diagram under appendix of this chapter). The 
overall mean age of the participants was 65.0 ± 1.6 years of age, with a mean Body Mass 
Index (BMI) of 27.3 ± 1.1 kg/m2, and mean HbA1c value of 42 ± 1 mmol/mol. Participant 
baseline characteristics are reported in Table 5.1. Eight out of 19 participants had other 
accompanying comorbidities such as hypertension, high cholesterol and heart disease and 
were taking medications on a consistent basis. These medications were assessed to have no to 
minimal influence on glucose metabolism. Two participants were withdrawn from the study 
due to problems obtaining enough blood samples via cannulation during visits.  
Stratification of the participants into the two subgroups of prediabetes (healthier 
versus less healthy group) was based on their glucose and insulin peak times at baseline [56]. 
The baseline characteristics of the participants after the stratification are presented in Table 
5.1. Baseline 1h and 2h postprandial glucose, as well as 2hPI were significantly different 























mean (± SEM) 




N 19 10 9 NA 
Gender (M/F) 5/14 2/8 3/6 NA 
Age (years) 65.0 ± 1.6 63.0 ± 2.5 67.2 ± 1.9 0.21 
Body Mass Index (kg/m2) 27.3 ± 1.1 26.0 ± 1.7 28.6 ± 1.3 0.25 
Fasting blood glucose 
(mmol/L) 
5.7 ± 0.1 5.6 ± 0.2 5.9 ± 0.2 0.37 
1h postprandial glucose 
(mmol/L) 
8.5 ± 0.7 6.6 ± 0.5 10.6 ± 0.9 0.001* 
2h postprandial glucose 
(mmol/L) 
6.9 ± 0.7 5.0 ± 0.3 8.9 ± 1.2 0.003* 
Fasting insulin  (mU/L) 8.0 ± 1.1 7.2 ± 1.2 9.0 ± 2.0 0.42 
1h postprandial insulin 
(mU/L) 
70.5 ± 9.2 78.4 ± 12.1 61.8 ± 14.2 0.39 
2h postprandial insulin 
(mU/L) 
50.5 ± 5.8 38.6 ± 6.5 70.1 ± 11.0 0.022* 
Glycated haemoglobin 
A1c (mmol/mol) 
42 ± 1 41 ± 1 43 ± 1 0.25 
Systolic blood pressure 
(mm Hg) 
135 ± 5 130 ± 5 141 ± 8 0.24 
Diastolic blood pressure 
(mm Hg) 
79 ± 3 79 ± 5 80 ± 4 0.92 
Values were presented as means ± SEM. The less healthy subgroup consisted of participants with 
combined delayed glucose (60 min) and delayed insulin peaks (≥60 min), or normal glucose peak 
time (30 min) with very delayed insulin peaks (120 min). * indicates significant difference between 
healthier and less healthy subgroups, p<0.05 using the student t-test assuming equal variance. 
 
5.3.2 Plant extracts and their impact on overall glucose and insulin indices in 
participants 
The impact of each plant extract (grape seed, rooibos tea and olive leaf) on glucose 
and insulin responses in comparison to placebo are shown in Table 5.2. Overall, there were 
no significant differences in glucose and insulin indices between plant extracts and placebo, 















Table 5.2 Overall results of glycaemic indices of participants in all the trials 
Analysis Control 
(placebo) 
Grape seed Rooibos 
tea 
Olive leaf p value 
Glucose indices 
Mean incremental area 












2h postprandial glucose 
(mmol/L) 
6.9 ± 0.7 6.6 ± 0.7 6.9 ± 0.7 7.0 ± 0.7 0.82 
Glucose peak time (min) 39.5 ± 4.1 43.4 ± 4.1 43.5 ± 4.2 36.8 ± 4.2 0.10 
Metabolic clearance rate 
of glucose (mL/kg.min) 
7.5 ± 0.6 7.6 ± 0.6 7.5 ± 0.6 7.1 ± 0.6 0.31 
Insulin sensitivity indices 
Matsuda index 5.3 ± 0.7 5.3 ± 0.7 5.4 ± 0.7 5.1 ± 0.7 0.87 











Stumvoll overall insulin 
sensitivity index 
(pmol/L) 
0.08 ± 0.01 0.08 ± 0.01 0.08 ± 0.01 0.07 ± 0.01 0.15 
Early and late phase insulin response and sensitivity indices 
Insulinogenic index 0.9 ± 0.2 1.0 ± 0.2 0.9 ± 0.2 1.0 ± 0.2 0.63 
Stumvoll first phase 











Stumvoll second phase 











β-cell function indices 
Insulin-secretion-
sensitivity-index  
34.0 ± 3.5 33.7 ± 3.5 33.7 ± 3.6 34.5 ± 3.6 1.00 
Oral disposition index  
(by insulin) 
0.12 ± 0.03 0.14 ± 0.03 0.13 ± 0.03 0.15 ± 0.03 0.68 
Insulin secretion and response indices 
Mean incremental area 












2h postprandial insulin 
(mU/L) 
53.5 ± 7.1 50.9 ± 7.1 51.4 ± 7.3 62.4 ± 7.3 0.15 
Insulin peak time (min) 75.8 ± 6.4 74.2 ± 6.4 82.9 ± 6.7 67.1 ± 6.7 0.15 
Values were adjusted means ± SEM based on linear mixed model using compound symmetry as 
repeated covariance with restricted maximum likelihood (REML) estimation.  
 
	  




5.3.3 Plant extracts and their impact on glucose and insulin indices after 
stratification of participants based on glucose and insulin peak time patterns 
Figure 5.2 shows the postprandial glucose and insulin responses of the participants in 
the healthier and less healthy subgroups after the stratification based on the Takahashi et al. 
method (2018).  
In the healthier subgroup, there was no significant impact on either glucose or insulin 
indices with any of the three plant extracts except for a significantly higher 2hPI in the olive 
leaf extract treatment compared to placebo (p=0.030, 49.5% higher) (Table 5.3). The higher 
insulin concentration inevitably led to a reduced ISIoverall (p=0.032, 12.5% decrease) and 
MCR (p=0.040, 10.2% decrease). 
In the less healthy subgroup, grape seed was shown to significantly reduce iAUCglucose 
(p=0.016, 21.9% reduction), 2hPG (p=0.034, 14.7% reduction), 2hPI (p=0.029, 22.4% 
reduction), and improve ISIoverall (p=0.028, 15.0% increase) and MCR (p=0.016, 16.7% 
increase) compared to placebo (Table 5.3). Rooibos tea extract significantly improved DI 
(p=0.031, 32.4% increase) and showed trend toward improvement for ISSI-2 (p=0.07, 18.3% 
increase) compared to placebo (Table 5.3). Olive leaf extract was observed to significantly 
increase iAUCinsulin (p=0.040, 16.7% increase), and showed trend toward improvement for 
ISIfirst (p=0.08, 17.8% increase), ISIsecond, (p=0.06, 15.6% increase), as well as IGI30 (p=0.08, 
27.8% increase) compared to placebo (Table 5.3). 
There were no significant differences in both glucose and insulin indices amongst the 
treatments in both subgroups (p>0.05). 
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Figure 5.2 Unadjusted mean postprandial plasma glucose and insulin of participants during an oral 
glucose tolerance test (OGTT). (A) Postprandial glucose of participants in the healthier subgroup (n=10) 
(normal glucose and insulin peak times (30 min) or delayed insulin peak (60 min) at control visit and 
treatment visits. (B) Postprandial glucose of participants in the less healthy subgroup (n=9) (combined 
delayed glucose (60 min) and delayed insulin peaks (≥60 min), or normal glucose peak time (30 min) with 
very delayed insulin peaks (120 min)) at control visit and treatment visits. (C) Postprandial insulin of 
participants in the healthier subgroup (n=10). (D) Postprandial insulin of participants in the less healthy 
subgroup (n=9). Linear mixed model for repeated-measures with repeated covariance compound 
symmetry was used to derive statistical significance. * indicates treatment with extract was significantly 
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Values were adjusted means ± SEM based on linear mixed model using compound symmetry as repeated covariance with restricted maximum likelihood (REML) estimation. * indicates significant difference 
(p<0.05) between treatment and placebo.




Grape seed Rooibos tea Olive leaf p value 
Control 
(placebo) 




Mean incremental area under 
the curve of glucose 
(mmol/L.min) 
126.3 ± 38.5 190.8 ± 38.5* 203.1 ± 40.1* 171.0 ± 40.1 0.050 422.0 ± 71.4 329.5 ± 71.4* 381.0 ± 71.4 405.7 ± 71.4 0.08 
2h postprandial glucose 
(mmol/L) 
5.0 ± 0.5 5.8 ± 0.5 5.4 ± 0.5 5.7 ± 0.5 0.51 8.9 ± 1.2 7.6 ± 1.2* 8.4 ± 1.2 8.5 ± 1.2 0.18 
Glucose peak time (min) 31.5 ± 3.2 39.0 ± 3.2 34.2 ± 3.5 31.2 ± 3.5 0.16 48.3 ± 7.3 48.3 ± 7.3 53.3 ± 7.3 43.3 ± 7.3 0.23 
Metabolic clearance rate of 
glucose (mL/kg.min) 
8.9 ± 0.7 8.4 ± 0.7 8.6 ± 0.7 8.0 ± 0.7* 0.18 5.8 ± 0.8 6.8 ± 0.8* 6.3 ± 0.8 6.0 ± 0.8 0.08 
Insulin sensitivity indices 
Matsuda index 5.9 ± 1.0  5.7 ± 1.0 5.9 ± 1.0 5.9 ± 1.0 0.99 4.6 ± 0.8 4.7 ± 0.8 4.8 ± 0.8 4.2 ± 0.8 0.26 
Oral glucose insulin sensitivity 
(mL/min.m2) 
405.4 ± 16.8 392.2 ± 16.8 410.9 ± 17.7 402.3 ± 17.7 0.62 353.7 ± 18.3 365.0 ± 18.3 360.0 ± 18.3 351.6 ± 18.3 0.53 
Stumvoll overall insulin 
sensitivity index (pmol/L) 0.09 ± 0.01 0.08 ± 0.01 0.09 ± 0.01 0.08 ± 0.01* 0.15 0.06 ± 0.01 0.07 ± 0.01* 0.07 ± 0.01 0.06 ± 0.01 0.10 
Early and late phase insulin response and sensitivity indices 
Insulinogenic index 1.3 ± 0.4 1.4 ± 0.4 1.2 ± 0.4 1.5 ± 0.4 0.84 0.5 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.24 
Stumvoll first phase insulin 
sensitivity index (pmol/L) 
1389.8 ± 209.9 1335.3 ± 209.9 1321.5 ± 218.0 1295.2 ± 218.0 0.93 858.4 ± 185.4 1007.5 ± 185.4 890.3 ± 185.4 1011.1 ± 185.4 0.17 
Stumvoll second phase insulin 
sensitivity index (pmol/L) 
362.2 ± 50.3 351.2 ± 50.3 348.6 ± 52.4 339.5 ± 52.4 0.94 240.8 ± 44.9 273.9 ± 44.9 246.9 ± 44.9 278.4 ± 44.9 0.15 
β-cell function indices 
Insulin-secretion-sensitivity-
index  
43.7 ± 4.4 41.5 ± 4.4 38.9 ± 4.6 42.6 ± 4.6 0.58 23.2 ± 4.2 25.0 ± 4.2 27.4 ± 4.2 25.6 ± 4.2 0.34 
Oral disposition index  
(by insulin) 
0.18 ± 0.04 0.20 ± 0.04 0.16 ± 0.05 0.22 ± 0.05 0.65 0.07 ± 0.02 0.08 ± 0.02 0.09 ± 0.02* 0.08 ± 0.02 0.18 
Insulin secretion and response indices 
Mean incremental area under 
the curve of insulin 
(mU/L.min) 
5857.1 ± 991.3 6352.2 ± 991.3 5935.7 ± 1024.6 6158.6 ± 1024.6 0.85 5448.0 ± 1031.8 5175.2 ± 1031.8 5451.0 ± 1031.8 6359.3 ± 1031.8* 0.048 
2h postprandial insulin (mU/L) 38.6 ± 8.4 47.8 ± 8.4 42.8 ± 9.0 57.8 ± 9.0* 0.15 70.1 ± 11.3 54.4 ± 11.3* 60.8 ± 11.3 68.4 ± 11.3 0.11 
Insulin peak time (min) 57.0 ± 7.5 69.0 ± 7.5 64.7 ± 8.3 49.7 ± 8.3 0.27 96.7 ± 7.7 80.0 ± 7.7 100.0 ± 7.7 83.3 ± 7.7 0.06 







Plant extracts have been increasingly gaining attention over the past decade as 
functional agents to improve glycaemic control [10, 87, 88]. The uniqueness of the plant 
extracts used in the present study was the high concentrations of polyphenols and 
antioxidants they contained that could potentially have an impact on glucose metabolism [27-
29, 32, 33, 35, 89-93]. 
To the best of our knowledge the present study is the first to investigate the 
hypoglycaemic impact of grape seed, rooibos tea, and olive leaf extracts in a solely 
prediabetes cohort. No significant results were seen for the group as a whole. As impaired 
glycaemic control involves a set of heterogeneous disorders [55], we stratified the GLARE 
study participants into two distinct metabolic subgroups (healthier versus less healthy group) 
[56] and observed significant differences in response to the intervention given.  
At baseline, participants in the healthier subgroup had significantly lower glucose and 
glucose peak time values, lower 2hPI and insulin peak time, higher OGIS insulin sensitivity, 
Stumvoll ISIoverall, ISIfirst, ISIsecond and IGI30, higher β-cell function and MCR compared to the 
less healthy subgroup. The differences in glucose and insulin levels as well as insulin 
sensitivity justify the stratification of participants into two subgroups with distinct glucose 
metabolic profiles. 
There were no significant changes in glucose and insulin responses in the healthier 
subgroup compared to placebo nor between treatments (p>0.05), except for an increased 2hPI 
and reduced insulin sensitivity in the olive leaf extract due to the increased insulin level 
compared to placebo. Although there was a significantly greater iAUCglucose with grape seed 
(p=0.022) and rooibos tea (p=0.013) extracts compared to placebo in the healthier subgroup, 
the values were significantly lower than the baseline values of the less healthy subgroup. 
In the less healthy subgroup, grape seed extract was shown to be the most effective in 
improving glucose and insulin responses compared to rooibos tea or olive leaf extract. 
Postprandial glucose and insulin concentrations were significantly reduced (p<0.05), whilst 
there was significant improvement in overall insulin sensitivity (p=0.028) and MCR 
(p=0.016) compared to placebo. This finding agrees with previous acute randomised 
controlled trials investigating grape seed extracts of various concentrations (100-500 mg) and 
they were found to improve markers of glucose metabolism in healthy individuals and those 






trials on healthy participants and those with T2DM or metabolic syndrome that showed no 
significant improvement in glycaemia with grape seed extract (150-400 mg/day) [21, 22, 24, 
26]. Differences in the extract grade, doses, small sample sizes and study duration might 
explain the inconsistencies in results.  
Rooibos tea extract was shown to improve the DI (p=0.031, 32.4% increase) 
indicating the possibility of potential improvement to the β-cell function in the less healthy 
subgroup. This was coupled with improved insulin sensitivity ISSI-2 (p=0.07, 18.3% 
increase). These improvements were indicative of improved glycaemic control and were 
aligned with research showing that restoring β-cell function is pivotal to restoring glucose 
homeostasis and delaying T2DM development [94-97]. A previous clinical trial showed 
significant reduction in iAUCglucose in healthy participants after consuming 760 mg of rooibos 
tea extract [29]. However, in the present study although the iAUCglucose (p=0.26, 9.7% 
reduction) and 2hPG (p=0.43, 5.2% reduction) were reduced with an increase in MCR 
(p=0.20, 8.4% increase) indicating higher glucose clearance with rooibos tea extract 
compared to placebo, these did not reach statistical significance. The difference in results 
might be due to the metabolic differences in the participants in the two studies and the higher 
dose used in the previous study. 
Olive leaf extract was consistently shown to elevate insulin levels in the present 
study, with a higher 2hPI in the healthier subgroup (p=0.030) and an elevated iAUCinsulin in 
the less healthy (p=0.040) subgroups compared to placebo. Prior research has demonstrated 
that olive leaf might be an insulin secretagogue and might be suitable for hyperglycaemic 
individuals secreting low levels of insulin due to impairment of the pancreas [98, 99]. 
However, clinical trials have shown a decrease in insulin secretion with subsequent 
improvement in insulin sensitivity. de Bock and co-workers (2013) conducted a 12-week 
clinical study on olive leaf extract (51.1 mg oleuropein, 9.7 mg hydroxytyrosol/day) and 
demonstrated a reduction in insulin secretion with subsequent improvement in insulin 
sensitivity and postprandial glycaemia in overweight participants [33]. Similarly, Wainstein 
and colleagues (2012) also demonstrated significant reduction in fasting insulin with 
accompanying improvement in glucose response in T2DM participants after consuming 500 
mg/day of olive leaf extract for 14 weeks [32]. Komaki and colleagues (2003) also 
demonstrated that 1000 mg of olive leaves consumed with 300 g of cooked rice in a 3h 
OGTT significantly reduced PG at 30 min and 1h in borderline diabetic subgroup (n=7; FBG 
of 6.1-7.8 mmol/L) [31]. Araki and colleagues (2019) also demonstrated significant reduction 






mg/100 g oleuropein, 1.2 mg/100 g hydroxytyrosol in 330 mL of tea beverage three times a 
day) [37]. 
In contrast, a six-week chronic study showed no significant improvements in fasting 
glucose or insulin sensitivity with the consumption of a supplement mix containing 500 
mg/day of olive leaf (80-120 mg oleuropein/day) along with other extracts in hypertensive 
men [34]. Likewise, no significant improvements in glucose and insulin responses were seen 
with pre-hypertensive men after consuming olive leaf extract in juice form (136 mg 
oleuropein, 6 mg hydroxytyrosol/day) for six weeks [35]. The extract types and doses, study 
duration and metabolic profile of participants might have contributed to the differences in 
results observed in comparison to the present acute study.  
A delay in insulin peak or a loss of early phase insulin response is often a glucose 
metabolic defect associated with impaired glycaemic control [100, 101]. Early phase insulin 
response is critical for maintaining glucose homeostasis in the postprandial state by 
suppressing glucagon secretion and inhibiting hepatic glucose production [102-104]. Studies 
have revealed the possibility of restoring healthy postprandial glucose levels or reversing β-
cell function by regenerating the first phase insulin response [103-105]. The present study 
showed that grape seed was able to shorten the time to insulin peak in the less healthy 
subgroup (p=0.054). This was accompanied by a non-significant improvement in ISIfirst 
(p=0.08, 17.4% increase) and IGI30 (p=0.08, 27.8% increase). Olive leaf extract was also 
shown to improve both ISIfirst (p=0.08, 17.8% increase) and IGI30 (p=0.08, 27.8% increase) in 
the less healthy subgroup. Similarly in the study conducted by de Bock and colleagues 
(2013), IGI30 was significantly improved (p=0.013) in non-diabetic, overweight men after a 
12-week consumption of olive leaf extract [33]. Therefore, although changes were not 
significant, this could indicate a possibility of restoring an earlier insulin secretion and 
sensitivity with grape seed and olive leaf extracts. Research has shown that the second or late 
phase insulin secretion is also critically important and is an independent predictor of T2DM 
[106, 107]. In the less healthy subgroup, second phase insulin sensitivity ISIsecond was 
improved with grape seed (p=0.10, 13.7% increase), as well as with olive leaf (p=0.06, 
15.6% increase), however not reaching statistical significance. 
Although the plant extracts tested were matched for total antioxidant capacity to 
efficacy comparison, it was observed that the outcomes were not similar amongst the 
extracts. Several studies have corroborated that the phenolic or antioxidant content of plant 
extracts might not necessarily correlate with the hypoglycaemic actions exhibited [108-111]. 






structurally interact to inhibit digestive enzymes and glucose transporters including utilising 
other glucose metabolism pathways to impact glucose uptake and absorption [10, 11, 18, 19].  
The strengths of the GLARE study included the use of a crossover design where 
participants were their own control resulting in a smaller sample size required. The plant 
extracts examined were also matched for TAC using the ORAC assay that is a well-
researched method, and allowed the comparison of efficacy amongst the extracts. 
Nevertheless, the present study is not without limitations. The current definition of 
prediabetes is somewhat arbitrary and is still expanding, and hence it is yet unclear whether it 
is truly a continuum or spectrum of heterogeneous worsening of glycaemic control [112], or 
whether it is defined by distinct metabolic phenotypes [45]. Studies have elucidated the 
existence of prediabetes spectrum: IFG, IGT and IFG/IGT, and demonstrated them to be 
driven by different underlying dysfunctional metabolic profiles of glucose metabolism that 
included differences in glucose and insulin patterns [100, 101]. The present study had 
recruited participants with prediabetes based solely on their HbA1c values and not on these 
distinct metabolic phenotypes as a much larger sample size would be required. Moreover, 
HbA1c measurement was also not able to distinguish between IFG and IGT individuals 
[113], resulting in a heterogeneous mixture of participants with various glycaemic profiles, as 
demonstrated by studies showing HbA1c-defined prediabetes as exhibiting a mixture of 
metabolic defects of both IFG and IGT [114-116]. In this study three participants had 
IFG/IGT, and two had IFG, and one had IGT in addition to having an elevated HbA1c value. 
The other participants exhibited normal fasting blood glucose (FBG) and 2hPG values but 
also had elevated HbA1c. For this present study stratification and investigation of the 
effectiveness of plant extracts on two metabolically distinct prediabetes subgroups based on 
glucose and insulin response patterns has occurred. However, a limitation of the stratification 
was the smaller sample size in each subgroup. 
One of the merits of using HbA1c for prediabetes screening is its consistency in 
identifying individuals with prediabetes and its reproducibility [64, 115, 117, 118]. It is not 
uncommon that the day-to-day intra-individual variability in both FBG and 2hPG were 
greater than HbA1c [118-120], especially as individuals in transition from normoglycaemia 
into impaired glycaemic control tend to have higher variability in response to an OGTT to 
obtain glucose responses [121-125]. This was corroborated by a study that variation with 
2hPG was 16.7% and FBG, 5.7%, and comparatively less reproducible to HbA1c with a 
variation of only 3.6% [119]. This might be due to HbA1c measuring chronic exposure to 






[126]. However, HbA1c values can be influenced by other factors such as ethnicity, age, 
gender, FPG, BMI, lifestyle and habits such as smoking and alcohol consumption, and 
haemoglobin related conditions [127-129]. This demonstrates the need to include a range of 
surrogate markers of glucose in order to refine the definition of prediabetes for a more 
accurate diagnosis [130, 131]. 
The GLARE study consisted of participants who were only having borderline 
prediabetes (mean HbA1c 42 ± 1), and study outcomes observed in this study might not be 
replicable to those with worsening glycaemic control and having a higher HbA1c reading 
closer to the diabetic range. Furthermore, some study participants (n=6), who at the point of 
screening, had HbA1c values (38-40 mmol/mol) below the NZSSD stipulated 41-49 
mmol/mol [64]. However, the participants were recruited only after being assessed to have at 
least one risk factor for T2DM (overweight or obese, high blood pressure, had prediabetes 
before, and family history of T2DM or CVD). A study conducted by Marini et al. (2014) on 
338 non-diabetic offspring of T2DM parents using American Diabetes Association criteria 
for prediabetes revealed that those with HbA1c values above 39 mmol/mol (5.7%) already 
suffered from a significant faltering insulin sensitivity and β-cell function [132]. Edelman et 
al. (2004) in their research also recommended closer scrutiny for patients with prediabetes 
having high-normal HbA1c (37.7-42.1 mmol/mol, 5.6-6.0%) to elevated HbA1c (43.2-51.9 
mmol/mol, 6.1-6.9%) especially if they were obese, as their diabetes incidence were higher 
each year, 2.5% and 7.8%, respectively [133]. In addition, considering that red blood cell 
renewal cycle varies even in healthy individuals from 38-60 days and 39-56 days in diabetics, 
HbA1c readings might be significantly altered if measurements were taken at different times 
of the cycle [134]. Hence, these participants were included as part of the present study. 
Future studies could also look at using mixed meals instead of liquid glucose as a 
better representation of a typical meal consumed [135]. A recent review concluded from 
studies investigating polyphenol-rich sources that glucose and insulin responses may differ 
based on the polyphenol-carbohydrate combination [136]. In contrast, another study 
discussed the merits of liquid glucose as opposed to mixed meals and concluded that glucose, 
insulin, C-peptide and β-cell function levels were comparable between standardised mixed 
meals and liquid glucose in both healthy and T2DM participants, although such responses 
were higher in healthy participants [137]. 
The present study has only collected data of glycaemic response based on a two-hour 
OGTT. Due to the high phenolic content present in the plant extracts, these plant extracts 






hypoglycaemic effects from the plant extracts may only become apparent after a prolonged 
period of metabolism. Future studies may investigate the metabolites generated from the 
consumption of the plant extracts to understand the type and extent of metabolism of the 
extracts in relation to their effects on glycaemic control. 
Finally, it is recommended for future studies to measure C-peptide, which is co-
secreted in equimolar amounts with insulin and does not undergo hepatic first pass before 
circulation and is not affected by impaired insulin clearance in insulin resistant individuals 
and hence represents a more accurate indication of insulin secretion [140-142]. Furthermore, 
C-peptide based indices have been shown to provide a better prediction and evaluation of 
progression to diabetes and therefore useful for the study of prediabetes [140, 143, 144]. 
In conclusion, the current study has shown the potential acute hypoglycaemic effects 
of grape seed, rooibos tea and olive leaf extracts in improving indices of glucose and insulin 
responses in individuals with prediabetes, particularly those with less healthy metabolic 
profiles. Future chronic study of the plant extracts in individuals with prediabetes will help to 


















Figure 5.1 CONSORT flow diagram for the GLARE study 
Assessed for eligibility (n= 130) 
Excluded (n= 104): 
• Not meeting inclusion 
criteria (n= 49) 
    (HbA1c <38 mmol/mol) (n= 19) 
    (Smoker) (n= 2) 
    (Takes metformin/ sugar control 
med) (n= 8) 
    (Diabetic) (n= 2) 
   (Others: location, blood disorder, 
allergy to test extracts, consumes 
antioxidant rich foods, old age 
etc.) (n= 18) 
• Declined to participate after 
reading criteria/ non-
respondent (n= 55) 
 
Analysed (n= 19) 
Excluded from 
analysis  
(give reasons) (n= 0) 
Discontinued  
intervention: 
Failed cannulation (n= 7) 
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Short communication: Inhibitory 
actions of antioxidant-rich plant 
extracts on alpha-amylase and 
dipeptidyl peptidase-4 enzymatic 
activities. A mechanistic insight into 
their hypoglycaemic effects 
	  
This chapter presents the study outcomes examining potential mechanisms for the 
hypoglycaemic effects of the four plant extracts: grape seed, rooibos tea, olive leaf and New 
Zealand pine bark. The mechanistic study involved investigating the potential inhibition on 
enzymes involved in glycaemic control: α-amylase and dipeptidyl-peptidase-4. This chapter 
has been presented in a short-communication manuscript format and prepared for submission 












Grape seed, rooibos tea, olive leaf and the New Zealand pine bark extracts have shown acute 
hypoglycaemic effects in humans. Assays of inhibition on digestive enzyme α-amylase and 
dipeptidyl-peptidase-4 enzyme as potential underlying mechanisms for improved glycaemic 
control were conducted on the extracts at various concentrations. Grape seed, rooibos tea and 
pine bark at 5 mg/mL inhibited α-amylase at 27.8% ± 1.0%, 32.7% ± 0.8%, and 58.9% ± 
1.6%, respectively, with pine bark having the strongest inhibition (p<0.001). Grape seed, 
rooibos tea and pine bark at 5 mg/mL also inhibited dipeptidyl-peptidase-4 enzyme at 49.6% 
± 0.4%, 57.2% ± 2.1% and 70.5% ± 1.1%, respectively. The IC50 of pine bark on α-amylase 
and dipeptidyl-peptidase-4 enzymes were 3.98 ± 0.11 mg/mL and 2.51 ± 0.04 mg/mL, 
respectively. Olive leaf extract did not inhibit any enzymes. The present findings indicate the 
potential for these extracts to improve postprandial glycaemia by delaying carbohydrate 
digestion and enhancing the incretin effect via the inhibition of digestive enzyme α-amylase 
and dipeptidyl-peptidase-4 enzyme, respectively. 
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There is increasing evidence that antioxidant-rich plant-derived extracts have 
properties that improve glucose metabolism and glycaemic control [1-3]. Inhibiting glucose-
regulating enzymes such as α-amylase [4-8] and dipeptidyl peptidase-4 (DPP4) [9, 10] have 
been proposed as possible underlying mechanisms by which the plant extracts exert their 
hypoglycaemic effects. 
Alpha-amylase is a key enzyme involved in the digestion of starch to glucose for 
absorption and therefore plays a crucial role in regulating postprandial glycaemia [2]. 
Salivary and pancreatic α-amylases catalyse the endo-hydrolysis of α-1,4-glucosidic linkages 
from starch amylose to release maltose, maltotriose and related α-1,6-oligomers that are 
eventually broken down by α-glucosidase to produce glucose [2]. Inhibiting α-amylase may 
prevent or slow carbohydrate digestion leading to subsequent suppression of postprandial 
hyperglycaemia, and therefore a useful mechanism for improving glycaemic control [4-8]. 
Dipeptidyl peptidase-4 enzyme plays a critical role in cleaving endogenous active 
forms of incretins such as gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 
(GLP-1) into inactive compounds leading to the loss of incretin effect [11-13]. The incretin 
effect is stimulated during a glucose load and is crucial for establishing postprandial glucose 
homeostasis by secreting insulin [14], suppressing glucagon release [15, 16] and hunger [17-
19], and delaying gastric emptying [18, 20]. However, incretin levels or activity tend to 
decrease in situations of persistent hyperglycaemia such as in prediabetes and type 2 diabetes 
mellitus (T2DM) [13, 21-29]. Inhibiting DPP4 enzyme may help preserve circulating 
endogenous incretins and their activity prolonged in the body to regulate postprandial 
glycaemia [9, 10, 30, 31].  
We have previously demonstrated that the New Zealand pine bark exhibited the 
ability to moderate glycaemic control in healthy participants (Pine Bark study) [32], whilst 
grape seed, rooibos tea and olive leaf extracts showed significant impact on glycaemic 
indices in participants with prediabetes in the GLARE study (unpublished). However, the 
specific mechanisms of hypoglycaemic action of these extracts have yet to be fully 
elucidated. Several in vitro and in vivo studies have investigated the inhibitory effects of 
grape seed [33-37], rooibos tea [38, 39], olive leaf [36, 40-47], and pine bark [48-50] extracts 
on α-amylase enzyme though comparative results are inconclusive due to differences in test 
products and methodologies [36, 51]. The inhibition of DPP4 enzyme has not been explored 






to show inhibitory action on DPP4 enzyme [52, 53]. Thus, the aim of the current study was to 
investigate the potential inhibitory action of grape seed, rooibos tea, olive leaf and New 
Zealand pine bark extracts on two key digestive enzymes important for glucose metabolism: 
α-amylase and DPP4. We have also determined the IC50 values (concentration of extract 
required to inhibit 50% of enzymatic activity) of the New Zealand pine bark extract on α-
amylase and DPP4 enzymes as this has not been previously reported. 
6.2 Methods 
6.2.1 Materials  
Grape seed extract (Vitis vinifera) (Nutra-Life, Vitaco Health (NZ) Limited), 
unfermented green rooibos tea extract (Aspalathus linearis, E2CCJ) (Rooibos Limited, South 
Africa), olive leaf extract (Olea europaea) (Comvita NZ Limited), and the New Zealand pine 
bark extract (Pinus radiata) (ENZO nutraceutical Limited) were obtained commercially. 
All chemicals used for the analysis and sample preparation were of analytical grade. 
Ultrapure water was prepared using a Millipore water purification system. Stock phosphate 
saline buffer (PBS, pH 6.8-6.9) was purchased from Thermo Fisher Scientific. Acarbose, α-
amylase from porcine pancreas, 3,5-dinitrosalicylic acid (DNS) reagent, and soluble starch 
(potato), were purchased from Sigma-Aldrich. The DPP4 inhibitor screening assay kit was 
purchased from Abcam (Ab133081, Cambridge, UK). The kit contained human recombinant 
DPP4 enzyme, dipeptidyl-peptidase (DPP) substrate (H-Gly-Pro-AMC), assay buffer (20mM 
Tris-HCl, pH 8.0, containing 100 mM NaCl and 1 mM EDTA), and sitagliptin as a positive 
control inhibitor. 
6.2.2 Sample preparation 
Sample extracts of grape seed, rooibos tea, olive leaf and New Zealand pine bark 
were sent to Callaghan Innovation (Wellington, New Zealand) to determine their inhibition 
on α-amylase and DPP4 enzymes. Powdered extracts of grape seed, rooibos tea and pine bark 
were solubilised in dimethyl sulfoxide (DMSO) at 20 mg/mL and diluted with pure water 
(Milli-Q) into various concentrations. The olive leaf extract was dissolved in a solvent 
mixture (ethanol:DMSO 4:1) to 40 mg/mL as a stock solution, then diluted with Milli-Q 






6.2.3 Enzyme inhibition assays 
α-amylase and DPP4 enzyme inhibition assays were conducted on extracts of grape 
seed, rooibos tea, olive leaf and pine bark based on previous studies [40, 54] with some 
modifications. At least two concentrations of each plant extract were tested. In cases where 
negligible inhibition was observed, higher concentrations were tested. All samples were 
performed in 96-well plate format on a microreader (SpectraMax 4M, Molecular Devices). 
The positive controls acarbose and sitagliptin were tested at two concentrations at least to 
ensure assays were working correctly. 
6.2.3.1 α-amylase inhibition assay 
Grape seed and rooibos tea extracts were measured at 2 and 5 mg/mL. Olive leaf 
extract was measured at 2, 5, 10 and 20 mg/mL. In order to determine the IC50 value, pine 
bark extract was measured at 0.5, 1, 2.5, 5 and 10 mg/mL. Positive control inhibitor acarbose 
was measured at 2 and 5 mg/mL. Samples were incubated with α-amylase at 30°C for 15 min 
before the addition of 1% starch solution. The hydrolysis of starch by α-amylase in the 
absence and presence of the sample was kept at 30°C for 30 min and stopped by adding 1% 
DNS solution. The mixture was heated at 100°C for 10 min and then diluted 4-fold with 
water before being read at 540 nm.  
6.2.3.2 Dipeptidyl peptidase-4 (DPP4) inhibition assay 
Grape seed and rooibos tea extracts were measured at 1 and 5 mg/mL. Olive leaf 
extract was measured at 1, 5, 10 and 20 mg/mL. In order to determine the IC50 value, pine 
bark extract was measured at 0.25, 0.5, 1, 2.5 and 5 mg/mL. Positive control inhibitor 
sitagliptin was measured at 0.001, 0.01, 0.1, 1, and 10 M. The reaction was initiated by the 
addition of DPP substrate and incubated at 37°C for 30 min. Readings were done at Ex355 
nm and Em 460 nm. 
6.2.4 IC50 determination of pine bark extract on enzymes 
The IC50 values of the pine bark extract on α-amylase and DPP4 enzyme inhibition 
were determined using similar methodology as a previous study [40]. The IC50 was defined as 
the concentration of an inhibitor required for reducing 50% of the enzyme activity obtained 
from a dose-dependent activity versus concentration plot. The data points of five different 
concentrations of pine bark extract were fitted into a non-linear sigmoid plot to take into 







6.2.5 Statistical analysis 
Statistical analysis was performed by general linear model univariate analysis using 
SPSS software version 25 (IBM Corporation, New York, NY, USA) with Tukey-Kramer 
multiple comparison test (p≤0.05) to compare between plant extracts. The data are presented 
as mean ± SEM, with a minimum of n=3 samples of the same batch tested. 
6.3 Results 
6.3.1 α-amylase activity inhibition 
At a concentration of 5 mg/mL, pine bark extract showed the highest α-amylase 
inhibition (58.9% ± 1.6%), followed by rooibos tea (32.7% ± 0.8%), then grape seed (27.8% 
± 1.0%) (Figure 6.1). There was a significant difference between pine bark and rooibos tea 
(p<0.001), as well as pine bark and grape seed (p<0.001). However, there was no significant 
difference between grape seed and rooibos tea (p=0.066). Pine bark, grape seed and rooibos 
tea extracts had lower inhibitory activity than acarbose (74.3% ± 6.3%) at a similar 
concentration, however the difference was statistically insignificant (p=0.241). Olive leaf 
extract had negligible inhibition against α-amylase at similar concentrations, but showed 
inhibition of 29.2% ± 2.7% only at a higher concentration of 20 mg/mL. 
6.3.2 Dipeptidyl peptidase-4 (DPP4) activity inhibition 
At a concentration of 5mg/mL, pine bark extract showed the highest DPP4 inhibition 
(70.5% ± 1.1%), followed by rooibos tea (57.2% ± 2.1%), then grape seed (49.6% ± 0.4%) 
(Figure 6.1). The DPP4 inhibition with pine bark was significantly stronger than grape seed 
(p<0.001) and rooibos tea (p=0.001). Rooibos tea was able to inhibit DPP4 enzyme to a 
greater extent than grape seed (p=0.018). Their inhibitory activities were lower compared to 
that of sitagliptin (97.4% at 4.1 x 10-4 mg/mL). Olive leaf extract had negligible inhibition 
against DPP4 enzyme at all concentrations tested. 
6.3.3 IC50 of pine bark extract on enzymes 
The IC50 values of pine bark extract for α-amylase and DPP4 enzymes were 3.98 ± 









Figure 6.1 Bar charts showing percentage inhibition of grape seed, rooibos tea and pine 
bark extracts on (A) α-amylase at 5 mg/mL and (B) dipeptidyl-peptidase-4 (DPP4) 
enzyme at 5 mg/mL. Data are presented as mean percentage inhibition ± SEM. * 
indicates significant difference of p<0.05. ** indicates significant difference of p≤0.001. 
6.4 Discussion 
The present study demonstrated that the New Zealand pine bark extract exhibited the 
greatest inhibitory effects against digestive enzyme α-amylase and DPP4 enzyme for the four 
extracts. Grape seed and rooibos tea extracts showed good inhibition of both enzymes tested. 
Whereas, olive leaf extract showed minimal inhibition on α-amylase and no inhibition action 
against DPP4 enzyme. 
These mechanisms may have important clinical implications for individuals with 











































































preserving biologically active incretins to stimulate glucose-dependent insulin secretion in 
the body thereby improving glycaemic control post-meal [9, 10, 30, 31].  
Grape seed was shown to be a good inhibitor of α-amylase in the present study. The 
α-amylase inhibitory activity of grape seed has been attributed to the procyanidins 
(condensed tannins) abundantly present in grape seed, with increasing polymerisation of the 
procyanidin producing a higher inhibition on α-amylase [35, 37]. This finding was in 
agreement with previous studies showing grape seed to be an inhibitor of α-amylase [33, 34, 
36]. The inhibitory action of grape seed was further ascertained by an acute human study 
demonstrating postprandial glucose reduction in healthy participants after a high 
carbohydrate meal, elucidating the inhibition of α-amylase as one of the underlying 
mechanisms for attenuating glucose response [55]. 
Rooibos tea extract showed good inhibition of α-amylase in the present study, which 
was in agreement with an in vitro study demonstrating inhibition on porcine α-amylase (IC50 
of 18 mg/mL), with subsequent attenuation in postprandial glucose in a mice model [38].  
For this study olive leaf extract showed minimal inhibition on α-amylase. Olive leaf 
has been shown to be a weak inhibitor of α-amylase [40]. This is with agreement with Kerimi 
and colleagues (2018) who demonstrated weak inhibitory effect of olive leaf on human 
salivary α-amylase (IC50 of 0.8 mg/mL), with no significant postprandial glucose responses in 
healthy participants [43]. However, other studies have ascertained the inhibition of olive leaf 
on several digestive enzymes such as α-amylase [41, 46, 47]. One study attributed glycaemic 
improvement in borderline diabetic participants to the inhibitory effects of olive leaf on 
human pancreatic α-amylase, with luteolin and oleanolic acid identified as responsible for α-
amylase inhibition [42]. Nonetheless, there were other studies conducted by Pyner, Kerimi 
and co-workers elucidating that olive leaf might be more effective in inhibiting sucrase 
instead, potentially leading to reduced sucrose digestion in humans [43-45]. There is 
therefore evidence that olive leaf exhibits inhibition on α-amylase. However, differences in 
extraction methods, extract sources and concentrations, as well as enzyme origins [7, 36, 51, 
56, 57] used might have resulted in outcome variations observed between the present study 
and previous studies.  
The New Zealand pine bark extract exhibited considerable inhibition against α-
amylase (IC50 of 3.98 mg/mL) in the present study. Similarly, a Korean pine bark extract also 
showed inhibitory potency against α-amylase (IC50 of 1.69 µg/mL), although the exact 






In the present study grape seed, rooibos tea and New Zealand pine bark extracts have 
demonstrated relatively strong inhibition of DPP4 enzyme, and their DPP4 inhibition was 
greater compared to their inhibition on α-amylase at the same concentration of 5 mg/mL. The 
inhibitory action of the pine bark extract on DPP4 (IC50 of 2.51 mg/mL) suggesting an 
indirect increase in active GLP-1 levels may help explain the improved postprandial glucose 
responses (p<0.05) seen in healthy participants in our previous study [32]. Likewise, the 
inhibition on DPP4 enzyme by grape seed and rooibos tea extracts may also support the 
improvements observed in postprandial glycaemic responses and insulin sensitivity (p<0.05) 
in participants with prediabetes conducted by our group (unpublished). The present findings 
were also supported by in vivo studies that demonstrated that grape seed extract was able to 
inhibit intestinal DPP4 enzyme resulting in an increase in active GLP-1 levels in rats [52, 53]. 
In our previous study, olive leaf extract was shown to increase mean incremental area under 
the curve of insulin (iAUCinsulin) in participants with prediabetes (16.7% increase, p=0.040) 
(unpublished). However as olive leaf has demonstrated negligible inhibitory action on 
enzymes in the present study, other underlying mechanistic actions that caused an increase in 
insulin secretion in the participants should be further explored. 
The merits of the present study included understanding the inhibitory action of grape 
seed, rooibos tea, olive leaf and pine bark extracts on enzymes such as α-amylase and DPP4 
involved in regulating postprandial glycaemic control. Moreover, this study has also helped 
to elucidate the inhibition of DPP4 enzyme as one of the potential underlying mechanistic 
actions in enhancing the incretin effect to improve glycaemia in the two human studies (Pine 
Bark study and GLARE study) conducted by our group.  
However, there are some limitations to the study. The IC50 values of the plant extracts 
except for pine bark have not been measured, making comparisons difficult with other similar 
studies that have reported IC50 values.  
This study was only a preliminary in vitro study to determine the presence of 
inhibitory capabilities of grape seed, rooibos tea, olive leaf and pine bark extracts. The in 
vitro outcomes were based on the un-metabolised forms of the plant extracts interacting with, 
and inhibiting the α-amylase and DPP4 enzymes, rather than their active metabolites 
typically produced in the body after being metabolised. This may therefore not translate into 
equivalent outcomes in humans, given the knowledge that plant polyphenols undergo 
extensive metabolism in the body that could alter their enzymatic inhibitory effects [58-62]. 
For example, metabolites of grape seed were not shown to inhibit plasma DPP4 enzyme, 






not effective in inhibiting DPP4 [52]. It may therefore be more useful to identify and purify 
active metabolites of the extracts of interest and subject them to similar α-amylase and DPP4 
inhibitory assays in order to obtain outcomes that are more representative of human 
physiology [61, 63]. 
In addition, doses used in the present in vitro study were greater than would be for a 
normal intake, and hence may not reflect the actual plasma concentrations of the extract 
metabolites, which rarely exceed nanomoles per litre (nmol/L), that are available to 
potentially inhibit α-amylase and DPP4 enzymes in the body [61, 62].  
Even though the present study has used recombinant human DPP4 enzyme that is 
highly relevant to human physiology for the in vitro DPP4 inhibitory assay, this occurred in a 
cell-free environment. It was shown that phenolic compounds such as flavonoids or grape 
seed was able to more strongly inhibit recombinant human DPP4 in a cell-free assay but 
exhibited weak to negligible inhibitory activity on DPP4 isolated from human plasma, 
intestinal CaCo2 cells, or saliva [52, 64].  One of the reasons might be that polyphenols such 
as flavonoids were hindered from inhibiting the DPP4 enzyme due to interactions with 
proteins naturally present within the blood such as human serum albumin being most 
abundant, rendering them unavailable to bind to DPP4 [64]. It was suggested that DPP4 
enzymes obtained from whole blood or plasma should be used as the enzyme source for the 
assay. This would provide better physiological resemblance and a more accurate assay result 
when determining potential inhibitory effects of polyphenols in vivo [65]. However, it may be 
challenging to obtain sufficient DPP4 in the plasma due to low circulating concentrations 
[66]. 
Sources of human DPP4 enzymes may also play a role in influencing the inhibitory 
activity of plant extracts on DPP4 enzyme. DPP4 enzyme exists as two forms within the 
body; one being the soluble form in the blood, and the other membrane-bound on the luminal 
surface of the vascular endothelium [65]. Although these two forms may have identical 
catalytic regions to interact with polyphenols, they are not 100% structurally similar [66]. 
This may therefore result in varying inhibitory efficacies depending on which form and 
enzymatic site of the DPP4 the polyphenols interact with within the body [65]. For example, 
1 g grape seed/ kg body weight treatment was shown to reduce intestinal DPP4 enzyme by 
34.3% but showed negligible inhibitory activity with blood plasma soluble DPP4 in a rat 
model [52]. It was likely either due to the generally low bioavailability of polyphenols in the 
body to be absorbed into the bloodstream, or that grape seed metabolites in the plasma would 






and inhibit DPP4 [64]. Studies have elucidated that the inhibition of intestinal DPP4 rather 
than its circulating, soluble form would be more relevant to incretin and glucose metabolism 
[52, 67-70]. This is because DPP4 activity proximate to incretin production site may have a 
greater impact on glycaemic control when inhibited, as rapid degradation of incretins already 
occurs prior to entering systemic circulation, and that soluble plasma DPP4 only constitutes a 
small proportion of the DPP4 concentration in the body [52, 67-70]. Therefore, it is 
noteworthy for future studies that the inhibitory efficacy of plant extracts may differ 
depending on the target site of DPP4 inhibition, whether using human caco-2 cells for 
intestinal inhibition, or ex vivo human plasma for plasma inhibition, although intestinal 
inhibition of DPP4 may be more relevant for improving glucose homeostasis. 
It has also been demonstrated that different substrates used for the DPP4 assay may 
generate differing degrees of inhibitory outcomes. The present study has used H-Gly-Pro-
AMC, which was a fluorometric substrate due to its higher sensitivity for biological samples 
[64]. It was shown that using the fluorometric substrate may generate 10-fold higher 
inhibitory activity on DPP4 enzyme than a colorimetric substrate (Gly-Pro-p-nitroanilide 
hydrochloride), but a luminescent substrate (Gly-Pro-aminoluciferin) would produce an even 
higher inhibitory activity compared to the fluorometric substrate [71]. Hence, there is a 
possibility that polyphenols undergoing the DPP4 enzyme inhibition assay may also interact 
with the colorigenic, fluorogenic and luminescent substrates rather than the DPP4 enzyme to 
alter assay sensitivity [65]. To detect any unwanted interaction between polyphenols in the 
DDP4 inhibition assay it is important to include a control without presence of polyphenols 
[65]. It is also vital to take note of the specific substrate used for the DPP4 inhibition assay 
when comparing between plant extracts and other similar studies. 
Similarly, the α-amylase assay using DNS reagent has been widely used to investigate 
the inhibition of compounds including polyphenols on the α-amylase enzyme. However, 
polyphenols such as epigallocatechin gallate (EGCG), gallic acid, phlorizin, have been 
demonstrated to interfere with the assay by interacting with the DNS reagent [7]. It was 
suggested that the interference increased with the number of hydroxyl (OH) groups present in 
the phenolic structures [7, 72]. Therefore the removal of various polyphenols that have been 
shown to interfere with the assay, for example by using solid phase extraction [73], should be 
considered in pre-tests if DNS reagent is to be used. However, this may prove to be a 
challenge as plant extracts predominantly contain polyphenols that contribute to the 







Additionally, porcine-derived α-amylase was used in the present study, where the 
amino acid composition of the porcine α-amylase is 14% different to the human α-amylase 
leading to functional differences [7, 74]. Therefore, using human salivary α-amylase may be 
a better representation of human physiological inhibition of α-amylase [73]. As differences in 
enzyme sources can play a part in different inhibitory outcomes, this should be taken into 
account when extrapolating the in vitro results to explain the possible underlying mechanisms 
of plant extracts in impacting glycaemia in humans [7, 56].  
Considering that the enzyme inhibition is only effective during a meal, their 
bioavailability and subsequent functionality may also be influenced by several dietary factors 
such as presence of macronutrients [63, 75, 76]. Therefore, the present findings on the 
mechanistic actions of enzyme inhibition should be further validated in humans. The 
inhibition of the plant extracts on α-amylase could be confirmed in hydrogen tests [77] and 
13C breath tests [78-80] in humans to quantify degree of carbohydrate malabsorption. 
Similarly, the inhibition of DPP4 enzyme can be ascertained by measuring concentrations of 
active circulating incretins (e.g. GLP-1) in plasma samples collected from participants. 
6.5 Conclusions 
Extracts of grape seed, rooibos tea, and New Zealand pine bark are capable of 
inhibiting α-amylase and DPP4 enzymes. Their role in inhibiting these enzymes may be one 
of the mechanisms in which these extracts improved glycaemic responses in humans. Further 
human studies are warranted to validate the underlying hypoglycaemic mechanisms of action 
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Discussion and conclusions 
 
This chapter provides an overview of findings from this PhD study with the assessment of 


























7.1 Summary of key findings 
This chapter discusses the main findings of the investigation of the hypoglycaemic 
impact of the antioxidant-rich plant extracts (New Zealand pine bark, grape seed, rooibos tea 
and olive leaf) in an acute trial in both healthy participants (Pine Bark study) and participants 
with prediabetes (GLARE study) living in New Zealand. A summary of the key findings 
aligned with the four Research Questions formulated for this PhD Study (Chapter 1) are 
outlined below: 
 
1. Do plant extracts improve postprandial glycaemia in individuals with 
prediabetes?  
Human clinical trials examined in the narrative review (Chapter 3) demonstrated that 
a number of plant extracts have hypoglycaemic potential and improved glycaemic 
responses in people with prediabetes. More interestingly when participants were 
grouped by prediabetes subgroup types (IFG, IGT and IFG/IGT), some plant extracts 
exhibited preferential improvements in either fasting or postprandial glycaemic 
indices. This means not all plant extracts exert the same impact on glycaemic control 
and that some extracts may be more effective in improving IFG or IGT, respectively, 
with IFG/IGT benefiting from either improvement.  
2. Does New Zealand pine bark improve postprandial glycaemia in healthy 
individuals?  
Primary analysis showed no significant change in glucose incremental area under the 
curve (iAUC) with the lower dose (50 mg) (p=0.123, 13.4% reduction) but a 
significant reduction in iAUCglucose with the higher dose (400 mg) (p=0.016, 21.3% 
reduction) compared to control in healthy participants. Secondary analysis with 
stratification showed that New Zealand pine bark improved iAUCglucose in both doses 
(50 and 400 mg) compared to control only in participants exhibiting monophasic 
glucose curve shapes. The higher dose (400 mg) also improved other glycaemic 
indices such as percentage increment of postprandial glucose (% PG), glucose peak, 
and 2h postprandial glucose (2hPG) in monophasic participants. 
3. Do extracts of grape seed, rooibos tea and olive leaf improve postprandial 
glycaemia in individuals with prediabetes? 
Primary overall analysis showed no significant differences in glucose and insulin 






Secondary analysis with stratification demonstrated that all plant extracts showed 
improvements in various glycaemic measures compared to control in participants with 
prediabetes who had a less healthy metabolic profile of delayed glucose and insulin 
peak times. 
4. What are the underlying hypoglycaemic mechanisms of these plant extracts on 
improving glucose homeostasis? 
The outcome of the mechanistic study elucidated the presence of potential inhibitory 
action of the New Zealand pine bark, grape seed and rooibos tea on digestive enzyme 
(α-amylase) and dipeptidyl-peptidase-4 (DPP4) enzyme.  
7.2 Discussion of main findings 
The investigation of the hypoglycaemic potential of four antioxidant-rich plant 
extracts (New Zealand pine bark, grape seed, rooibos tea and olive leaf) in the Pine Bark 
study and the GLARE study elucidated the hypoglycaemic effects of the extracts with 
improvements in a range of glycaemic measures. 
The narrative review (Chapter 3) has set the stage in understanding the impact of 
plant extracts on glycaemia in individuals with prediabetes. Eleven human clinical trials 
including two acute studies and the rest being chronic studies and involving a total of eight 
different plant extracts demonstrated promising hypoglycaemic potential of the plant extracts 
in the prediabetes cohort. Further examination of the impact of plant extracts on the 
subgroups of prediabetes showed plant extracts such as Artemisia princes Pampanini [1, 2], 
soy (Glycine max (L.) Merrill) leaf [3, 4] and Citrus junos Tanaka peel [5] have been shown 
to improve fasting glycaemia and thus may benefit individuals with IFG. In contrast, white 
mulberry (Morus alba Linn.) leaf [6-8], persimmon (Diospyros kaki) leaf [9] and Acacia. 
Mearnsii bark [10] were shown to improve postprandial glycaemia and hence may be more 
beneficial for individuals with IGT. Elaeis guineensis leaf was observed to improve both 
fasting and postprandial glycaemic measures depending on the concentration used [11], and 
hence may be useful for all prediabetes subgroups. It follows that treatments should be made 
available that are specific for each of the subgroup to obtain optimal glycaemic outcomes. 
However, more studies are required to ascertain the usefulness and practicality of giving 
targeted interventions to individuals with respect to their prediabetes subgroups. 
Therefore, an important aspect of the PhD work was to understand the impact of 






in humans. A decision was made to include participant stratification in the data analysis of 
both the Pine Bark study and the GLARE study following growing research corroborating the 
existence of heterogeneity in impaired glycaemic control due to varying metabolic profiles 
that resulted in high variability in inter-individual responses to interventions [12-17]. This 
phenomenon was demonstrated in both the Pine Bark study and the GLARE study that 
individuals with worsening glycaemic control or metabolic profiles responded significantly 
better to intervention. Faerch and colleagues (2013) as well as Krishnan and co-workers 
(2012) have also advocated the importance of stratification in studies based on different 
metabolic profiles to determine the efficacy of interventions [13, 18]. This method of analysis 
by stratification based on glycaemic profiles was in line with other nutrition intervention 
studies that have explored secondary analysis of participant stratification, based on for 
example, delayed glucose peaks [19], differential prediabetes subgroups [20], and degrees of 
fasting glucose [21, 22], and observed differences particularly in participants with worsening 
clinical outcomes.  
The differential degrees of glycaemic control in participants have shown varying 
responses to intervention in both the Pine Bark study (chapter 4) [23] and the GLARE study 
(chapter 5). Therefore stratification based on the different metabolic profiles was important in 
order to elucidate the impact of intervention with plant extracts on both responders and non-
responders [12, 13, 19, 23, 24].  
The Pine Bark study suggests that the New Zealand pine bark may have 
hypoglycaemic effects in healthy participants, particularly those exhibiting monophasic 
glucose curve shapes. The stratification of participants based on postprandial glucose curve 
shapes was first introduced by Tschritter and group [25], where monophasic shapes were 
associated with poorer glycaemic control and an increased risk of T2DM compared to 
complex shapes (biphasic or triphasic) [25-29]. Significant improvements in iAUCglucose were 
observed in both doses 50 mg (p=0.034) and 400 mg (p=0.012) in the monophasic subgroup 
compared to control. The higher dose (400 mg) also significantly improved other glycaemic 
indices such as %PG (p=0.010), glucose peak (p=0.025) and 2hPG (p=0.027) indicating 
improved glycaemic control in this group [30-32]. The study elucidated the importance of 
examining effectiveness of intervention in participants with different postprandial glucose 
curve shapes, even though being normoglycaemic and supposedly healthy. This also 
highlights that pine bark should be further examined in a longer-term human study, after 
having observed its acute impact on glycaemic control in healthy participants. The outcomes 






bark that have been extensively studied. Studies on the French pine bark (100 to 300 mg/day) 
showed improvements in glycaemic responses in humans [33-38]. However, all the studies 
on French pine bark were chronic studies (three weeks to six months) in individuals who 
were healthy, having T2DM or metabolic syndrome, and were different to the participant 
demographics and study duration in the Pine Bark study. Further studies are warranted to 
examine the effect on other measures, such as insulin on a longer-term basis, and in other 
population groups, such as those with prediabetes or T2DM who may be in greater need of 
intervention. 
The GLARE study has elucidated the hypoglycaemic effects of grape seed, rooibos 
tea and olive leaf extracts in participants with prediabetes, particularly those exhibiting 
delayed glucose and insulin responses (less healthy subgroup), which indicated poorer 
glycaemic control. The stratification was based on the methodology developed by Takahashi 
and colleagues (2018) [39]. A delay in insulin peak or a loss of early phase insulin response 
is often a glucose metabolic defect associated with impaired glycaemic control [40, 41], as an 
early phase insulin response is important to suppress glucagon release and inhibit hepatic 
glucose production [42-45]. The stratification based on glucose and insulin peak times 
following the Takahashi et al. (2018) method was employed in the GLARE study instead of 
the stratification using postprandial glucose curve shapes used in the Pine Bark study for two 
main reasons. Firstly, participants with prediabetes have a higher variability in response to 
OGTT [46-50], compared to healthy participants [51], that could result in the glucose shapes 
being less reproducible [28, 52, 53]. The decreased reproducibility might introduce the risk of 
misclassifying participants into the wrong glucose curve shape group. Secondly, postprandial 
glucose curve shapes do not take into account insulin responses, which are important 
parameters of glycaemia. Hence, it was more favourable to employ the stratification based on 
the Takahashi et al. (2018) method in the GLARE study. 
In the less healthy subgroup, grape seed consumption was shown to improve various 
glucose and insulin indices such as significant reductions in 2hPG (p=0.034) and 2hPI 
(p=0.029), with significant improvements in mean ISIoverall (p=0.028) and MCR (p=0.016) 
compared to control. Grape seed also showed a trend towards improvement in time to insulin 
peak in the less healthy subgroup (p=0.054) and early phase insulin response measured by 
mean ISIfirst (p=0.082) and IGI30 (p=0.078), an indication of acute restoration of early phase 
insulin secretion and a possible amplification of early insulin response via incretin effect to 
aid glycaemic control [54]. This finding agrees with previous acute RCTs demonstrating 






metabolism such as iAUCglucose in healthy individuals or those with metabolic syndrome [55-
57]. However, the findings were in contrast to other chronic trials on healthy participants, 
those with T2DM or metabolic syndrome that showed no significant improvement in fasting 
blood glucose (FBG), glycated haemoglobin A1c (HbA1c) or fasting insulin (FI) with grape 
seed extract (150-400 mg/day) [58-61]. Differences in the extract grade, doses, small sample 
sizes and study duration might explain the inconsistencies in results. Furthermore, most of the 
previous studies on grape seed extract have not measured changes in insulin outcomes, 
making comparisons with GLARE study difficult. 
Rooibos tea extract was shown to improve acute β-cell function as observed in an 
improved oral disposition index (DI) (p=0.031) and a trend towards improvement in insulin-
secretion-sensitivity index-2 (ISSI-2) (p=0.074) in the less healthy subgroup. These outcomes 
were indicative of improved glycaemic control and suggest the potential to restore β-cell 
function [62-65]. A previous study conducted by Chepulis et al. (2016) showed significant 
reduction in iAUCglucose in healthy participants after consuming 760 mg (≥30% polyphenols) 
of rooibos tea extract [56], in contrast to the GLARE study where rooibos tea extract (1,714 
mg, 485 mg total polyphenols) had no significant improvement in iAUCglucose and 2hPG in 
participants with prediabetes. The difference in results might be due to the metabolic 
differences in the participants in the two studies, with a much higher dose required for 
participants with prediabetes to elicit a significant reduction in iAUCglucose. 
Although olive leaf did not demonstrate any improvement in postprandial glucose 
responses, it exhibited a trend toward improvement in various insulin sensitivity measures 
such as mean IGI30 (p=0.078), ISIfirst (p=0.075) and ISIsecond (p=0.062) in the less healthy 
subgroup compared to control. The improvement in early phase insulin responses might be 
associated with amplification of the incretin effect in this subgroup of participants [54]. The 
improvement in oral disposition index (IGI30) was in agreement with the study conducted by 
de Bock and colleagues (2013) that also demonstrated significant improvement in IGI30 in 
non-diabetic, overweight men, which was an indication of enhanced β-cell function, after a 
chronic 12-week consumption of olive leaf extract (51.1 mg oleuropein, 9.7 mg 
hydroxytyrosol/day) [66]. Previous chronic studies of similar design have shown beneficial 
effects in glycaemia such as HbA1c, FI, and area under the curve (AUC) of glucose and 
insulin in healthy or T2DM participants after olive leaf consumption [66, 67]. An acute study 
conducted by Komaki and colleagues (2003) also demonstrated significant postprandial 
glucose (PG) reduction in borderline diabetic subgroup of participants [24]. A 12-week study 






330 mL of tea beverage three times a day) also showed significant reduction in FBG in 
participants with prediabetes, although no significant changes were seen in HbA1c, FI, and 
homeostatic model assessment of insulin resistance (HOMA-IR) [68].  
On the contrary, other chronic and acute studies did not show significant 
improvements in glycaemic responses such as FBG, insulin, HOMA-IR, and PG in healthy 
participants or those with metabolic syndrome [69-71]. Again, the extract types and varying 
doses, study duration and metabolic profile of participants might have contributed to the 
differences in results observed.  
Olive leaf extract was also shown to significantly elevate insulin levels in the study 
without significantly altering postprandial glucose levels, which could partly explain the 
improvement in IGI30. The increase in insulin levels with olive leaf might be attributed to its 
ability as an insulin secretagogue in in vitro and animal studies [72, 73]. Further human 
studies are required to determine the effects of olive leaf extract on insulin levels in the 
prediabetes cohort.  
The post-stratification analysis showed no significant improvements in glycaemic 
measures in the healthier subgroup. The outcomes of the GLARE study therefore emphasised 
the importance of investigating the impact of intervention based on the different metabolic 
profiles of individuals, which concurs with the outcome of the narrative review in Chapter 3.  
Multiple underlying mechanisms of action in glucose metabolism might have played a 
crucial role in the observed improvements in glycaemic response in both the Pine Bark study 
and the GLARE study. Therefore an in vitro mechanistic study was undertaken to explore the 
potential inhibition of the New Zealand pine bark, grape seed, rooibos tea and olive leaf 
extracts on two key enzymes (α-amylase and DPP4 enzymes) as one of the possible 
mechanistic actions leading to improved glycaemic outcomes. 
The mechanistic study (Chapter 6) demonstrated that the New Zealand pine bark, 
grape seed and rooibos tea extracts possessed inhibitory action on digestive enzyme α-
amylase and DPP4 enzyme to various degrees. The New Zealand pine bark exhibited the 
greatest inhibitory effects against both enzymes compared to the other extracts. The ability to 
inhibit α-amylase with the ingestion of the extracts at mealtimes suggests a possibility of 
delayed carbohydrate digestion into glucose for absorption [74-78], and potential enhanced 
incretin effect via DPP4 enzyme inhibition [79-82]. However, although the results of the 
inhibition of α-amylase could not be used to explain the observed glycaemic improvements in 
both the Pine Bark study and the GLARE study as liquid glucose was used in the oral glucose 






carbohydrate load. The inhibitory action of the pine bark extract on DPP4 enzyme suggests 
that an indirect increase in active GLP-1 levels may help explain the improved postprandial 
glucose responses (p<0.05) seen in healthy participants in our Pine Bark study [23]. 
Likewise, the inhibition on DPP4 enzyme by grape seed and rooibos tea extracts may also 
support the significant improvements observed in postprandial glycaemic responses and 
insulin sensitivity in participants with prediabetes in the GLARE study.  
In contrast, olive leaf extract showed minimal inhibition on α-amylase and no 
inhibition action against DPP4 enzyme. Although olive leaf extract was found to inhibit 
digestive enzymes such as α-amylase in other studies [24, 67, 71, 83-87], the current 
mechanistic study showed negligible inhibition on the enzymes tested, suggesting that 
differences in extraction methods, extract sources and concentrations, as well as enzyme 
origins [77, 88-91] used might have resulted in outcome variations observed. In the GLARE 
study olive leaf extract was shown to increase mean iAUCinsulin in participants with 
prediabetes (16.7% increase, p=0.040). Other underlying mechanisms of action might be 
responsible for the observed increased in insulin levels, such as olive leaf being an insulin 
secretagogue and promoting insulin secretion [72, 73]. 
Similar to other intervention study procedures, the Pine Bark study and the GLARE 
study were with short-term, acute trials to determine the initial primary intervention outcomes 
before proceeding into chronic trials. Therefore, the study outcomes from both trials might 
differ in comparison to chronic studies looking at sustainability of effect of the plant extracts 
under daily life conditions. Conducting chronic trials on plant extracts is especially important 
as there is yet insufficient data regarding their storage in the body to have a prolonged impact 
on glucose metabolism. Research has shown that polyphenol metabolites of plant extracts in 
the body reach maximal plasma concentrations within 1-3 h [92-94], with some taking 5-7 h, 
or up to 24 h [95-98]. The elimination half-life of polyphenols is 1-18 h, but with most 
polyphenols excreted in less than 8h [99]. The quick passage through the body may 
undermine the potential impact of plant extracts on glycaemia. This may explain why the 
abovementioned chronic studies that investigated the New Zealand pine bark, grape seed, 
rooibos tea and olive leaf that showed inconsistent results concerning their sustained effects 
on glycaemic responses. Nonetheless, the slower rate of elimination for some polyphenols 
may indicate the possibility that high plasma concentrations could be maintained with regular 
consumption of phenolic-rich plant extracts [100, 101], that can elicit small but appreciable 






and olive leaf warrant further investigation in chronic studies in the prediabetes cohort to 
determine their prolonged hypoglycaemic effects. 
7.3 Strengths 
The strengths of the PhD study included the use of a robust crossover design where 
participants were their own control and underwent each of the treatments, and therefore a 
smaller sample size was required to reach a similar level of significance in both the Pine Bark 
study and the GLARE study [102, 103]. Based on previous work a prospective power 
calculation was done so that sufficient sample size was determined to see a potential 
difference in each study.  
The measurement of HbA1c has been the recommended screening tool for prediabetes 
because it a quick test that measures blood glucose levels without the need to undergo 
fasting, unlike FBG or 2hPG measurement [104]. HbA1c gives an indication of chronic 
glycaemic control by measuring average blood glucose value over several months 
(approximately 2-3 months) without confounding factors such as acute perturbations from 
stress, diet and exercise [105], and therefore may confer a higher reproducibility compared to 
FBG or 2hPG [106]. Therefore, HbA1c was used as a screening tool in the GLARE study 
recruitment. In the Pine Bark study, both HbA1c and FBG were taken for healthy participants 
as recommended in research to use more than one test to ascertain glycaemic status [107, 
108]. 
The plant extracts investigated in both the Pine Bark study and the GLARE study 
were commercially manufactured based on Good Manufacturing Practice (GMP) and have 
been characterised and standardised with respect to their main bioactive components for 
research purposes. The plant extracts in the GLARE study were also standardised based on 
their total antioxidant capacity (TAC) using a well-evaluated method of Oxygen Radical 
Absorbance Capacity (ORAC) [109, 110], and therefore efficacy could be compared amongst 
the extracts. 
An important merit from both clinical trials was the use of multiple glycaemic indices 
to determine various potential specific changes in glucose (glucose peak, glucose peak time, 
%PG, MCR), insulin measures such as overall insulin sensitivity (Matsuda index (ISI/M), 
oral glucose insulin sensitivity (OGIS), Stumvoll ISIoverall), first and second phase insulin 
sensitivity indices (ISIfirst, ISIsecond and IGI30), and β-cell function (ISSI-2, DI) in response to 







The main limitations of the Pine Bark study included not having measurements of 
insulin or C-peptide and insulin sensitivity to ascertain their changes and effect on glycaemia. 
A smaller sample size after stratification of participants into two distinct glucose curve 
shapes was another limitation of the Pine Bark study. Although a prospective power 
calculation was done, this did not take into account the stratification of participants into 
subgroups. 
One of the challenges encountered in the GLARE study was the prolonged 
recruitment of participants with prediabetes. The initial plan was to contact general 
practitioners (GPs) for collaboration in order to obtain eligible participants with prediabetes 
via enrolment in primary care. Although several GPs were keen to collaborate to help recruit 
their patients who had prediabetes, it was unfortunate that approval to proceed was not given 
by the Procare Health Limited that was part of the New Zealand Primary Health Organisation 
(NZ PHO). Other GPs that were contacted had a lack of funding and manpower for the 
additional collaborative work. There was also a general lack of awareness regarding the 
existence of prediabetes within the population, which has prevented eligible individuals from 
being interested and enrolling in the study. This has led to the slower than expected 
recruitment of eligible participants for the GLARE study. The GLARE data collection took 
approximately two years for recruitment, where n=130 participants were assessed for 
eligibility but n=104 of them were excluded due to having lower than required HbA1c, being 
diabetic or taking metformin or glucose control medications. 
Moreover, due to the higher prevalence of prediabetes in the older population [111-
113], overweight and obese cohort [112, 114], the GLARE study recruited older participants 
(mean age 65.0 ± 1.6 years) as well as overweight participants (body mass index (BMI) 27.3 
± 1.1 kg/m2). However, this population group has led some participants to encounter 
difficulty in cannulation of the antecubital fossa region of the arm, with 34.6% of the 
participants withdrawn from the study. There were n=7 participants who withdrew after the 
first trial visit, and n=2 participants who dropped out after the third trial visit.  
Nonetheless, another initiative to collaborate with Auckland Diabetes Association 
Mobile Diabetes Awareness service to recruit eligible participants from the public, along with 
the continued interest of past participants from previous clinical trials, meant sufficient 






A further challenge was the disruption to a part of the GLARE study experiment 
involving the analysis of incretin levels in the samples collected to quantify the incretin effect 
due to the COVID-19 pandemic. Hence, the incretin concentrations could not be determined 
in this PhD study.  
The study limitations of the GLARE study included not having a larger sample size to 
account for participant stratification into different glucose and insulin peak times using the 
Takahashi et al. (2018) method [39]. In hindsight it would have also been useful to have a 
large enough sample size to enable the sub-classification of participants into prediabetes 
subgroups (IFG, IGT and IFG/IGT) to elucidate the impact of intervention on each subgroup. 
A larger sample size could also help account for gender differences in response to 
intervention, as studies have shown that men and women exhibit different pathogenesis of 
T2DM [115-117]. 
Although HbA1c measurement was the NZSSD recommended method to screen for 
prediabetes in the GLARE study [118], it has certain limitations. HbA1c values can be 
influenced by ethnicity, age, gender, FBG, BMI, and haemoglobin related conditions, and 
other biological determinants of haemoglobin glycation [108, 119-121]. HbA1c may also 
misclassify or underestimate prediabetes prevalence [104, 122, 123], due to the reduced 
sensitivity of HbA1c and/or specificity to detect prediabetes that is characterised by low to 
intermediate levels of dysglycaemia [123, 124]. Therefore, it is recommended that HbA1c 
value be taken in conjunction with FBG or 2hPG [107, 108, 123]. However, a confirmatory 
test with either FBG or 2hPG for prediabetes in addition to HbA1c has not been carried out in 
the GLARE study. This has led to n=13 participants in the GLARE study having an elevated 
HbA1c value but exhibiting normal FBG and 2hPG based on baseline measurements at the 
control visit. It was evident that there was discordance with other glycaemic measures such as 
FBG and 2hPG that are equally important clinical outcome indicators of glycaemic status 
[125], and that HbA1c measured different aspects of glycaemia compared to FBG or 2hPG 
[108, 124, 126]. Therefore it is crucial that a combination of glycaemic measures (HbA1c, 
FBG and 2hPG) be taken in order to have a more accurate quantification of prediabetes status 
of the participants.  
Furthermore, HbA1c measurement was also unable to distinguish between 
pathophysiologically different prediabetes subgroups: IFG and IGT [127], resulting in a 
heterogeneous mixture of participants with various glycaemic profiles in the GLARE study 
with participants having IFG (n=2), IGT (n=1) and IFG/IGT (n=3), in addition to having an 






Some study participants (n=6), who at the point of screening, had HbA1c values (38-
40 mmol/mol) below the prediabetic range of 41-49 mmol/mol [118]. However, the 
participants were recruited based on having at least one risk factor for T2DM (overweight or 
obese, high blood pressure, prediabetes history, and family history of T2DM or 
cardiovascular disease (CVD)). A study conducted by Marini et al. (2014) elucidated that the 
offspring of diabetic parents (one of T2DM risk factors) and having HbA1c values above 39 
mmol/mol (5.7%) were already suffering from significant faltering insulin sensitivity and β-
cell function [131]. Edelman et al. (2004) in their research also recommended closer scrutiny 
for patients with prediabetes having baseline high-normal HbA1c (37.7-42.1 mmol/mol, 5.6-
6.0%) to elevated HbA1c (43.2-51.9 mmol/mol, 6.1-6.9%) especially if they were obese, as 
their diabetes incidence were higher each year, 2.5% and 7.8%, respectively [132]. Therefore 
it was found justifiable to include participants with lower HbA1c values in the GLARE study.  
The GLARE participants who took part in the study only had borderline prediabetes 
(mean HbA1c 42 ± 1 mmol/mol), and therefore the study outcomes might differ from those 
with more severe prediabetic status with a higher HbA1c value. Other factors such as 
ethnicity [133, 134], age [111-113], gender [115-117], abdominal and visceral obesity [114, 
135] may also produce different study outcomes and warrant further study.  
The plasma insulin was collected and analysed in the GLARE study to investigate 
insulin responses to the plant extracts. However, insulin concentrations in contrast to C-
peptide, might be influenced by its pulsatile nature of secretion, where it undergoes first-pass 
metabolism in the liver where insulin is cleared from the bloodstream [136]. In addition, 
individuals have been shown to exhibit different rates of insulin clearance resulting in 
different levels of circulating insulin in the blood [137]. These factors might increase the 
variability in insulin concentrations collected in the study.  
The reproducibility of the stratification using postprandial glucose curve shapes for 
the Pine Bark study and glucose and insulin peak times in the GLARE study has yet to be 
examined. Misclassification may take place where participants do not fit into a certain preset 
definition of the stratification. However, the postprandial glucose curve shapes (Pine Bark 
study) and the glucose and insulin peak times of participants (GLARE study) were plotted 
and checked against to confirm that there was no misclassification of participants. 
Furthermore, as the sample size was small in both studies, the probability of misclassifying 
was greatly reduced. 
Both the Pine Bark study and the GLARE study employed the OGTT with liquid 






The primary reason for choice was because OGTT was a simple, gold standard model to 
understand the impact of plant extracts on glycaemia without the interferences from other 
nutrients such as fats and proteins found in a mixed meal [138, 139]. A study conducted by 
Meier and colleagues (2009) has also demonstrated that an OGTT was significantly 
correlated to a standardised mixed meal [140]. Therefore, the OGTT suited the purposes of 
the Pine Bark study and the GLARE study. Nonetheless, a mixed meal is typically used to 
represent normal food intake and studies have shown that in prediabetes and T2DM 
glycaemic measures such as insulin, glucagon, β-cell function and incretin might have altered 
responses depending on the type of meal consumed along with the intervention [140-144]. 
Glucose and insulin responses may also differ depending on the polyphenol-carbohydrate 
combination present, particularly when a plant extract is consumed together with a 
carbohydrate load [145]. In addition, research has also elucidated the higher variability and 
decreased reproducibility of the OGTT procedure, with individuals transitioning from 
normoglycaemia into having impaired glycaemic control tending to have a higher intra-
individual variability in response to an OGTT [46-50]. Mixed meal tolerance test (MMTT) 
has been shown to have good repeatability for glucose and insulin responses from healthy 
individuals to those with prediabetes and diabetes [146, 147]. Hence, future studies may 
explore the use of mixed meal in the longer-term study of plant extracts on glycaemic 
responses in humans.  
The bioavailability of the extracts in the body has not been investigated to understand 
the degree of metabolism and post-metabolism hypoglycaemic efficacy of the extracts, 
especially in participants with poor glycaemic control. Therefore it is an area of potential 
research in the future to quantify the postprandial metabolites of plant extracts to determine 
the effective doses required to improve glycaemic responses in humans. 
The limitations of the mechanistic study included only examining only a small aspect 
of various mechanistic actions (enzyme inhibition on α-amylase and DPP4) displayed by 
plant extracts to impact glycaemic control and other mechanisms should also be explored. 
7.5 Future directions 
The current PhD work has identified a few recommendations for further research in the 







1. Acute and chronic human studies of the impact of the New Zealand pine bark on 
glycaemic responses in those with prediabetes is required, with the inclusion of 
measurements such as insulin, C-peptide, insulin sensitivity, and β-cell function 
(e.g., HOMA-IR, Matsuda index, and other glycaemic indices). 
2. A chronic human study (of at least 12 weeks, which is the minimum duration 
required to reliably detect sustained effect of dietary intervention [148]) of the 
impact of grape seed, rooibos tea and olive leaf extracts of similar or higher dose 
on individuals with prediabetes is warranted. Moreover, recruiting a larger 
sample size to account for stratification of participants with prediabetes into their 
subgroups (IFG, IGT and IFG/IGT) is recommended. 
3. Future research extending from the GLARE study could also look into the impact 
of intervention with plant extracts on hyperinsulinaemia as an independent risk 
for T2DM in participants with prediabetes [149-152]. Individuals with impaired 
glucose control may also suffer from an overall higher insulin secretion than both 
normal glucose tolerant and diabetic individuals [44, 153, 154]. Future studies 
could employ the methodology established by Hayashi et al. (2013) [155] and 
Crofts and colleagues (2016) [156] to determine hyperinsulinaemia in 
participants with prediabetes [157]. 
4. Future human studies on prediabetes should employ more than a single test 
(HbA1c, FBG and 2hPG) to indicate presence of prediabetes in the participants 
during recruitment, especially that prediabetes subgroups exist and are associated 
with significantly different metabolic profiles (as highlighted in the GLARE 
study and narrative review). It is also equally important to measure potential 
changes in FBG, 2hPG and HbA1c in chronic human studies in response to 
interventions with plant extracts in order to determine the specific impact of 
intervention on the prediabetes subgroups. 
5. Dietary records (three-day dietary record) may be included for chronic studies 
extending from the Pine Bark study and the GLARE study. 
6. Future studies could also look at using mixed meals instead of liquid glucose as a 
better representation of a typical meal consumed.  
7. As prevention strategies are increasingly emphasised in prediabetes, health 
practitioners may prescribe anti-diabetic drugs such as metformin for patients 
with prediabetes at a high risk for T2DM, especially those with BMI >35kg/m2 or 






combining metformin with plant extracts as a therapy for prediabetes without 
potential adverse effects. 
8. Future studies could also look at how other effective strategies such as weight 
loss, increasing physical activity and improving diet quality in combination with 
plant extract consumption could have an additive or synergistic benefit on 
glycaemia in individuals with prediabetes [158-160]. 
9. As one of the clinical endpoints of a prediabetes clinical trial is to reduce CVD 
risk [161], further study may investigate how plant extracts could aid in reducing 
CVD risk factors such as obesity, dyslipidaemia, low high-density lipoprotein 
(HDL) cholesterol, high low-density lipoprotein (LDL) cholesterol, increased 
triglycerides (TG), increased systolic/diastolic blood pressure, enthothelial 
dysfunction, and inflammation (cytokines such as interleukin-6 (IL-6), C-reactive 
protein (CRP)) [162]. 
10. The measurement of changes in total and active concentrations of incretins (GLP-
1) in GLARE study participants with the consumption of grape seed, rooibos tea 
and olive leaf extracts as another potential underlying mechanism of glucose 
metabolism. The measurement of GLP-1 may also ascertain the findings from the 
mechanistic study regarding the inhibitory action of grape seed and rooibos tea 
extracts on DPP4 enzyme. 
11. Future studies could utilise mammalian α-glucosidase from rat intestine 
containing both maltase and sucrase to examine potential inhibition of extracts on 
α-glucosidase, another vital digestive enzyme responsible for carbohydrate 
metabolism [163-170]. In addition, the inhibitory action of the plant extracts, 
namely the New Zealand pine bark, grape seed, and rooibos tea on α-amylase 
could be further ascertained in hydrogen tests [171] and 13C breath tests [172-
174] in humans to quantify degree of delayed carbohydrate digestion in humans.  
12. The other mechanistic actions as illustrated in the literature review section of the 
thesis could also be explored, namely the inhibition of sodium-dependent glucose 
co-transporter-1 (SGLT1) and sodium-independent glucose transporter-2 
(GLUT2) on glucose uptake using caco-2 cell model of the human small intestine 
with the consumption of the plant extracts [175, 176]. A similar methodology 
from previous studies investigating plant extracts could be used [71, 177-179].  
13. Due to the high phenolic content present in the plant extracts, these plant extracts 






studies may investigate the metabolites generated from the consumption of the 
plant extracts to understand the type and extent of metabolism of the extracts and 
their influence on glycaemic control. This could be done by utilising an in vitro 
digestion model with the inclusion of the colonic phase, or the collection of 
biological samples (urine and faeces) from participants and taking measures such 
as polyphenol metabolite analysis and antioxidant capacity assays. 
7.6 Conclusions 
An early treatment in the prediabetes stage such as with plant extracts may be helpful 
in halting or delaying the onset of T2DM. To the best of my knowledge, this PhD research is 
the first to report on the glycaemic outcomes of the plant extracts: New Zealand pine bark in 
healthy participants, and grape seed, rooibos tea and olive leaf in the prediabetes cohort in 
New Zealand. The plant extracts investigated warrant further study in examining their long-
term impact on glucose and insulin responses in the prediabetes cohort. In addition, a 
significant finding in this study was the importance of examining glycaemic responses to 
interventions based on the different metabolic profiles of individuals. It follows from this 
PhD work that treatments for prediabetes should be made available that are specific for each 
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Appendix 2.2 – Pine Bark study participant information sheet 
Participant Information Sheet 
 
Study title: A dose-response study to assess the effects of pine bark extract 
(EnzogenolTM) on glycaemic (blood sugar) responses in healthy 
participants 








Wen Xin Janice Lim Contact email: wen.xin.lim.1@uni.massey.ac.nz 
 
Researcher Introduction 
My name is Janice Lim, and I am a PhD student at Massey University, School of Health 
Sciences. My supervisors are A/Prof Rachel Page (Main), A/Prof Pam von Hurst, Dr Cheryl 
Gammon and Dr Lynne Chepulis.  
 
Invitation to Participate in this Research Study 
You are invited to take part in a dose-response study to assess the effects of pine bark extract 
(EnzogenolTM) on glycaemic (blood sugar) responses in healthy participants.  Whether or not 
you take part is your choice.  If you don’t want to take part, you don’t have to give a reason.  
If you do want to take part now, but change your mind later, you can pull out of the study at 
any time.   
 
This Participant Information Sheet will help you decide if you’d like to take part.  It sets out 
why we are doing the study, what your participation would involve, what the benefits and 
risks to you might be, and what would happen after the study ends.  We will go through this 
information with you and answer any questions you may have. You do not have to decide 
today whether or not you will participate in this study. Before you decide you may want to 
talk about the study with other people, such as family, whānau, friends, or healthcare 
providers.  Feel free to do this. 
 
If you agree to take part in this study, you will be asked to sign the Consent Form.  You will 
be given a copy of both the Participant Information Sheet and the Consent Form to keep. 
 
This document is 7 pages long.  Please make sure you have read and understood all the pages. 
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WHAT IS THE PURPOSE OF THE STUDY? 
Obesity and diabetes are epidemic in New Zealand (and in other Western countries), and 
many individuals now have problems controlling their blood sugar levels within normal 
levels.  
 
Foods are ranked, nowadays, based on their effects on blood sugar levels and this is termed 
the glycaemic index (GI) of the food. Generally, lower GI foods are recommended for those 
with glucose (sugar) intolerance; however the reality is that typical New Zealand diets are 
high in high-GI sugars and processed foods with the average person now consuming an extra 
22 teaspoons of sugar a day.  
 
Certain foods and extracts, including berries, teas and French pine bark extracts have been 
shown to reduce blood sugar levels. Data suggests that this may be due to the high levels of 
antioxidants that are present in these foods, though other substances may also be involved. 
The effects of New Zealand pine bark extract on blood sugar levels has not been studied, thus 
this study aims to measure whether blood sugar levels can be reduced in healthy participants 
when taking a pine bark extract capsule along with a sugary drink.  
 
This study is a placebo-controlled, blinded, crossover, dose-response study. A placebo-
controlled study means that you will also take part in the control session where a placebo 
capsule will be consumed along with a sugary drink to examine the response of your blood 
sugar without the active ingredient. A blinded study means that you will not know what type 
and concentration of the capsule you will be having. A crossover study means that you, the 
participant, serves as your own control where you will take part in both the control visit as 
well as the study visit with the pine bark extract. Any difference in the results between your 
control and study visit can thus be attributed to the effects of pine bark extract alone. A dose-
response study means that you will be having a certain concentration of the pine bark extract 
and your blood sugar response to it will be measured during the study.  
 
The study is funded by NZ ENZO Nutraceuticals Ltd and the pine bark extract (Enzogenol) 
that will be given to you during the study sessions are provided by NZ ENZO Nutraceuticals 
Ltd. The pine bark extract is available for sale in NZ and approved as a food supplement in 
NZ and overseas. According to Regulatory Status of Enzogenol in New Zealand, Enzogenol, 
a Pinus radiata bark extract, is classified as a dietary supplement.  
 
WHAT WILL MY PARTICIPATION IN THE STUDY INVOLVE? 
You have been chosen to participate in the study because you have met the criteria to be 
included in the study. The criteria includes: 
• 18-40 years of age 
• BMI 18.5-25.0 kg/ m2 
• HbA1c < 40 mmol/ mol 
• Fasting glucose < 5.5 mmol/ L 
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• Not taking any medications that include blood glucose/ sugar lowering prescriptions 
• Not pregnant or breastfeeding 
• Not allergic to pine bark extract 
• Non-smoker 
• Generally healthy and not suffering from chronic diseases or diabetes 
• Able to communicate well in English 
 
The study will involve you coming to the Massey University Nutrition Research Facility, 
located at Albany campus, North Shore. If you are eligible after the screening visit, you will 
need to be available for two mornings taking approximately 2.5 hours each. Each session, 
including the screening visit, will require you to fast overnight (i.e. no food or drink except 
water) for at least 10 hours before coming to the research facility. 
 
Whole Study at a Glance 
 








*OGTT stands for Oral Glucose Tolerance Test, which comprises a 300 mL sugary drink 




Visit 2 Interval 
(≥ 48 h) 
Visit 3 
 
• Maintain the same diet throughout study and consume similar dinners prior to every 
study visit 
• No consumption of pine bark extract throughout the study 
• No strenuous activity within 24 h to visit 
• No caffeine (coffee, tea, coke, energy drinks, or chocolates etc.) past 12 noon the day 
before visit 
• No tea or coffee formulations, even decaffeinated ones past 12 noon the day before visit 
• No alcohol a day before visit 
• Refrain from all health supplements a day before visit 
• Fast for at least 10 h (No food and drink except water) 
Consume placebo or pine bark capsule + OGTT* 
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What happens during the Screening visit (Visit 1) 
 
During an initial screening session we will assess whether you fit these inclusion criteria. 
You will be required to arrive at the research facility at 7:30am ONE morning after at least a 
10-hour overnight fast, to have a screening blood sample collected. The session will take 
approximately less than an hour. A qualified phlebotomist will measure your fasting blood 
sugar, lipid profile and HbA1c levels (the latter is a measure of how stable your blood sugar 
levels have been over the last three months) to check that you are not pre-diabetic. If your 
results come back and indicate that you have glucose tolerance issues you will NOT be able 
to participate. With your permission, we will refer you to your GP for follow-up and you may 
show them your blood sugar level results.  
 
In addition, trained researchers will determine your body mass index (BMI) by measuring 
your weight and height. They will also be taking your waist and hip circumference, and also 
your percentage of body fat and lean body mass (as measured by a bioelectrical impedance 
scale). This can be done privately and you do not need to undress. Blood pressure and heart 
rate measurement will also be taken. You will also be asked about your medical history, and 
any medication use. 
 














During the study visits (visits 2 and 3), one or two finger-prick blood samples will be taken to 
measure your baseline blood sugar level. You will then be asked to consume a capsule 




End of  
session 
Baseline blood sampling 
via finger prick 
OGTT* Consume placebo/ 
test capsule 
Baseline blood sampling via 
finger prick 
 
*OGTT stands for Oral Glucose Tolerance Test, which comprises a 300 mL sugary drink 
(containing 75 g carbohydrates).  
7-7:30 am 09:00-09:30 am 
Time point (min):       -20     0      15     30     45     60              90          120     
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cellulose. After 20 minutes you will have another baseline finger prick. You will then be 
asked to consume a sugary drink of 300 mL containing 75 grams of carbohydrates. You will 
need to remain in the research facility for the next two hours and not undertake any physical 
activity. Study and quiet activities are allowed, as are trips to the bathroom. Further finger 
prick tests will be taken at 15, 30, 45, 60, 90 and 120 minutes after consuming the sugary 
drink, and the blood sugar levels recorded. At the completion of this period you are welcome 
to eat and drink as normal (this will be provided). We will have DVDs available for viewing 
also to help pass the time. 
 
You will be asked to keep your diet and lifestyle as constant as possible throughout the study 
and to refrain from engaging in any strenuous physical activity (walking is fine) or 
consumption of alcohol in the 24-hour period prior to each study session. Furthermore, avoid 
caffeine products (coffee, tea, coke, energy drinks, or chocolates etc.) from noon on the day 
prior to your study session. You will also be asked to avoid the active test foods/extracts 
(pine bark extract) throughout the duration of the study period (including avoiding other teas 
and formulations where the pine bark extract may be present).  
 
WHAT ARE THE POSSIBLE BENEFITS AND RISKS OF THIS STUDY? 
Research is a big part of medicine and healthcare and being involved can be very rewarding. 
You can learn a lot about the processes that are involved in research by actively participating 
and it can be satisfying to know that you are contributing to knowledge. Furthermore, by 
participating in the study you also obtain information about your general health status, 
HbA1c value, body composition and blood pressure measurement entirely at no cost to you. 
In addition, there will be a reimbursement for involvement in the study. 
It is highly unlikely that you will be injured during this study. Finger prick blood sampling is 
safe and routinely used. A registered personnel will be available during each study session 
and researchers will be present to assess for adverse events (i.e. feeling nauseous, dehydrated 
or faint) during each blood sampling, and any event will be documented in alignment with 
Massey Code of Ethical Conduct. Furthermore, the pine bark extract has been tested 
previously and recorded as safe for consumption by the US FDA.  
 
WHO PAYS FOR THE STUDY? 
There is no cost to you, the participant, for taking part in this study.  
 
In recognition of your time and participation in this study, you will be reimbursed $20 for 
screening and $30 for completion of each session. You will be reimbursed a total of $80 for 
completing the whole study (1 screening visit and 2 study visits) in the form of a gift 
voucher.  If for any reason you are unable to complete the study, you will be reimbursed for 
your total time contributed to the study.  
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WHAT IF SOMETHING GOES WRONG? 
If you were injured in this study, which is unlikely, you would be eligible for compensation. 
The study is insured by Chubb Insurance New Zealand Limited. If your claim is accepted, 
you will receive funding to assist in your recovery.   
 
If you have private health or life insurance, you may wish to check with your insurer that 
taking part in this study won’t affect your cover. 
 
WHAT ARE MY RIGHTS? 
Participating in this study is completely voluntary and you are free to decline to participate, 
decline to answer any particular question, or to withdraw from the research at any practicable 
time, without experiencing any disadvantage. 
 
You, the participant has a right to access information about you, collected as part of this 
study. You will be told of any new information about adverse or beneficial effects related to 
this study which may impact upon your health.  
 
It is important to us that we maintain your privacy throughout this study. Your name and 
contact information will be held electronically and stored on the Principal Investigators 
computer only for data recording purposes. Each participant in the study will be allocated a 
number. Staff involved in blood sampling and analysis will have access to participant 
numbers only. All data from study sessions will be recorded against your participant ID 
number and your name will never be used in any report, correspondence or publication. Your 
involvement in this study is confidential. 
 
WHAT HAPPENS AFTER THE STUDY OR IF I CHANGE MY MIND? 
You are able to pull out of the study at any time, and will be compensated accordingly for 
your time. Further you are welcome to discuss any concerns you have with the research team 
at any time, and you have free access to your data. If you pull out of the study all of the data 
that was related to you will be shredded. 
The treatment intervention (pine bark extract) will not be available to any participant after the 
study. The study data will be stored at a secure location at Massey University Albany 
Campus. Electronic data and records will be the responsibility of the Principal investigator. 
All data will be kept for 5 years, at which point it will be destroyed using University Security 
methods for removal of confidential material.  
 
Participants are welcome to discuss the findings of this study with the researchers at any 
time. You will also be provided with a full copy of the final study report, if requested. It is 
very likely that the results of this study will be written up for publication in a peer-reviewed 
journal and/or presentation and a Nutrition conference within 12 months of completing the 
study. If this happens no participant identification information will be included.  
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WHO DO I CONTACT FOR MORE INFORMATION OR IF I HAVE CONCERNS? 
If you have any questions, concerns or complaints about the study at any stage, you can 
contact the following researchers involved in the study: 
 
Dr Lynne Chepulis: Senior Research Fellow, Medical Research Unit, University of 
Waikato, Hamilton.  
Phone: +64 (07) 3468754  
Email lynne.chepulis@waikato.ac.nz 
 
A/Prof Rachel Page: Head of School of Health Sciences 
Phone 0800 627739 ext. 63462  
Email: R.A.Page@massey.ac.nz  
 
A/Prof Pam von Hurst: Associate Professor, School of Sport, Exercise and Nutrition, 
Massey University, Albany 
Phone: +64 (09) 2136657  
Email: P.R.vonHurst@massey.ac.nz 
 
Dr Cheryl Gammon:  Lecturer, School of Sport, Exercise and Nutrition, Massey University, 
Albany 
Phone: +64 (09) 4140800 ext. 43437  
Email: C.Gammon@massey.ac.nz 
 
Wen Xin Janice Lim: PhD student, School of Health Sciences, Massey Institute Food 
Science & Technology, Albany 
Email: wen.xin.lim.1@uni.massey.ac.nz 
 
You may also contact the Massey University Human Ethics Committee (MUHEC) involving 
any concerns that you may have:  
 
This project has been reviewed and approved by the Massey University Human Ethics 
Committee: Southern A, Application 17/73.  If you have any concerns about the conduct of 
this research, please contact Dr Lesley Batten, Chair, Massey University Human Ethics 
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mmol/L Not on blood sugar 
regulation medication 
Not pregnant  
Not a smoker 
No asthma or allergic to 
trial food extract 
THE PINE BARK EXTRACT STUDY 
Dr. Lynne Chepulis, A/Prof Rachel Page, Dr. Pam Von Hurst, Cheryl Gammon, Owen Mugridge, Janice Lim  
• To find out whether natural plant extracts can help improve glycaemic control 
• Prevention better than treatment for diabetes 
• The pine bark extract is provided by NZ ENZO Nutraceuticals Ltd.  
• According to Regulatory status of Enzogenol, NZ pine bark (Pinus radiata) is a dietary supplement 
Study Background 
Will consuming NZ  
pine bark extract 




















Visit 2 Interval 
(≥ 48 h) 
Visit 3 
Whole Study at a Glance 
• Maintain the same diet throughout study and consume similar dinners prior to every 
study visit 
• No consumption of pine bark extract throughout the study 
• No strenuous activity within 24 h to visit 
• No caffeine (coffee, tea, coke, energy drinks, or chocolates etc.) past 12 noon the day 
before visit 
• No tea or coffee formulations, even decaffeinated ones past 12 noon the day before visit 
• No alcohol a day before visit 
• Refrain from all health supplements a day before visit 
• Fast for at least 10 h (No food and drink except water) 
Consume placebo or pine bark capsule + OGTT* 
What the Study Involves 
1 Screening 
visit (1h) 
2 Trial visits  










HbA1c, fasting blood glucose & 
lipids, weight, height, hip & 




























Are there any Study Risks?  
Possible minor 











will always be 
present 
All adverse 
events will be 
documented 
and monitored 




End of  
session 
Baseline blood sampling 
via finger prick 
OGTT* Consume placebo/ 
test capsule 
Baseline blood sampling via 
finger prick 
 
*OGTT stands for Oral Glucose Tolerance Test, which comprises a 300 mL sugary drink 
(containing 75 g carbohydrates).  
7-7:30 am 09:00-09:30 am 
Time point (min):       -20     0      15     30     45     60              90          120     
   




















Your Rights and Benefits 





$20 after  
screening visit 
Reimbursement of $60 
for the whole study  









You may decline to 
participate, or withdraw 
from study without 
disadvantages 










Your name will 






about you will 
be shredded  
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A dose-response study to assess the effects of 
pine bark extract (Enzogenol™) on glycaemic 





































1. Is!the!subject!aged!18940?! ! ! ! ! ! !!!!!YES!/!NO!
2. Does!the!subject!have!a!BMI!between!18.5925.0?! ! ! !!!!!YES!/!NO!
3. Does!the!subject!have!an!HbA1c!of!<!40!mmol/!mol! ! ! !!!!!YES!/!NO!
4. Does!the!subject!have!a!fasting!glucose!of!<!5.5!mmol/!L!! ! !!!!!YES!/!NO!
5. Is!the!subject!non9smoking?! ! ! ! ! ! !!!!!YES!/!NO!







2. Does!the!subject!have!any!known!clinically!significant!disease?! ! !!!!!YES!/!NO!
3. Does!the!subject!take!any!medications!that!include!blood!glucose/!sugar!!!!!YES!/!NO!
lowering!prescriptions!
4. Does!the!subject!have!any!allergies!to!pine!bark?! ! ! !!!!!YES!/!NO!
!
5. Pregnant!or!brestfeeding! ! ! ! ! ! !!!!!YES!/!NO!
!
!
! ! !! ! !












































































! System! Yes! No! ! ! System! Yes! No!
!
1! Cardiovascular! ! ! ! 9! Neoplasia! ! !
2! Respiratory! ! ! ! 10! Neurological! ! !
3! Hepato9billary! ! ! ! 11! Psychological! ! !
4! Gastro9intestinal! ! ! ! 12! Immunological! ! !
5! Genito9urinary! ! ! ! 13! Dermatological! ! !
6! Endocrine! ! ! ! 14! Allergies! ! !
7! Haematological! ! ! ! 15! Eyes,!ears,!nose,!throat! ! !
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Appendix 2.5 – Pine Bark study consent form 
 
 
 Consent for Participation 
 
A dose-response study to assess the effects of pine bark extract (Enzogenol™) on 
glycaemic (blood sugar) responses in healthy subjects 
 
 
I have read the Information Sheet and have had the details of the study explained to me. My 
questions have been answered to my satisfaction, and I understand that I may ask further 




I agree/ do not agree to participate as per the outlined requirements and am aware that I may 




In signing this consent form I declare that I am in no way being subjected to coercion or 















Signed_____________________________     Date_____________________ 
 







This consent form will be kept securely according to Massey University Human Ethics Committee (MUHEC) 
requirements for a period of five years following the study and remain confidential throughout. 
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Appendix 2.6 – Pine Bark study record sheet for participants to take home 
 
The Pine Bark Extract Study
Date:




* Based on NZ Heart Foundation
< 18.5 = Underweight
18.5 - 24.9 = Normal weight
25.0 - 29.9 = Overweight
> 30.0 = Obese
Hip circumference (cm)
        Systolic                    
Diastolic
      < 120          and          < 80
   120 - 129      and           < 80 
      130 - 139      or            80 - 
89 







* Based on AHA 
60 - 100 = Normal
Fasting glucose (mmol/ L)*
* Based on Diabetes New Zealand
≤ 6.0 = Normal
6.1 - 6.9 = Prediabetes
≥ 7.0 = Diabetes
Lipid Profile*:
* Based on Southern Cross Medical Society
Recommended to be:
Total cholesterol (TC) (mmol/ L),
which is HDL + LDL +20% TG
< 4.0
Triglycerides (TG) (mmol/ L) < 1.7
High-density lipoprotein (HDL) (mmol/ L) > 1.0
Low-density lipoprotein (LDL) (mmol/ L) < 2.0
Non-HDL (total bad cholesterol) (mmol/ 
L)
< 4.0
TC/HDL ratio < 4.0
≤ 40 = Normal
41-49 = Prediabetes
≥ 50 = Type 2 Diabetes
Blood pressure (mm/ Hg)*
* Based on American Heart Foundation 
(AHA) recommendations 
Waist circumference (cm)*
*Based on International 
Diabetes Federation (IDF)
HbA1c (mmol/ mol)*
*Based on New Zealand Medical 
Association (NZMA)
Increased disease risk if:
Men ≥ 90, while for
European men ≥ 94
Women ≥ 80
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The Pine Bark Extract Study 
 
A dose-response study to assess the effects of pine bark extract (EnzogenolTM) on glycaemic 
(blood sugar) responses in healthy participants  
 
Form for Study Visits 2 and 3 
Visit 2     3 
Dietary Compliance Yes/ No 
1 day abstinence from supplements Yes/ No 
Tea or coffee abstinence Yes/ No 
Fasted at least 10-12h? Yes/ No 
Sport restriction Yes/ No 
Alcohol abstinence Yes/ No 
General condition of participant (Stress level) High/ Medium/ Low 
Name of researcher-in-charge  
 
Procedure Tick for completion Time taken Remarks 
Baseline blood taken at t=-20    
Consumption of treatment capsule    
Baseline blood taken at t=0    
Consumption of glucose drink    
Blood taken at t=15    
Blood taken at t=30    
Blood taken at t=45    
Blood taken at t=60    
Blood taken at t=90    
Blood taken at t=120    
Participant Identifier  
DOB  
Date  








THE PINE BARK STUDY DATA COLLECTION 
 
Study visit Date 
Blood glucose levels (mmol/ L) at each time point (min) 
-20 0 15 30 45 60 90 120 
2          








      Participant Initials: 
 




Appendix 3 – GLARE study documents 
The following section of the Appendices includes participant recruitment and documents, and 
data collection forms pertaining to the GLARE study: 
Appendix 3.1 – GLARE study recruitment poster ................................................................. 248 
Appendix 3.2 – GLARE study online screening questionnaire ............................................. 249 
Appendix 3.3 – GLARE study participant information sheet ................................................ 252 
Appendix 3.4 – GLARE study reference during screening ................................................... 261 
Appendix 3.5 – GLARE study case record form ................................................................... 265 
Appendix 3.6 – GLARE study consent form ......................................................................... 267 
Appendix 3.7 – GLARE study record sheet for participants to take home ........................... 268 
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Appendix 3.2 – GLARE study online screening questionnaire 
Screening Questionnaires (For telephone screening): 
1. Unique ID (Please find your ID in your email subject box) 
2. Address  
3. GP Name 
4. GP Address (Clinic, Road and Suburb of your GP) 
5. Date of birth  (dd / mm / yyyy) 
6. Gender 
7. Country of Birth 
8. Years in NZ 
9. Which ethnic group(s) do you belong to? 
ü New Zealand European 
 Maori 
 Pacific 
 South Asian 
 Chinese 
 Korean 
 Southeast Asian 
ü if other please specify:    
 
10. Whereabouts did you hear about the GLARE Study? 
(Facebook (Massey/through a friend), word of mouth, poster, GP surgery etc.) 
11. What is your approximate height (cm)? 
12. What is your approximate weight (kg)? 
13. Medical History 
Have you ever been diagnosed with any of the following: 








ü if other please specify:    
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14. Does anyone in your immediate family (blood relative) have diabetes? 
ü Yes 
ü No 
ü If yes, please detail relationship, gender and age of diagnosis 
 




ü If yes, please detail relationship, gender and age of diagnosis 
 
16. Does anyone in your immediate family (blood relative) have prediabetes? 
ü Yes 
ü No 
ü If yes, please detail relationship, gender and age of diagnosis 
 
17. When were you diagnosed with high blood glucose/prediabetes? 
 
18. Select here if you have not been diagnosed with high blood glucose by a doctor 
(Go to Q23) 
ü Not diagnosed 
19. How long have you had high blood glucose? 
20. Date of last test (Approximate month/year) 
21. What type of test did you have? Select all that apply. 
ü HbA1c 
ü Fasting glucose 
ü Don't know 
ü If other please specify:    
 
22. What advice were you given in regards to having high blood glucose? 
 
23. Have you made any lifestyle changes since being told you have high blood 
glucose? 
 
24. Additional Health Questions 
Please select the box if you are: 
ü allergic to plasters or antiseptic wipes 
ü have any disorder of bleeding or clotting of the blood 
ü have had a cold or feverish illness in the last month 
ü prone to fainting 
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ü a smoker of cigarettes 
ü a drinker of alcohol 
25. If you drink alcohol, approximately how many standard drinks per week do you 
drink? 
 
26. Are you taking any prescription medications or any other medications, pills or 
supplements, including traditional, homeopathic medicine, or natural health ? If 























Appendix 3.3 – GLARE study participant information sheet 
 
Participant Information Sheet 
 
 
Study title: The GLARE Study (Glucose Lowering Antioxidant Rich Plant Extracts) 
 
Locality: Massey University Campus, Auckland 
Ethics committee ref.:  17/STH/82 




You have been invited to take part in the GLARE (Glucose Lowering Antioxidant Rich Plant 
Extracts) study which is looking at the effects of antioxidant-rich plant extracts on blood 
sugar levels in men and women.  Whether or not you take part is your choice.  If you don’t 
want to take part, you don’t have to give a reason, and it won’t affect the care you receive.  If 
you do want to take part now, but change your mind later, you can pull out of the study at any 
time.   
 
This Participant Information Sheet will help you decide if you’d like to take part.  It sets out 
why we are doing the study, what your participation would involve, what the benefits and 
risks to you might be, and what would happen after the study ends.  We will go through this 
information with you and answer any questions you may have.    You do not have to decide 
today whether or not you will participate in this study. Before you decide you may want to 
talk about the study with other people, such as family, whānau, friends, or healthcare 
providers.  Feel free to do this. 
 
If you agree to take part in this study, you will be asked to sign the Consent Form on the last 
page of this document.  You will be given a copy of both the Participant Information Sheet 
and the Consent Form to keep. 
 
This document is 9 pages long, including the Consent Form. Please make sure you have read 
and understood all the pages. 
 
WHAT IS THE PURPOSE OF THE STUDY? 
The purpose of the study is to look at certain antioxidant-rich plant extracts (which include 
grape seed, rooibos tea and olive leaf extract) and the impact they have on blood sugar levels 
in people diagnosed with prediabetes. Prediabetes is a warning sign for development of type 
2 diabetes. It is a term given for when you have blood sugar levels higher than normal but 
not high enough yet to be considered type 2 diabetes. Antioxidants are substances that are 
able to fight against unstable molecules formed in the body.  The plant extracts chosen for 




This study aims to build on information from a recent study (Chepulis et al, 2016), which 
showed that 4 antioxidant-rich plant extracts (amla berry, grape seed, rooibos tea and green 
tea extracts) had a positive impact on blood sugar response in subjects with normal blood 
sugar levels. Little is known about whether these plant extracts can be used to improve blood 
sugar control in people with prediabetes, or whether they can slow the development to type 2 
diabetes (a more serious condition than prediabetes).This study aims to examine the short 
term effects of these antioxidant-rich plant extracts (rooibos tea, grape seed and olive leaf) 
on blood sugar control in people with prediabetes. 
 
The sources of funding for this study have been provided by the Massey University Research 
Fund, COMVITA NZ Ltd., Rooibos Council of South Africa and Toiohomai Institute 
Technology. Should you have any questions about this study during your participation in the 
study you can contact the following people: 
 
Dr Lynne Chepulis: Senior Research Fellow, Medical Research Unit, University of Waikato, 
Hamilton 
Phone +64 7 837 9553 (work) or 022 675 3353 
Email: lynne.chepulis@waikato.ac.nz 
 
A/Prof Rachel Page: Head of School of Health Sciences, Massey University 
Phone 0800 627739 ext. 63462 
Email: R.A.Page@massey.ac.nz 
 
Dr. Pam Von Hurst : Associate Professor, School of Sport, Exercise and Nutrition, Massey 
University, Albany Campus 
Phone: +64 (09) 2136657 
Email: P.R.vonHurst@massey.ac.nz 
 
The ethical considerations of this study have been approval by the Southern Heath & 
Disabilities Ethics Committee (HDEC). You can contact HDEC via email on 
hdecs@moh.govt.nz 
 
WHAT WILL MY PARTICIPATION IN THE STUDY INVOLVE? 
You have been chosen to participate in the study because you have met the criteria to be 
included in the study.  The criteria includes: 
• A high blood sugar level (known as prediabetes), (HbA1c between 41-49 mmol/mol) 
• Not being on medication that influences blood sugar levels 
• Not a smoker 
• Able to speak and read English   
 
The study will involve you coming to the Massey University Food & Nutrition Laboratory, 
located at the Albany Campus, North Shore. You will need to be available for FIVE visits at 
your preferred time. Each visit will be for approximately 2.5 hours from 7 -7.30 am – 9.30 -
10 am in the morning. You will be required to fast overnight (i.e. no food or drink except 
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water) for at least 10 hours prior to coming into the Lab for each visit (with the exception of 
your first screening visit). The research team will provide you with breakfast and tea or 
coffee after each of your visits.  
 





















Your first visit will be the screening visit, which will include collecting the following data: 
• Collection of some personal health information such as weight, height, hip and waist 
circumference, body fat percentage (as measured by a bioelectrical impedance (BIA) 
scale), blood pressure, medical history, and any medication use.  
• Additional information will be collected around your diagnosis of prediabetes, 
particularly around duration of prediabetes and the dietary and lifestyle advice given 
to you at the time of diagnosis.  
 
Your subsequent visits (visits 2-5) will involve consuming either a placebo or antioxidant-
rich plant extract capsule and drinking a 300 mL sugary drink (contains 75 g of glucose). 
This study is a placebo-controlled blinded study. This means that you will not know what test 














(≥ 48 h) 
Test 
Visit 5 
*Active test extracts are the grape seed, rooibos tea and olive leaf extracts 
 
**OGTT stands for Oral Glucose Tolerance Test, which comprises a 300 mL sugary drink 
(containing 75 g carbohydrates).  
• Maintain the same diet throughout study and consume similar dinner prior to 
every study visit 
• No consumption of the active test extracts* throughout the study 
• No strenuous activity within 24 h to visit 
• No caffeine (coffee, tea, coke, energy drinks, or chocolates etc.) past 12 noon 
the day before visit 
• No tea or coffee formulations, even decaffeinated ones past 12 noon the day 
before visit 
• No alcohol 24 h before visit 
• Refrain from all health supplements 24 h before visit 
• Fast for at least 10 h (No food and drink except water) 
Consume test capsule + OGTT** 
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be consuming with a sugary drink. The placebo capsule contains no antioxidant or active 
substance and acts as a control as it will have no effect on your blood sugar levels. 
 
The last visit will also involve collecting personal health information again (including; 
weight, waist and hip circumference, body fat percentage and blood pressure). Blood 
pressure will be recorded at every visit.  
 
















When you arrive at 7-7.30 am on your visit, a small plastic chute will be inserted into one of 
your veins in your arm to allow a blood sample to be taken to measure your baseline blood 
sugar level. Ten minutes before drinking a 300 mL sugary drink you will be given a capsule 
that will either contain an antioxidant-rich plant extract (rooibos, olive leaf or grape seed 
extract) or a placebo capsule. Once you have consumed your sugary drink, you will then 
need to remain in the Massey University Food and Nutrition lab for the next two and half 
hours and not undertake any physical activity. Study and quiet activities are allowed, as are 
trips to the bathroom. Further blood samples will be taken from the same chute at 15, 30, 45, 
60, 90 and 120 minutes after consuming the antioxidant-rich extract or placebo, and the 
blood sugar levels, insulin levels and antioxidant activity will be determined at a later date. 
We will have qualified phlebotomists (people trained to draw blood) on site to collect these 
blood samples. 
 
At the completion of your 2.5 hour visit you are welcome to eat and drink as normal (this will 




End of session 
and removal of 
cannula 
Baseline blood draw  
(13 mL per time point) 
OGTT* Consume placebo/ 
test capsule 
Blood sampling  
(13 mL per time point) 
*OGTT stands for Oral Glucose Tolerance Test, which comprises a 300 mL sugary drink 
(containing 75 g carbohydrates).  
All blood samples collected will be used to quantify blood glucose levels, insulin levels, antioxidant 
capacity, and peptide levels.  
7-7:30 am 09:30-10:00 am 
Time point (min):       -10     0      15     30     45     60              90          120     
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What happens between Visits 2-5 
You will be asked to keep your diet and lifestyle as constant as possible throughout the study 
and to refrain from engaging in any strenuous physical activity (walking is fine) or 
consumption of alcohol in the 24-hour period prior to each test session. You will also be 
asked to avoid the active test foods/extracts for at least seven days prior to the first test 
session and throughout the duration of the test period, including avoiding other teas and 
formulations where the extracts may be present. 
 
The research team understands that some of the information that we are collecting is very 
sensitive and it will be treated as such. Only the research team and you, the participant, will 
have knowledge of your personal information.  
 
WHAT ARE THE POSSIBLE BENEFITS AND RISKS OF THIS STUDY? 
Direct benefits of participating in this study include; an increased awareness and knowledge 
of the processes involved in research by actively participating in it, and a satisfaction in 
knowing that you are contributing to nutrition knowledge in the community. Additionally, 
there is also a monetary payment for involvement in this study. 
 
Foreseeable risks, adverse-effects and discomforts that you may encounter by taking part in 
this study are minimal, but could include possible infection from the site in which blood is 
drawn and there may be some minor bruising at this site as well. You may also feel some 
nausea or gastrointestinal discomfort from ingestion of the glucose (in the sugary drink) for 
the oral glucose tolerance test. These discomforts will be managed by the presence of a 
qualified health professional who will be available to assist you should you require it. A 
record of all adverse events will be monitored and maintained throughout the course of the 
study.  
 
WHO PAYS FOR THE STUDY? 
There is no cost to you, the participant, for taking part in this study. 
 
In recognition for your time and participation in this study, you will be reimbursed a total of 
$210. This total amount is based on your attendance to all FIVE visits to the Massey 
University Food and Nutrition Laboratory on Albany campus. If for any reason you are 
unable to complete the study, you will be reimbursed for your total time contributed to the 
study. You will receive $10 for completing the screening visit and then for each study visit 
that you complete, you will be reimbursed with $50. 
 
WHAT IF SOMETHING GOES WRONG? 
If you were injured in this study, which is unlikely, you would be eligible for compensation 
from ACC just as you would be if you were injured in an accident at work or at home. You 
will have to lodge a claim with ACC, which may take some time to assess. If your claim is 




If you have private health or life insurance, you may wish to check with your insurer that 
taking part in this study won’t affect your cover. 
 
 
WHAT ARE MY RIGHTS? 
Participating in this study is completely voluntary and you are free to decline to participate, 
or to withdraw from the research at any practicable time, without experiencing any 
disadvantage.  
 
You, the participant has a right to access information about you, collected as part of this 
study.  
 
You will be told of any new information about adverse or beneficial effects related to this 
study which may impact upon your health. 
   
It is important to us that we maintain your privacy throughout this study. Your name and 
contact information will be held electronically and stored on the Principal Investigators 
computer only for data recording purposes. Each participant in the study will be allocated a 
number. Staff involved in blood sampling and analysis will have access to participant 
numbers only. All data from test sessions will be recorded against your participant ID 
number and your name will never be used in any report, correspondence or publication.  
Your involvement in this study is confidential. 
 
WHAT HAPPENS AFTER THE STUDY OR IF I CHANGE MY MIND? 
You are able to pull out of the study at any time, and will be compensated accordingly for 
your time.  Further you are welcome to discuss any concerns you have with the research 
team at any time, and you have free access to your data.  If you pull out of the study all of the 
data that was related to you will be shredded. 
 
The treatment intervention (antioxidant capsules being tested in the GLARE study) will not be 
available to any participant after the study. The outcomes of this study will enable selection 
of antioxidant-rich plant extracts that can be investigated further in a long term intervention 
study.  
 
The study data will be stored at a secure location at Massey University Albany Campus. 
Electronic data and records will be the responsibility of the Principal investigator. All data 
will be kept for 10 years, at which point it will be destroyed using University Security 
methods for removal of confidential material. At the completion of the study all biological 
samples collected will be disposed of using established methods for discarding biological 
waste. Any participant can request to have their remaining blood sample returned to them.  
 
You may hold beliefs about a sacred and shared value of all or any tissue samples removed. 
The cultural issues associated with sending your samples overseas and/or storing your tissue 
should be discussed with your family/whanau as appropriate. There are a range of views held 
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by Maori around these issues; some iwi disagree with storage of samples citing whakapapa 
and advise their people to consult prior to participation in research where this occurs. 
However it is acknowledged that individuals have the right to choose.  
 
We anticipate that the results of this study will be published in a peer-reviewed journal within 
12 months of completing the study. Participants are welcome to discuss the findings of this 




WHO DO I CONTACT FOR MORE INFORMATION OR IF I HAVE CONCERNS? 
If you have any questions, concerns or complaints about the study at any stage, you can 
contact:  
 
Researchers in the Study:  
 
You can contact the following researchers: A/Prof Rachel Page, Dr Lynne Chepulis or Dr 
Pam von Hurst. Contact details are at the beginning of this information sheet.  
 
If you want to talk to someone who isn’t involved with the study, you can contact an 
independent health and disability advocate on: 
 
Phone:  0800 555 050 
Fax:   0800 2 SUPPORT (0800 2787 7678) 
Email:   advocacy@hdc.org.nz 
 
 
You can also contact the health and disability ethics committee (HDEC) that approved this 
study on: 
 
 Phone:  0800 4 ETHICS 


















Please tick to indicate you consent to the following (Add or delete as appropriate) 
 
I have read, or have had read to me in my first language, and I 
understand the Participant Information Sheet.   Yes o No o 
I have been given sufficient time to consider whether or not to 
participate in this study. Yes o No o 
I have had the opportunity to use a legal representative, whanau/ 
family support or a friend to help me ask questions and understand 
the study. 
Yes o No o 
I am satisfied with the answers I have been given regarding the 
study and I have a copy of this consent form and information sheet. Yes o No o 
I understand that taking part in this study is voluntary (my choice) 
and that I may withdraw from the study at any time without this 
affecting my medical care. 
Yes o No o 
I consent to the research staff collecting and processing my 
information, including information about my health. Yes o No o 
If I decide to withdraw from the study, I agree that the information 
collected about me up to the point when I withdraw may continue to 
be processed. 
Yes o No o 
I consent to my GP or current provider being informed about my 
participation in the study and of any significant abnormal results 
obtained during the study. 
Yes o No o 
I am aware that my blood samples will be disposed of using 
established guidelines for discarding biological waste. Yes o No o 
I understand that my participation in this study is confidential and 
that no material, which could identify me personally, will be used in 
any reports on this study. 
Yes o No o 
I understand the compensation provisions in case of injury during 
the study. Yes o No o 
I know who to contact if I have any questions about the study in 
general. Yes o No o 
I understand my responsibilities as a study participant. Yes o No o 
I wish to receive a summary of the results from the study. Yes o No o 
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Declaration by participant: 







Declaration by member of research team: 
 
I have given a verbal explanation of the research project to the participant, and have 
answered the participant’s questions about it.   
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THE GLARE STUDY 
Research team: Dr. Lynne Chepulis, A/Prof Rachel Page, Dr. Pam Von Hurst, Cheryl Gammon, Owen Mugridge, Alexandra Tava, Jasmine Foote, Janice Lim  
• Prediabetes is where you have blood sugar levels above normal but below defined thresholds of diabetes 
• High risk for diabetes with 5-10% conversion rate every year 
• Goal to achieve normal blood sugar levels in prediabetic people 
• Prevention better than treatment for diabetes 
• Natural food sources may be a better strategy than diabetic medication 
Study Background 
Non-diabetic 



























No asthma or 






1. Their effects on 


























(≥ 48 h) 
Test 
Visit 5 
Whole Study at a Glance 
*Active test extracts are the grape seed, rooibos tea and olive leaf extracts 
 
**OGTT stands for Oral Glucose Tolerance Test, which comprises a 300 mL sugary drink 
(containing 75 g carbohydrates).  
• Maintain the same diet throughout study and consume similar dinner prior to 
every study visit 
• No consumption of the active test extracts* throughout the study 
• No strenuous activity within 24 h to visit 
• No caffeine (coffee, tea, coke, energy drinks, or chocolates etc.) past 12 noon 
the day before visit 
• No tea or coffee formulations, even decaffeinated ones past 12 noon the day 
before visit 
• No alcohol 24 h before visit 
• Refrain from all health supplements 24 h before visit 
• Fast for at least 10 h (No food and drink except water) 
Consume test capsule + OGTT** 
What the Study Involves 
1 Screening 
visit (1h) 
4 Trial visits  










HbA1c, weight, height, hip 
& waist circumference, body 
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End of session 
and removal of 
cannula 
Baseline blood draw  
(13 mL per time point) 
OGTT* Consume placebo/ 
test capsule 
Blood sampling  
(13 mL per time point) 
*OGTT stands for Oral Glucose Tolerance Test, which comprises a 300 mL sugary drink 
(containing 75 g carbohydrates).  
All blood samples collected will be used to quantify blood glucose levels, insulin levels, antioxidant 
capacity, and peptide levels.  
7-7:30 am 09:30-10:00 am 
Time point (min):       -10     0      15     30     45     60              90          120     
   












will always be 
present 
All adverse 
















































about you will 
be shredded  
Your Rights and Benefits 




Receive a gift 
voucher of $10 after 
screening visit 
Receive $100 in a 
Prezzy card after 2 
trial visits 
 
4 trial visits entitle 












You may decline to 
participate, or 












> duration of prediabetes
> dietary and lifestyle advice 











Blood Pressure                   /                     /                     /   
Heart Rate (bpm)
HbA1c
If F - Are you post-
menopausal?  
(Answer YES, if your last 
menstrual period 
was over one year ago?) Y/N
Notes 


































































Consent for Participation in the GLARE Study 
 
This form should only be completed and signed if there is full agreement with the details and 
terms given below. 
 
 
I _________________________________ (full name) give my full consent to participate in 
the study “A placebo-controlled, single blind trial to assess the effect of antioxidant-rich plant 
extracts on glucose levels in prediabetic subjects” as conducted by principal investigator Dr. 
Lynne Chepulis and the GLARE team.  
 
I have read the information sheet provided to me that details the study, my role and 
responsibilities and the role and responsibilities of the research team.   
 
I have had the opportunity to discuss the study with the researchers and to ask questions and 
have received a satisfactory response for any concerns I have voiced. 
 
I agree to participate as per the outlined requirements and am aware that I may withdraw at 
any time. 
 
In signing this consent form I declare that I am in no way being subjected to coercion or 
duress and am consenting of free will. 
 
I understand that involvement in this study requires me to undertake a number of oral glucose 
tolerance tests, but that this will be done under the supervision of a study team member. 
 








This consent form will be kept securely according to the Health & Disability Ethics 






















































Appendix 3.8 – GLARE study visit form 
	  
GLARE	  Study	  
A placebo-controlled blinded trial to investigate the effect of antioxidant-rich food extracts 
on postprandial blood glucose response in people with prediabetes. 
Form for Study Visits 2-5 
Visit 2     3     4     5 
Dietary Compliance Yes/ No 
1 day abstinence from supplements  Yes/ No 
Fasted at least 10-12h? Yes/ No 
Abstinence from tea coffee since 12nn? Yes/ No 
Sport restriction?  Yes/ No 
Alcohol abstinence? Yes/ No 
Taking medication (if any) consistently?  Yes/ No 
General condition of participant (Stress level) High/ Medium/ Low 
Intervention C     E1     E2     E3 
Blood pressure (mm Hg):  
Heart rate (bpm):  
Name of researcher-in-charge  
 
Procedure Tick for completion Actual time Remarks 
Baseline blood taken at t=-10    
Consumption of treatment capsule    
Baseline blood taken at t=0    
Consumption of glucose drink    
Blood taken at t=15    
Blood taken at t=30    
Blood taken at t=45    
Blood taken at t=60    
Blood taken at t=90    






Participant Identifier  
DOB  
Date  








A placebo-controlled blinded trial to investigate the effect of antioxidant-rich food 
extracts on postprandial blood glucose response in people with prediabetes. 
 
Form for Laboratory Processing of Blood Sample 
Visit 2     3     4     5 
Dietary Compliance Yes/ No 
1 day abstinence from supplements  Yes/ No 
Fasted at least 10-12h Yes/ No 
Abstinence from tea coffee since 12nn? Yes/ No 
Sport restriction?  Yes/ No 
Alcohol abstinence? Yes/ No 
Taking medication (if any) consistently? Yes/ No 
General condition of participant (Stress level) High/ Medium/ Low 
Intervention C     E1     E2     E3 
Treatment Placebo/ Grape seed/ Rooibos tea/ OLE 
Name of researcher-in-charge  
 
Participant Identifier  
DOB  
Date  
Blood Sample Processing 
Time Actual start time Procedure 
Tick for 
completion Remarks 
  Blood put in ice box at t=-10 
-­‐ Centrifuge tubes at 3500 
rpm for 15min at 4°C 
-­‐ Aliquot samples for 





*ORAC test to be 
done 
 
  Blood put in ice box at t=0 
-­‐ Centrifuge tubes at 3500 
rpm for 15min at 4°C 
-­‐ Aliquot samples for 
















  Blood put in ice box at t=15 
-­‐ Centrifuge tubes at 3500 
rpm for 15min at 4°C 
-­‐ Aliquot samples for 




*Red serum tube 
(S10, t=-10) to be 
centrifuged. 
 
  Blood put in ice box at t=30 
-­‐ Centrifuge tubes at 3500 
rpm for 15min at 4°C 
-­‐ Aliquot samples for 




*Red serum tube 





At t=30 for Incretins (0 & 30): 
-­‐ Centrifuge EDTA tubes at 
2900 rpm for 10min at 4°C 
-­‐ Aliquot samples for 







  Blood put in ice box at t=45 
-­‐ Centrifuge tubes at 3500 
rpm for 15min at 4°C 
-­‐ Aliquot samples for 







*Red serum tube 
(t=15) to be 
centrifuged. 
*ORAC test to be 
done  
  Blood put in ice box at t=60 
-­‐ Centrifuge tubes at 3500 
rpm for 15min at 4°C 
-­‐ Aliquot samples for 






*Red serum tube 
(t=30) to be 
centrifuged. 
*ORAC test to be 
done  
  Centrifuge red serum tube 
(t=45) 
-­‐ Centrifuge tubes at 3500 
rpm for 15min at 4°C 
-­‐ Aliquot samples for 


































  Blood put in ice box at t=90 
-­‐ Centrifuge tubes at 3500 
rpm for 15min at 4°C 
-­‐ Aliquot samples for 






*Red serum tube 
(t=60) to be 
centrifuged. 





At t=90 for incretins (60 & 
90): 
-­‐ Centrifuge EDTA tubes at 
2900 rpm for 10min at 4°C 
-­‐ Aliquot samples for 









Blood put in ice box at t=120 
-­‐ Centrifuge tubes at 3500 
rpm for 15min at 4°C 
-­‐ Aliquot samples for 






*Red serum tube 
(t=90) to be 
centrifuged 





At t=120 for incretin (120): 
-­‐ Centrifuge EDTA tubes at 
2900 rpm for 10min at 4°C 
-­‐ Aliquot samples for 








Centrifuge red serum tube 
(t=120) 
-­‐ Centrifuge tubes at 3500 
rpm for 15min at 4°C 
-­‐ Aliquot samples for 
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Appendix 4.1 – Formulas of glucose and insulin indices considered in the GLARE study 










measure? Definition/ Formula Interpretation Reference 
 Reduced risk of T2DM 





Yes Yes Average incremental area 
under the curve of glucose 
using the trapezoidal rule. 
Values falling under the 
baseline were not included. 
Lower iAUC Higher iAUC Wolever, T.M.S. and D.J.A. Jenkins, The use of the 
glycemic index in predicting the blood glucose 
response to mixed meals. American Journal of 
Clinical Nutrition, 1986. 43(1): p. 167-172. 
 
Lefloch, J.P., et al., Blood glucose area under the curve: 
methodological aspects. Diabetes Care, 1990. 








Buysschaert, M., et al., An elevated 1-h post-load glucose 
level during the oral glucose tolerance test 
detects prediabetes. Diabetes & Metabolic 
Syndrome-Clinical Research & Reviews, 2017. 
11(2): p. 137-139. 
Bergman, M., et al., Petition to replace current OGTT 
criteria for diagnosing prediabetes with the 1-
hour post-load plasma glucose >= 155 mg/dl (8.6 
mmol/L). Diabetes Research and Clinical 
Practice, 2018. 146: p. 18-33. 
 
Pareek, M., et al., Enhanced Predictive Capability of a 1-
Hour Oral Glucose Tolerance Test: A 
Prospective Population-Based Cohort Study. 








Hulman, A., et al., Heterogeneity in glucose response 
curves during an oral glucose tolerance test and 
associated cardiometabolic risk. Endocrine, 
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Peak glucose value 
(mmol/L) 






2017. 55(2): p. 427-434. 
Peak glucose time 
(min) 
Yes Yes Time of peak glucose value Shorter time to 
peak 
Longer time to 
peak 
Kramer, C.K., et al., Emerging parameters of the insulin 
and glucose response on the oral glucose tolerance test: 
Reproducibility and implications for glucose homeostasis 
in individuals with and without diabetes. Diabetes 





Yes Yes Glucose shapes (monophasic, 
biphasic or triphasic). Both 
biphasic and triphasic shapes 




Monophasic Tschritter, O., et al., Assessing the shape of the glucose 
curve during an oral glucose tolerance test. Diabetes Care, 
2003. 26(4): p. 1026-1033. 
Stumvoll metabolic 






Yes Yes 19.240  −  0.281  ×  BMI  − 







Faster rate of 
glucose 
disposal 
Slower rate of 
glucose disposal 
Stumvoll, M., et al., Oral glucose tolerance test indexes 
for insulin sensitivity and secretion based on various 
availabilities of sampling times. Diabetes Care, 2001. 
24(4): p. 796-797. 
Insulin secretion and response indices 
*Insulin concentrations must be interpreted with insulin resistance to indicate degree of β-cell dysfunction and insulin sensitivity 
Mean iAUCinsulin 
(mU/L.min) 
No No Average incremental area 
under the curve of insulin 
using the trapezoidal rule. 
Values falling under the 
baseline were not included.  
NA NA Wolever, T.M.S. and D.J.A. Jenkins, The use of the 
glycemic index in predicting the blood glucose 
response to mixed meals. American Journal of 
Clinical Nutrition, 1986. 43(1): p. 167-172. 
 
Lefloch, J.P., et al., Blood glucose area under the curve: 
methodological aspects. Diabetes Care, 1990. 




No No Insulin value at 1h OGTT NA NA Crofts, C., et al., Identifying hyperinsulinaemia in the 
absence of impaired glucose tolerance: An 
examination of the Kraft database. Diabetes 





No No Insulin value at 2h OGTT NA NA 
Insulin peak value 
(mU/L) 
No No Highest insulin value during 
2h OGTT 
NA NA 
Insulin peak time Yes Yes Time of peak insulin value Shorter time to Longer time to Kramer, C.K., et al., Emerging parameters of the insulin 
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(min) peak peak and glucose response on the oral glucose 
tolerance test: Reproducibility and implications 
for glucose homeostasis in individuals with and 
without diabetes. Diabetes Research and Clinical 




complex) - Not 
validated by 
population studies 
to indicate risk of 
T2DM 
No No Insulin shapes (monophasic, 
biphasic or triphasic) 
 
Both biphasic and triphasic 
shapes are known as complex 
shapes 
NA NA NA 




under the curve / 
Glucose mean 
incremental area 
under the curve 
(iAUCinsulin / 
iAUCglucose)  











Levine, R. and D.E. Haft, Carbohydrate homeostasis. New 
England Journal of Medicine, 1970. 283(5): p. 237-+. 
Overall insulin sensitivity 
Matsuda index 
(ISI/M)  
Yes Yes 10000/(sqrt ((FBG x FI) x 




FBG and mean glucose 
(mg/dL) 
FI and mean insulin (mU/L) 
 
Mean glucose is calculated as 
(G0 x 15+G30 x 30+G60 x 
30+G90 x 30+G120 x 15)/120 
 
Higher ISI/M Lower ISI/M Matsuda, M. and R.A. DeFronzo, Insulin sensitivity 
indices obtained from oral glucose tolerance testing - 
Comparison with the euglycemic insulin clamp. Diabetes 
Care, 1999. 22(9): p. 1462-1470. 
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Mean insulin is calculated as 
(I0 x 15+I30 x 30+I60 x 30+I90 x 






Yes Yes Model based on glucose and 
insulin physiology during an 





FBG, glucose90 and glucose120 
(mg/dL) 
FI and insulin90 (mU/L) 
Higher OGIS Lower OGIS Mari, A., et al., A model-based method for assessing 
insulin sensitivity from the oral glucose tolerance test. 






Yes Yes 0.222  −  0.00333  ×  BMI  − 









Lower ISIoverall Stumvoll, M., et al., Oral glucose tolerance test indexes 
for insulin sensitivity and secretion based on 
various availabilities of sampling times. Diabetes 
Care, 2001. 24(4): p. 796-797. 




for fasting hepatic 
insulin sensitivity 












Lower QUICKI Katz, A., et al., Quantitative insulin sensitivity check 
index: A simple, accurate method for assessing 
insulin sensitivity in humans. Journal of Clinical 



















Higher HOMA-IR Matthews, D.R., et al., Homeostasis model assessment: 
insulin resistance and beta-cell function from 
fasting plasma glucose and insulin concentrations 
in man. Diabetologia, 1985. 28(7): p. 412-419. 
Stumvoll first 








Higher ISIfirst Lower ISIfirst Stumvoll, M., et al., Oral glucose tolerance test indexes 
for insulin sensitivity and secretion based on 
various availabilities of sampling times. Diabetes 







0-30 min of OGTT 
for first phase of 
insulin response 
(IGI30) 
Yes Not as robust 
compared to 
the others but 
commonly 









FBG and glucose30 (mg/dL) 
FI and insulin30 (mU/L) 
Higher ISI30 Lower ISI30 Phillips, D.I.W., et al., Understanding oral glucose 
tolerance. Comparison of glucose or insulin 
measurements during the oral glucose tolerance 
test with specific measurements of insulin 
resistance and insulin secretion. Diabetic 
Medicine, 1994. 11(3): p. 286-292. 
Late phase insulin sensitivity 
Stumvoll second 










FI and insulin60 (pmol/L) 
Higher 
ISIsecond 
Lower ISIsecond Stumvoll, M., et al., Oral glucose tolerance test indexes 
for insulin sensitivity and secretion based on 
various availabilities of sampling times. Diabetes 





Yes Yes (Total AUCinsulin / Total 
AUCglucose) x ISI/M 
 
where: 
Total AUCinsulin (mU/L.min) 
Total AUCglucose (mmol/L.min) 
 
and ISI/M uses: 
FBG and mean glucose 
(mg/dL) 
FI and mean insulin (mU/L) 
Higher ISSI-2 Lower ISSI-2 Retnakaran, R., et al., Hyperbolic relationship between 
insulin secretion and sensitivity on oral glucose tolerance 





Yes Not as robust 
(Relies on 
fasting values 
and not OGTT 
and equation 







Lower HOMA-β Matthews, D.R., et al., Homeostasis model assessment: 
insulin resistance and beta-cell function from 
fasting plasma glucose and insulin concentrations 









index at 30 min of 
OGTT/HOMA-IR) 




FBG and glucose30 (mg/dL) 
FI and insulin30 (mU/L) 
 










Kahn, S.E., The relative contributions of insulin resistance 
and beta-cell dysfunction to the pathophysiology of Type 2 




index at 30 min 
OGTT/fasting 
insulin) 




FBG and glucose30 (mg/dL) 








Utzschneider, K.M., et al., Oral Disposition Index Predicts 
the Development of Future Diabetes Above and Beyond 
Fasting and 2-h Glucose Levels. Diabetes Care, 2009. 
32(2): p. 335-341. 
	  
BMI, body mass index; FBG, fasting blood glucose; FI: fasting insulin; G0: glucose value at 0 min (baseline) of the oral glucose tolerance test; G30: glucose value at 30 min of 
the oral glucose tolerance test; G60: glucose value at 60 min of the oral glucose tolerance test; G90: glucose value at 90 min of the oral glucose tolerance test; G120: glucose 
value at 120 min of the oral glucose tolerance test; glucose30: glucose value at 30 min of the oral glucose tolerance test; glucose60: glucose value at 60 min of the oral glucose 
tolerance test; glucose90: glucose value at 90 min of the oral glucose tolerance test; glucose120: glucose value at 120 min of the oral glucose tolerance test; I0: insulin value at 0 
min (baseline) of the oral glucose tolerance test; I30: insulin value at 30 min of the oral glucose tolerance test; I60: insulin value at 60 min of the oral glucose tolerance test; I90: 
insulin value at 90 min of the oral glucose tolerance test; I120: insulin value at 120 min of the oral glucose tolerance test; iAUCglucose, glucose mean incremental area under the 
curve; iAUCinsulin, insulin mean incremental area under the curve; insulin30: insulin value at 30 min of the oral glucose tolerance test; insulin60: insulin value at 60 min of the 
oral glucose tolerance test; insulin90: insulin value at 90 min of the oral glucose tolerance test; insulin120: insulin value at 120 min of the oral glucose tolerance test; OGTT, 










Appendix 4.2 – Data analysis stratification options considered in the GLARE study 
Stratification method Criteria and Interpretation Remarks References 
Single stratification 
A. Averaging 
Using the mean average of each glucose 
and insulin index to separate 
participants into higher and lower 
groups 
Arbitrary and not based on previous 
studies. No significant, distinct 
pathophysiologic patterns could be 
identified from this stratification.  
 
Hence this method was not chosen 
for stratification in the GLARE 
study. 
NA 
B. Cut off value for 
Matsuda index 
Cut off point of <4.3 indicates reduced 
overall whole body insulin sensitivity 
(hepatic and peripheral) and indicates 
increased insulin resistance 
n=11 participants had Matsuda index 
>4.3, and n=8 had an index <4.3.  
 
However, no significant, distinct 
pathophysiologic patterns could be 
identified from this stratification. 
 
Hence this method was not chosen 
for stratification in the GLARE 
study. 
Gutch,	  M.,	  et	  al.,	  Assessment	  of	  
insulin	  sensitivity/resistance.	  
Indian	  Journal	  of	  
Endocrinology	  and	  





Monophasic shapes (only one peak) 
indicate higher T2DM risk compared to 
biphasic (2 peaks) or triphasic (2 
complete peaks) shapes. Both biphasic 
and triphasic are also considered as 
complex shapes and are grouped as one. 
n=11 participants exhibited 
monophasic glucose shapes at 
baseline, whilst n=8 exhibited 
complex glucose shapes.  
 
However, no significant, distinct 
pathophysiologic patterns could be 
identified from this stratification.  
 
Furthermore, prediabetes involves 
Tschritter,	  O.,	  et	  al.,	  Assessing	  
the	  shape	  of	  the	  glucose	  curve	  
during	  an	  oral	  glucose	  
tolerance	  test.	  Diabetes	  Care,	  
2003.	  26(4):	  p.	  1026-­‐1033. 
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significant changes to insulin 
secretion as well so looking 
specifically only at glucose changes 
would not be sufficient. 
 
Hence this method was not chosen 




glucose and insulin 
peak time patterns 
(Takahashi study) 
Increased glucose and insulin peak 
times indicate higher degree of impaired 
glucose metabolism and increased risk 
of T2DM. Research has elucidated that 
early insulin defects (causing delayed 
insulin peak) might lead to 
hyperinsulinaemia, and also worsened 
glycaemic control. 
 
There are four patterns in total: 
 
Pattern 1: Normal glucose and insulin 
peaking at 30min 
 
Pattern 2: Normal glucose peaking at 30 
min but insulin late >30min 
 
Pattern 3: Both glucose and insulin late 
>30min 
 
Pattern 4: Insulin very late >60min 
 
Participants exhibiting patterns 1and 2 
at baseline were classified as the 
n=9 participants exhibited less 
healthy patterns 3 and 4 at baseline, 
whilst n=11 exhibited healthier 
patterns 1 and 2.  
 
There were significant, distinct 
pathophysiologic patterns identified 
in the two groups classified by their 
postprandial glucose and insulin 
peak time patterns.  
 
This stratification method was also 
superior to just using the glucose 
shapes to classify participants. 
 
Hence this stratification method was 
chosen to be used for the GLARE 
study. 




Takahashi, K., et al., Four 
Plasma Glucose and 
Insulin Responses to a 
75g OGTT in Healthy 
Young Japanese Women. 
Journal of Diabetes 




healthier group, whilst participants 
exhibiting patterns 3 and 4 at baseline 
were classified as the less healthy 
group. 
E. Normal and 
hyperinsulinaemic 
groups (Hayashi 
and Kraft insulin 
patterns) 
According to Hayashi and Kraft studies, 
individuals at higher risk of T2DM have 
higher than normal secretion of insulin. 
Pattern 1 is considered to be having less 
abnormality in insulin response than 
subsequent patterns. Pattern 5 exhibits 
the worst insulin response abnormality. 
 
Kraft patterns: 
Generally five patterns (However only 
four patterns were applicable to the 
GLARE study as pattern 5 is for 
diabetic, hypoinsulinaemic individuals): 
 
Pattern 1: Normal insulin (Fasting 
insulin ≤30 mU/L AND 30 min or 1h 
peak) 
 
Pattern 2: Borderline hyperinsulinaemic 
(Fasting insulin ≤50 mU/L AND 30 min 
or 1h peak) 
 
Pattern 3: Hyperinsulinaemia (Fasting 
insulin ≤50 mU/L AND delayed peak 
(2h)) 
 
Pattern 4: Hyperinsulinaemia (Fasting 
insulin >50 mU/L) 
Using Kraft patterns, GLARE 
participants only exhibited patterns 
1-3. However, all participants had 
fasting insulin concentrations <30 
mU/L, which made accurate 
classification into the respective 
categories difficult. 
 
Hence this method was not chosen 



















Hayashi, T., et al., Patterns of 
Insulin Concentration 
During the OGTT Predict 
the Risk of Type 2 
Diabetes in Japanese 
Americans. Diabetes 
Care, 2013. 36(5): p. 
1229-1235. 
 
Crofts, C., et al., Identifying 
hyperinsulinaemia in the 
absence of impaired 
glucose tolerance: An 
examination of the Kraft 
database. Diabetes 
Research and Clinical 






Pattern 1: Peak insulin at 30 min, with 
60 min >120 min 
 
Pattern 2: Peak insulin peak at 30 min, 
with 60 min ≤120 min 
 
Pattern 3: Peak insulin at 60 min 
 
Pattern 4: Peak insulin at 120 min, with 
30min <60 min 
 
Pattern 5: Peak insulin at 120 min, with 
30 min ≥60 min 
Using Hayashi patterns, GLARE 
participants (n=9) exhibited peak 
insulin at 90 min or 120 min, with 
participants (n=10) having peak 
insulin at 30 min or 60 min. 
 
However, as Hayashi patterns do not 
consider insulin peaks at 90 min, this 
method was eventually not used. 
However it may be interesting to 
observe for the impact of the tested 
plant extracts on participants (n=9) 




Combined stratification (using two methods of stratification) 
C + D 
Categorising participants with double 
risk factors for T2DM (Monophasic and 
delayed glucose and insulin peak times) 
It was decided that combining two 
stratification methods might make 
data analysis too complex and so 
single stratification was preferred. 
Moreover no previous research has 
conducted a combination of two 
stratification methods although it 
was useful to do a preliminary 
exploration of each of these 
stratification methods. 
 
Hence these methods were not 
chosen for stratification in the 
GLARE study. 
NA 
C + E 
Categorising participants with double 
risk factors for T2DM (Monophasic and 
hyperinsulinaemic) 
NA 
D + E 
Categorising participants with double 
risk factors for T2DM 
(Hyperinsulinaemic and delayed 
glucose and insulin peak times) 
NA 
T2DM: Type 2 diabetes mellitus. 
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